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The DNA Mismatch repair (MMR) pathway is responsible for the repair of base-base 
mismatches and insertion/deletion loops that arise during DNA replication. MMR 
deficiency is currently estimated to be present in 15-17% of colorectal cancer cases and 
30% of endometrial cancers. MLH1 is one of the key proteins involved in the MMR 
pathway. MMR deficient tumours are often resistant to standard chemotherapies, 
therefore there is a critical need to identify new therapeutic strategies to treat MMR 
deficient disease. This study demonstrates that MLH1 deficient tumours are 
synthetically lethal with the mitochondrial-targeted agent Parthenolide which is known to 
induce reactive oxygen species (ROS) as one of its main mechanisms of action.   
 
Upon functional analysis, I show for the first time that loss of MLH1 is associated with 
deregulated mitochondrial function evidenced by a reduction in complex I expression 
and activity, reduced basal oxygen consumption rate and reduced spare respiratory 
capacity. This mitochondrial phenotype in the MLH1-deficient cell lines is accompanied 
by a reduction in mitochondrial biogenesis as evidenced by down regulation of pgc1β 
and decreased mitochondrial copy number. Furthermore, MLH1-deficient cancer cells 
have a decreased antioxidant defence capacity with reduced expression of the 
antioxidant genes NRF1, NRF2, Catalase, Glutathione peroxidase and SOD1 as well as 
increased ROS production when treated with Parthenolide. I further demonstrate that 
both MSH2- and MSH6-deficient cell lines also display deficiencies in complex I 
compared to their MMR-proficient counterparts.  
 
Taken together, the results of this study show a novel role for MLH1 in mitochondrial 
function and biogenesis. The MMR proteins MSH2 and MSH6 are also likely to have a 
role in the mitochondria.  My results suggest that targeting the mitochondria may be a 


























































































































































































































































O2•-   Superoxide anions  
HO•   Hydroxyl radical  
2DG   2-deoxy-D-glucose 
5-FU   5-fluorouracil  
8-oxodG   8-Oxo-2'-deoxyguanosine  
ADP   Adenosine diphosphate  
AID   Activation-induced deaminase  
AMPK   AMP-activated kinase 
ANT   Adenine nucleotide translocase 
AP    Apurinic/apyrimidinic  
APE1   AP endonuclease 1  
ARE   Antioxidant response element  
ASS1   Argininosuccinate synthase 1 
ATM   Ataxia telangiectasia mutated  
ATP   Adenosine triphosphate  
ATR   Ataxia telangiectasia and Rad3-related protein  
BAX   BCL2-associated X protein  
Bcl2   B-cell lymphoma 2  
BER   Base excision repair  
BRCA1   Breast Cancer type 1 susceptibility protein  
BRCA2   Breast Cancer type 2 susceptibility protein  
BSA   Bovine serum albumin  
cDNA   Complementary DNA  
Chk1   Checkpoint kinase 1  
Chk2   Checkpoint kinase 2  
Chr   Chromosome  
CIMP   CpG island methylator phenotype  
Coenzyme Q  Ubiquinone 




Complex II (CII)   Succinate dehydrogenase 
Complex III (CIII) Succinate- quinone oxidoreductase    
    (cytochrome bc1)  
Complex IV(CIV) cytochrome c oxidase, 
Complex V (CV)  F1FO-ATP synthase   
CRC   Colorectal cancer     
CSA   Cockayne syndrome protein A  
CSB    Cockayne syndrome proteins B 
CUL3   Cullin 3 
CYPD   Cyclophillin D 
D-loop   Non-coding displacement-loop  
DDR    DNA damage response  
DFS   Disease free survivial 
DLC   Delocalized lipophilic cations 
DMEM   Dulbecco's modified Eagle's medium  
dMMR   MMR deficiency 
DMSO   Dimethyl sulfoxide  
DNA   Deoxyribonucleic acid  
DNA pol   DNA polymerase  
dNTP    Deoxyribonucleotide  
DSB   Double strand break 
E. coli   Escherichia coli  
EDTA   Ethylenediaminetetraacetic acid  
EGFR   Epidermal growth factor receptor  
ELISA   Enzyme linked immunosorbent assay 
ERRα   Estrogen related receptor α 
ETC   Electron transport chain 
EXO1   Exonuclease 1 
FAD   Flavin adenine dinucleotide 
FapyGua   2,6-diamino-4-hydroxy-5-formamido-                  
    pyrimidine 
FBS   Fetal bovine serum  
FdUMP   Fluoroodeoxyuridine monophosphate 




FEN1   Flap endonuclease 1  
FMN   Flavin mononucleotide 
FOLFIRI   5-fu + Oxaliplatin+Irinotecan 
FOLFOX   5-fu+Oxaliplatin 
FOXO   Forkhead box O 
GCL   Glutamine cysteine ligase 
GCLC   Glutamine cysteine ligase catalytic 
GCLM   Glutamine cysteine ligase modifier 
GGR-NER  Global genome repair-Nucleotide excision repair 
GPx1   Glutathione peroxidase 1    
GPX2   Glutathione-s-transferase 
GSH   Glutathione 
GSTM1   Glutathione-s-transferase  
H. pylori   Helicobacter pylori 
H2O2   Hydrogen peroxide  
HK    Hexokinase 
HMOX1   Heme oxygenase 1  
HNF4alpha   Hepatic nuclear receptor 4alpha 
HNPCC   Hereditary nonpolyposis colon cancer  
HR   Homologous recombination  
NHEJ   Non-homologous end joining    
     IDL   Insertion/ deletion loop  
IHC   Immunohistochemistry  
IMS   Intermembrane space 
JAK2   Janus kinase 2 
KEAP1   Kelch-like ECH associated protein 1  
LIG1   DNA ligase 1 
LKB1   Liver kinase B1  
LP-BER   Long patch-base excision repair 
LV    Leucovorin  
MEF    Mouse embryonic fibroblast 
MGMT    O6-methylguanine DNA methyltransferase  




MMEJ   Microhomolgy-mediated end-joining 
MMP   Mitochondrial membrane potential 
MMR    DNA mismatch repair  
MNNG   N-methyl-N’-nitro-N-nitrosoguanidine  
MOMP   Mitochondrial outer membrane potential 
MPM   Malignant pleural mesotheliomas 
MSI   Microsatellite instability  
MSI-H   High microsatellite instability  
MSI-L   Low microsatellite instability  
MSS   Microsatellite stable  
mtDNA   Mitochondrial DNA 
mTOR   Mammalian target of rapamycin pathway  
mtTFB    Mitochondrial transcription factor B 
MUTYH   MutY homolog 
NAC   N-acetylcysteine  
NADPH    Nicotinamide adenine dinucleotide phosphate 
NEIL1   NEI endonuclease VIII-like 1 
NEIL2   NEI endonuclease VIII-like 2 
NEIL3   NEI endonuclease VIII-like 3 
NER   Nucleotide excision repair  
NER   Nucleotide excision repair mismatch repair  
NHEJ   Non-homologous end joining nucleotide    
    excision repair  
nM    Nanomolar  
NO•   Nitric oxide 
NQO1   NADPH:quinone oxidoreductase 1  
NRF1   Nuclear factor 1  
NRF2 (pg)  Nuclear factor erythroid 2-related factor 2 
NRs   Nuclear receptors 
NSCLC   Non-small cell lung cancer  
NTHI   Endonuclease three homolog 1 
O2    Oxygen  




O6meG   O6-methylguanine  
OCDL   Oxidatively induced clustered lesions 
OGG1   8-Oxoguanine glycosylase  
ONOO-   Peroxynitrite 
ONOOH   Peroxynitrous acid  
OS   Overall survival 
P    P-value 
PARP    Poly(ADP-ribose) polymerase 1  
PBR   Peripheral benzodiazepine receptor 
PBS   Phosphate buffered saline  
PCNA   Proliferating cell nuclear antigen  
PDK   Pyruvate dehydrogenase kinase 
PI3K   Phosphoinositide 3 kinase  
PIN   Prostate intraepilethial neoplasia  
PINK1   PTEN-induced putative kinase 1  
Polβ    DNA polymerase beta  
PRDX1   Peroxiredoxin 1  
PTEN   Phosphatase and tensin homolog  
PTPC   Permeability transition pore complex 
RFC   Replication factor C  
RFC   replication factor C 
RNA   Ribonucleic acid  
RNAPII    RNA polymerase II  
RO•   Alkoxyl radicals 
RO2•   peroxyl radicals 
ROS   Reactive oxygen species  
RPA   Replication protein A 
RPMI   Roswell Park Memorial Institute medium  
RR   Ribonucleotide reductase  
S-phase   Synthesis phase  
S. cerevisiae  Saccharomyces cerevisiae  
SEM   Standard error of mean  
siRNA   Small interfering RNA  




SOD   Superoxide dismutase 
SOD1   Cu, Zn-SOD  
SOD2   Mn-SOD 
SP-BER   Short patch-base excision repair 
SSB   Single strand break  
SSB   Single strand break 
ssDNA   Single stranded DNA 
TC-NER   Transcription-coupled NER  
TCA   Tricarboxylic acid cycle 
TCR-NER   Transcription coupled repair--Nucleotide   
    excision repair 
TDP1   Tyrosyl-DNA phosphodiesterase 1 
TFAM   Transcription Factor A 
TFB1M   Mitochondrial transcription factor B isoform 1 
TFB2M   Mitochondrial transcription bactor B isoform 2 
TFs   Transcription factors 
TLS    Translesional synthesis  
TMZ   Temozolomide  
TXN1    Thioredoxin 1  
TXNRD    Thioredoxin reductase  
UNG   Uracil-DNA glycosylase 
VDAC   Voltage-dependent anion channel 
YB1   Y-BOX binding protein   
YY1   yin yang 1 transcription factor 
µg    Microgram 








One of the key features of most tumours is genomic instability resulting in a multitude of 
different ways in which our DNA is altered ranging from nucleotide substitutions, 
insertions, deletions and changes in chromosomal copy number and structure [1]. 
These genomic changes occur as a result of continuous exposure to exogenous and 
endogenous sources of DNA damage. To combat this problem a complex system of 
several different mechanisms has evolved to repair DNA damage depending on the 
type of lesion present.  As a whole, this complex network of pathways is collectively 
known as the DNA damage response (DDR).  It has been estimated that in excess of 
150 proteins are involved in the DDR and control of cell-cycle checkpoints to allow DNA 
repair. It is therefore not surprising that if mutations occur within these DDR genes, this 
would lead to carcinogenesis. There is a considerable body of research ongoing into 
understanding and developing novel strategies to target the DDR as a therapeutic 
option for a wide variety of cancers [2]. 
 
Exogenous DNA damage is caused by substances including cigarette smoke, industrial 
chemicals, mustard gases and chemotherapeutic drugs. Chemotherapeutic agents 
achieve cell death by causing lesions such as interstrand crosslinks (platinum 
containing agents), base alkylation (Temozolomide), single strand and double strand 
breaks (SSBs and DSBs, respectively) (Etoposide). Endogenous DNA damage includes 
damage caused by reactive oxygen species (ROS) resulting in oxidative DNA damage 
and SSBs. DNA replication errors resulting in deoxyribonucleotide 5’-triphosphate 
(dNTP) misincorporation, depurination, deamination, base mismatches and 
insertions/deletions are also a potential threat to the genome [1].  
 
Mitochondrial DNA (mtDNA) is particularly prone to oxidative DNA damage for a variety 
of reasons, including its close proximity to the electron transport chain where the 
majority of ROS is generated and the fact that it is not protected by histones [3]. The 




given as much attention as the nuclear genome but with improvements in the ease of 
sequencing the mitochondrial genome, the key role mitochondrial mutations play in 
ageing, age-related diseases, neurodegenerative diseases and cancer has become 
apparent [4, 5]. 
 
The main repair pathways involved in the repair of DNA damage are: base excision 
repair (BER), double strand break repair (homologous recombination- (HR) and non-
homologous end joining (NHEJ)), nucleotide excision repair (NER), mismatch repair 
(MMR) and direct reversal (Figure 1.1). The focus of this study is on the MMR system 










DNA! is!continually!exposed!to!a! range!of! insults! leading!to!a!variety!of! lesions.!The!choice!of!
repair!mechanism! is! determined!by! the! type!of! lesion.! Key!DNA! repair! pathways,! associated!
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The main function of the MMR pathway is the repair of post replicative DNA errors, 
specifically base-base mismatches and insertion/deletion loops (IDLs). A schematic of 
this pathway is illustrated in Figure 1.2. The MutS and MutL family of proteins are highly 
conserved from lower organisms to eukaryotes and are the key players in the 
functioning of the MMR system [6]. The majority of evidence implicates MutSα 
(comprised of MSH2 and MSH6) in the recognition of single base-base mismatches and 
small IDLs of 1-2 mispairs. MutSβ (comprised of MSH2 and MSH3) is involved in the 
recognition of longer IDLs up to 16 nucleotides long [7, 8]. Furthermore, it is well 
established that the degree of mismatch recognition by the MutS Complex Is dependent 
on the actual mismatch with high affinity being demonstrated for the common mismatch 
G-T and to IDL’s with a single unpaired nucleotide compared with the less common C-C 
mispair which is not recognized by the MMR pathway [9, 10].   
 
There are several heterodimers of MutL homologues including MutLα (complex of 
MLH1 and PMS2), MutLβ (complex of MLH1 and PMS1) and MutLγ (complex of MLH1 
and MLH3). It is widely accepted that MutL homologues are able to bind to DNA and 
also hydrolyze ATP [11, 12]. The role of MutLα is the best described of all the MutL 
homologues. The evidence suggests that MutLα is recruited by a mismatch bound MutS 
and this signals the presence of the error, thereby allowing the recruitment of the 
downstream proteins necessary to complete repair [6, 13]. However, data about the 
exact nature of these protein interactions is limited. Plotz et al [14] have demonstrated 
that the association of MutSα and MutLα on DNA requires ATP and occurs through the 
N-terminal region of MLH1. The investigators also showed that MutSβ was able to bind 
to MutLα as effectively as MutSα and also through MLH1 [11]. MutLγ is thought to be 
involved in repairing some IDLs as well as having a role in meiotic recombination and 
no definitive role for MutLβ in the MMR pathway has been elucidated [6, 15, 16].  
 
The MMR protein complexes are ATPases and possess a Walker ATP-binding motif 
through which they are able to bind to ATP/ADP and carry out their mechanism of 
action [17]. For the MMR system to repair DNA replication errors that have occurred in 




template DNA and newly synthesized DNA. The exact mechanism which allows this 
differentiation is not clear but the current understanding is that gaps between okazaki 
fragments may serve as the discrimination signal on the lagging strand but no 
corresponding signal on the leading strand had been established until recently [18, 19]. 
The long unanswered question about the discrimination signal has potentially been 
addressed by a recent study by Pluciennik et al [20] . The authors of this study have 
shown that MutLα associates with a proliferating cell nuclear antigen (PCNA) molecule 
and incorporates additional nicks in the discontinuous strand allowing MMR to identify 
the nascent strand in both leading and lagging strands [20]. There are also several 
groups who have identified a possible additional mechanism, which may serve to make 
the process of identifying the nascent strand more efficient. This system is dependent 
on the RNases H1 and H2, which remove ribonucleotides from DNA leaving additional 
nicks which can be used as entry sites for EXO1[21]. 
 
Current evidence suggests that PCNA is likely to recruit components of the MMR 
system to replicating DNA [22] and may even have a role in assisting MutS in detecting 
mismatches within large regions of DNA [23]. PCNA has been shown to be able to 
associate with MutSα, MutSβ, MutLα.  
 
There are several proposed mechanisms of how the MMR system operates, which fall 
under the two main headings of “moving models” and “stationary models”[6]. Following 
the recognition of a mismatch by MutSα and in turn the recruitment of MutLα, the 
moving models essentially result in the MutS/MutL complexes leaving the mismatch 
they have encountered, made possible by the fact that these MMR complexes possess 
ATPase activity [24]. The resulting moving clamps diffuse along the DNA in a uni 
(“translocation model”) or bi-directional manner (“sliding clamp model”) from the 
mismatch [24, 25]. Repair of these lesions takes place when one of these clamps 
comes across a strand break 5’ from the mismatch where replication factor C (RFC) is 
present and is displaced, to allow exonuclease 1 (EXO1) to access the daughter strand 
DNA to initiate strand degradation in the 5’-3’ direction. The role of RFC is to load 
PCNA [26] which is essential for 3’-directed excision and inhibit EXO1 from carrying out 
hydrolysis in the 5’ to 3’ direction when the nick is 3’ to a mismatch [27]. Given that 
EXO1 can only function 5’ to 3’ it requires the EXO1 endonuclease activity of MutLα in 




associating with MutLα and in turn causing additional nicks in the discontinuous strand 
to be used as EXO1 loading sites [20]. Replication protein A (RPA) is responsible for 
stabilizing the parental strand [28] and once the mismatch is removed EXO1 ceases to 
be activated by MutSα and is possibly suppressed by MutLα [29, 30] 
 
The resulting gap is filled by the DNA polymerase, pol δ, and PCNA has also recently 
been implicated in this re-synthesis part of the pathway since it is a processivity factor 
for DNA polymerase δ and ε [31]. Ultimately DNA ligase I (LIG1) closes the gap in the 
strand to complete the repair process [6, 15].  
 
The “stationary” model, which is also termed the “DNA bending/verification” model, 
proposes that the MMR complexes remain at the mismatch allowing the DNA to bend or 
loop, thereby permitting contact between the mismatch and the strand discrimination 























carries!out! strand!degradation! in!a!5'! to!3'!direction.! !RPA! stabilizes! the! singleFstranded!gap.!
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MutLα was first discovered in 1995 as a consequence of a study by Li et al, which 
identified the hMLH1 and hPMS2 heterodimer [32]. The authors were able to restore 
MMR activity to nuclear extracts of the MMR deficient H6 colorectal cancer cell line by 
the addition of what is today known as MutLα from HeLa cells [32]. It was later 
ascertained by several authors that this heterodimer is recruited to heteroduplex DNA 
after MutS has recognized a mismatch and that this occurs in an ATP dependent 
fashion [32-34]. Studies in both yeast and mammalian cell lines have shown that the 
MLH1 protein is essential for functional MMR [35, 36].  The importance of MLH1 in the 
MMR pathway is evident from the fact that studies involving large databases 
(International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-
HNPCC) and current International Society for Gastrointestinal Hereditary Tumors 
(InSiGHT)) of patients with the heritable disorder HNPCC have shown that almost half 
of these patients have germline mutations associated with MLH1 loss [37]. Furthermore, 
it was shown amongst these patients there were in the region of 500 downstream 
mutations as a result of MLH1 loss. Hundreds of possible mutations in the MLH1 gene 
including missense mutations and have been identified in patients with HNPCC leading 
to a range of studies aiming to identify the functional significance of these mutations 
[38, 39]. In addition to the loss of MLH1 through germline mutations, the majority of 
MMR deficient (dMMR) sporadic tumours are also due to MLH1 loss mainly due to 
promoter hypermethylation of CpG islands in DNA [37]. The phenotype associated with 
promoter hypermethylation is known as CpG island methylator phenotype (CIMP) and 
has been found to be strongly linked to BRAF V600E mutations as well as older age 
and female sex [40, 41].  
 
The MutL homologues are known to part of the GHKL superfamily of ATPases [42]. 
MutLα has been shown to carry out the key role of recruiting proteins necessary for 
MMR by direct interaction through ATP binding and hydrolysis causing conformational 
changes.  [43, 44]. In both eukaryotes and prokaryotes it has been established that this 
occurs through ATP dependent conformational change in the N-terminus and resulting 
alterations to the orientation of this terminus relative to the C terminus [11]. . Plotz et al 
have shown that the interaction between DNA bound MutSα and MutLα takes place on 




that some MLH1 mutations can stop the interaction between MutS and MutL as well as 
abolish MMR activity [39] 
 
It was widely believed amongst investigators in the MMR field of study that MutLα had 
unexplored functions, which needed to be elucidated given the huge clinical significance 
of MLH1 loss. Kadyrov et al explored the role of MutLα in 2006 and were able to show 
that human MutLα has endonuclease activity that is essential for 3’-directed MMR [45] . 
The activity of MutLα was found to be RFC, PCNA, ATP and Mutsα dependent and 
biased to nicked hetroduplex DNA. Activated MutLα has been established to introduce 
additional nicks in heteroduplex DNA 5’ to the mismatch. This allows EXO1 to carry out 
5’ to 3ry out 5tc. This finding that MutLα has endonuclease activity and can provide a 5’ 
terminus cleared the unanswered question of how Exo1, which is known to hydrolyze 
nicked DNA in the 5’ to 3’ direction is able to carry out 3’ to 5’ activity.  The 
endonuclease active site is not fully ascertained but is thought to be on PMS2 [45]. 
Furthermore, the clinical relevance of the endonuclease activity of MutL is displayed 
by the fact that mutations in yeast that impair this activity result in genome instability 
and display a mutator phenotype [46].  A later study in 2009 aimed to re-examine the 
role of MutLa and RPA since there were conflicting studies present describing their 
function [30]. This study confirmed that whilst RPA was essential in terminating excision 
by MutSα-activated EXO1, MutLα does not participate in this process [30]. The most 
recent study aiming to further clarify the role of MutL was published in 2015 and used 
single cell fluorescence resonance energy transfer (FRET) to establish the nature of its 
interaction with MutS in Thermus aquaticus [47]. Qiu et al showed that MutLα actually 
has a more fundamental role than previously believed. MutLα in Thermus aquaticus 
was shown to trap MutS at a DNA mismatch before it formed a sliding clamp. This led to 
a structure of dynamic proteins at a mismatch, which was found to contain more MutL 
than MutS. This structure was found to be the area where PCNA could interact with 
MutL and MutS, and allowed for a more efficient mismatch repair system since MutL 







Although the main role of the MMR pathway is the repair of DNA replication errors, 
there is evidence that it has several other non-canonical roles including the repair of 
oxidative DNA damage, repair of DNA double strand breaks, participating in 
homologous recombination, mitotic and meotic recombination, immunoglobin class 
switching and co-activation of oestrogen receptor alpha [12, 15].  
 
1.3.1! Meiotic!and!mitotic!recombination!and!MMR!
The role of the MMR proteins in both mitotic and meiotic recombination has been 
confirmed in numerous in vitro and in vivo studies [48-52]. The function of MMR during 
recombination is believed to be due to the interaction of MMR factors with mismatches 




The MMR proteins MLH1 and MLH3 have been shown to function with a MutS 
homologue, hMSH4/hMSH5, which has no known role in the conventional MMR 
pathway to carry out their role in meotic recombination. The double holiday junction is 
an intermediate in meiotic recombination [56]  and the role of meiotic MMR is to process 
DSBs through this pathway resulting in genetic recombination and accurate segregation 
of homologs [51].  MSH4 and MSH5 have been found to be expressed in the testes and 
ovaries during early prophase I of meiosis and have been found to have a role in 
recombination and crossover events [56]. MSH4/MSH5 has been shown to bind to 
recombination intermediates and cause exchange of ADP with ATP leading to a 
conformational change resulting in a hydrolysis-independent sliding clamp, which 
dissociated from the holiday junction. This was proposed to stabilize the recombination 
intermediate until it was positioned to allow accurate parental chromosome segregation 
[52]. MLH3 is essential for the binding of MLH1 to meiotic chromosomes in early 
pachynema of prophase this heterodimer and I associates with MSH4/MSH5 to allow 





The MMR pathway has been found to have anti-recombinogenic activity and MMR 
deficiency has been shown to result in increased frequency of recombination between 
homeologous sequences including gene conversions and/or crossover [48-50]. The 
MMR proteins have a role in mitotic recombination by preventing strand exchange and 
recombination between divergent sequences. The exact mechanism by which the MMR 
system prevents strand exchange is unclear but is thought to be by blocking of the 
formation of heteroduplex DNA, whenever well-recognized mismatches are formed by 
strand exchange between non-identical parental sequences [58]. Genetic studies of 
homeologous recombination during mitosis in yeast suggest that there are two stages of 
regulation of recombination between divergent sequences. The first stage is that if 
recipient and donor sequences are too divergent (>10%), recombination is severely 
repressed likely due to an inability to form a sufficiently stable base-paired intermediate. 
At lower levels of divergence, MMR imposes an additional barrier to recombination so 
that it suppresses the formation of heteroduplex DNA in proportion to the increase in 
sequence diversion [59]. Analysis in S. cerevisae examining the requirement for 
different MMR complexes in repression of homeologous recombination and found that a 
mutation in the MSH2 gene results in the highest rate of recombination followed by 
MSH6 and MSH3. The MutL homologs (MLH1 and PMS2) resulted in a much lower 
homologous recombination level [50]. Furthermore, Nicholson et al have identified that 
different MMR proteins are required for the recognition of differing mismatches in mitotic 
recombination intermediates. For example, MSH2 was required for the recognition of all 
mismatches but MSH6 only recognized base-base mismatches and IDLs that were one 
base pair long [60].  MSH2 deficient mice have been found to have an increased rate of 
haematological maliganancies thought to be due to chromosomal rearrangements [61]. 
!
1.3.2! MMR!and!immunoglobulin!diversification!
To combat the huge variety of antigens that we are exposed to our immune system is 
required to constantly produce a range of antibodies. This diversity is accomplished by 
several mutagenic processes that take place at the immunoglobulin locus. This is a two 
stage process, the first of which occurs early in B cell development and the second after 




activation-induced deaminase (AID) which converts cytosine to uracil in single stranded 
DNA and initiates mutagenic processes such as U:G mismatches resulting in the 
recruitment of MutS and MutL[63]. The recruitment of the MMR proteins leads to 
activation of the exonuclease Exol and paradoxically leads to error-prone repair 
involving the translesional synthesis (TLS) DNA polymerase h that promotes A:T 
mutagenesis and DSBs . This results in enhanced mutation frequency of AID activity as 
well as broadening the spectrum of base mutations and efficiency of antibody 
maturation [64]. Studies have shown that MSH2, MSH6 and Exol-deficient B cells have 
a significantly lower (80-90% less) rate of A:T mutations [64, 65].  No role for MSH3 has 
been found in immunoglobulin diversification and studies suggest that MutSα is involved 
in this role of the MMR pathway [64]. MutSα has been found to interact with U:G 
mismatches as well as initiate its catalytic activity [66].  
"
1.3.3! MMR!and!chromatin!assembly!
MMR activity occurs in the chromatin environment, which led investigators to assess 
whether the MMR proteins have any role in chromatin assembly. Schopf et al and 
others have shown that presence of a mismatch in nicked plasmid heteroduplex DNA 
delays nucleosome loading in human cell extracts and once the mismatch is removed, 
repair of the single strand gap and nucleosome loading occurs [67, 68]. The 
investigators also illustrated that the chromatin assembly factor CAF-1 interacts with 
MSH6. Furthermore, PCNA was also found to interact with both CAF-1 and MutSα and 
in vivo this interaction was found to increase during S phase and was likely dependent 
on CAF-1 phosphorylation [68]. The authors proposed an outline of the function of MMR 
in chromatin assembly on mismatch containing DNA based on the study they 
performed: 1, MutSα sliding clamps may physically interfere with nucleosomes 2, 
MutSα may stop CAF-1 interacting with PCNA (dependent on CAF-1 phosphorylation 
status or physical interference) and once repair is completed and MutSα is no longer 
present, CAF-1 can interact with PCNA and resume chromatin assembly [68]. The 
histone mark H3K36me3 can interact with MSH6 to chromatin in S phase prior to DNA 
replication [68] and in yeast the  acetylated and deacetylated forms of the histone H3 
K56 has been shown to act synergistically with the MMR proteins to reduce 






Mitochondrial DNA is particularly prone to oxidative DNA damage for a variety of 
reasons, including its close proximity to the electron transport chain where the majority 
of ROS is generated and the fact that it is not protected by histones [3]. It is estimated 
that the levels of oxidative damage in the mitochondria are 2-3 times higher than in 
nuclear DNA [70, 71]. It has been established that mitochondria utilise BER as their 
primary mechanism for repairing mitochondrial oxidative DNA damage [72]. 
Nevertheless, there is increasing evidence that some form of MMR machinery is 
present in the mitochondria and that MMR proteins are potentially also involved in the 
repair of oxidative DNA damage to mtDNA [73-75].  
 
One of the earliest studies to illustrate that MMR activity may be present in the repair of 
mtDNA was carried out by Habano et al. who examined nine microsatellite sequences 
in the mtDNA of 45 sporadic CRCs [76]. The investigators found that in 44% of these 
cancers there was an alteration in a polycytidine (C)n tract within the non-coding 
displacement-loop (D-loop) region and that three of the samples exhibited frameshift 
mutations within microsatellite tracts in NADH dehydrogenase genes (Complex I (CI)) 
[76]. Since MSI is strongly associated with MMR deficiency, the authors concluded that 
given MSI is present in mtDNA, that some form of MMR activity is likely to be taking 
place in the mitochondria.  In addition, a mitochondrial MutS homolog (msh1) that 
detects mismatches has been identified in Saccharomyces cerevisiae [77]. Several 
studies have tried to definitively show the proteins and steps involved in a proposed 
mammalian mitochondrial MMR system but to date no clear pathway has been fully 
elucidated. Mason et al showed mismatch repair activity in rat liver mitochondrial 
lysates by using a nicked heteroduplex substrate in the β-galactosidase reporter gene  
(with a GT or GG mismatch) as a model and concluded that the MMR activity was 
bidirectional, ATP dependent and EDTA sensitive [74]. Hashiguchi et al. discovered that 
the mitochondrial extracts from three different human cell lines were able to bind 
mismatches and small insertion-deletion loops [73]. The authors hypothesised, using 
polyacrylamide gel migration, that the protein involved is likely to be 80-90kD and may 
function alone. The protein was able to bind 8-oxoG/G/A/T suggesting that it may be 





two studies have demonstrated that MSH2 is unlikely to be involved in mitochondrial 
MMR since mitochondrial extracts from MSH2 deficient cells retained mismatch repair 
activity [73, 75]. DeSouza et al are the first investigators to propose a novel protein that 
potentially functions as a player in MMR [75]. They were unable to detect mitochondrial 
localization of the nuclear MMR proteins, MLH1, MSH3 and MSH6 in the mitochondria 
of human HeLa cells by immunofluorescence but they identified that silencing the Y-
BOX binding protein (YB1) resulted in reduced MMR activity in mitochondrial extracts 
[75].  
 
A very recent study in retinal endothelial cells aimed to establish the role of the MMR 
proteins in diabetic retinopathy given that this hyperglycaemia related complication is 
known to cause mitochondrial dysfunction, ROS induction, increased oxidative damage 
in the mitochondria and decreased levels of POLG [78]. The authors showed that 
expression of MLH1 and MSH2 was significantly decreased in retinal endothelial cells 
exposed to high glucose compared to normal glucose. The expression levels of MSH6, 
YB1 and Pms2 were maintained in high glucose conditions. The deficiency in the MMR 
proteins was associated with an increased number of mismatches (increased sequence 
variants) in the non-coding D-loop in the mtDNA in association with decreased 
respiration and increased apoptosis. This phenotype was rescued by the 
overexpression of MLH1 but not with the overexpression of MSH2 [78] . 
 
As mentioned in the section on synthetic lethal approaches (section 1.3), we have 
recently shown further evidence of a potential role for MMR in the mitochondria [79]. No 
role for the conventional MMR proteins has to date been implicated in the mitochondria 
so this study was the first to identify a specific MMR protein, MLH1, to be involved in the 




Deficiency of one or more of the MMR proteins has been reported to be present in 
various tumour types including 15-17% of all primary colorectal cancers [80, 81], around 




These proteins have been found to be absent due to epigenetic silencing, inherited 
germline mutations and somatic mutations. Loss of MLH1 frequently due to promoter 
hypermethylation and MSH2 loss have been found to be the most common cause of 
sporadic mismatch repair deficient colorectal cancers [84, 85]. Studies have established 
that promoter hypermethylation is commonly bi-alleic and that the mechanism behind 
this process is still not clear but it has been found to be present in early colorectal 
adenomas [37]. Lynch syndrome is a heritable disorder, which predisposes affected 
individuals to several cancers such as colorectal, endometrial, ovarian, gastric, 
urothelial and small bowel [86]. This autosomal dominant disorder is caused by a 
germline mutation in one copy of an MMR gene, followed by a ‘second hit’ to the 
remaining normal allele, which results in complete gene loss. It has been estimated that 
Lynch syndrome accounts for 3-5% of CRC cases and in 70%-90% of these cases, the 
causative mutation is in the MLH1 or MSH2 gene [87].   
 
It is well established that mutation rates are significantly higher in human tumour cells 
with MMR deficiency compared to wild type cells, resulting in an accumulation of 
unrepaired mutations throughout the genome, commonly known as the ‘mutator 
phenotype’ [88]. Therefore MMR deficient tumour cells possess mutation rates that are 
100-1000-fold greater than that of normal cells [88, 89].  These mutations are normally 
frameshift mutations that arise during replication and result in truncated proteins. Due to 
their repetitive nature, the mutator phenotype has been found to result in mutations 
within microsatellite sequences (microsatellite instability (MSI)). MSI due to loss of MMR 
often occurs in genes that have an impact on tumour development and biology such as 
those involved in signal transduction (TGFBR2, PTEN, BRAF), apoptosis (BAX, 
Caspase-5), DNA repair (MRE11A, RAD50) and damage signalling (ATR, CHK1) [85, 
90]. The loss-of-function mutations in tumour suppressor genes and gain of function 
mutations in oncogenes associated with MMR deficiency are thought to not only drive 
the oncogenic process but are likely to also have an impact on tumour biology and 
treatment response [85].  
In clinical practice MMR deficiency and the frequently associated MSI (>90%) are 
diagnosed by DNA sequencing, PCR to detect changes in the length of microsatellites 
and immunohistochemistry staining for MMR proteins. Specific features have been 
associated with MMR-deficient tumours are described in Table 1.1 [86, 91]. The revised 




warrant testing for MSI with an emphasis on diagnosing patients with Lynch syndrome 
who’s management would be affected by this diagnosis [92] (Table 1.2). The PCR 
method to detect MSI involves using a fluorescent multiplex PCR assay to examine five 
primary microsatellite loci; Bat-25, Bat-26, D2S123, D5S346, and D17S250 which were 
established at the 1997 National Cancer Institute-sponsored conference on MSI 
[93].This method has been validated and is now internationally standardized with a 
defined panel of microsatellite markers and scoring system (Table 1.3) [85, 94]. It is 
important to note that that MSI has been validated to be a good marker for MMR-
deficient associated with MLH1, MSH2 and PMS2 but the vast majority of MSH6 






































• Colorectal cancer diagnosed in a patient who <50 years of age. 
• Presence of synchronous, metachronous colorectal, or other 
HNPCC-associated tumours regardless of age. 
• Colorectal cancer with the MSI-H histology (Table 1.3) diagnosed 
in a patient who is <60 years of age. 
•  Colorectal cancer diagnosed in one or more first-degree relatives 
with an HNPCC-related tumour, with one of the cancers being 
diagnosed <50 years. 
• Colorectal cancer diagnosed in two or more first- or second-
degree relatives with HNPCC-related tumours, regardless of age. 
 
• Proximal  
• Poorly differentiated 
• Histology-mucinous (15%), signet cell and medullary subtypes 
• Presence of tumor infiltrating lymphocytes, Crohn’s-like 
lymphocytic reaction 
• Enhances tumour formation from tubulovillous adenoma to 






MSI-Low 1/5 markers positive 
Microsatellite stable (MSS) 0/5 markers positive 





MMR deficiency is the cause of a significant number of colorectal cancers (4th most 
common cancer in the UK, CRUK 2013) and endometrial cancers (4th most common 
cause of cancer in women, CRUK 2013). Given the involvement of mismatch repair 
deficiency in some of the most common cancers, it is important to understand the 
biology of these cancers and the response to current treatments available  
 
Most in vitro and clinical studies have shown MMR deficient cancers to be resistant to 
standard chemotherapeutics including 5-FU [96], Cisplatin, Carboplatin and possibly 
topoisomerase inhibitors [85]. Overall is seems that patients with dMMR tumours have 
an improved overall survival when compared with MSS CRCs of the same stage 
including patients with metastatic disease [97]. Nevertheless, given the high incidence 
of colorectal cancer worldwide and the problems with drug resistance with dMMR 
tumours, there is still a huge need to identify the most effective way of treating this 
group of patients.  The MMR pathway is essential in the efficacy of many drugs due to 
the fact that it has a role in recognizing many drug-induced DNA adducts and 
coordinating the downstream DDR through ataxia-telangiectasia mutated (ATM) and 
ataxia telangiectasia and Rad3-related protein (ATR) [98, 99]. MutS has been shown to 
bind MutL in the presence of a drug-induced DNA adduct that cannot be repaired and 
then subsequently recruiting ATM/ATR leading to cycle cycle arrest (to allow repair) or 
apoptosis [6]. The two main models that are widely believed to be the method in which 
the MMR pathway recruits ATM/ATR are the futile cycling model and the direct 
signaling model.  The direct signaling model proposes that a drug-induced lesion would 
normally cause MutS and MutL to directly recruit ATM/ATR and cause cell cycle arrest 




mismatch would be recognized and removed from the newly synthesized strand by the 
MMR system leaving behind a strand that contains 5FdUTP. This would allow the 
synthesis of DNA with mismatches and subsequently set up a futile cycle of 
mismatches causing persistent strand breaks, stalled replication forks, recruitment of 
ATM/ATR and cell cycle arrest and apoptosis [100]. In a dMMR cell, the drug induced 
lesions would not be recognized to cause cell death and subsequently this leads to drug 
resistance.    
!
1.5.1.1!! 5TFU!and!dMMR!
The antimetabolite 5-FU is the most effective and commonly used drug for the 
treatment of CRC [101-103]. The current available evidence has led to adjuvant 5-FU 
based chemotherapy (usually in combination with Oxaliplatin) being recommended as 
standard of care for patients with stage III CRC [103, 104]. For patients with stage II 
CRC the benefit of adjuvant chemotherapy has been found to be small and therefore it 
is generally only recommended in patients with high risk features [104, 105]. The 
efficacy of 5-FU in dMMR tumours has not been definitively confirmed since several 
retrospective trials have produced differing results as described below [106-108]. 
 
A study by Meyers et al. found  that the MLH1-deficient CRC cell line HCT116 is 18 
times less responsive to 5-FU treatment compared to its isogeneticallymatched pair 
HCT116+chr3 in long-term clonogenic assays [100]. Upon further analysis of the 
mechanism behind this observation, the authors showed that there were a greater 
number of MMR proficient cells in the G2/arrest phase of the cell cycle which would 
eventually lead to cell death and apoptosis compared to the MMR deficient cell lines 
[109] 
 
From a clinical perspective, the management guidelines in most centers, based on the 
current available evidence is that 5-FU based chemotherapy should be recommended 
to patients with MSI tumours only in stage III CRC and not in stage II CRC [104] 
.Several studies have shown no benefit for treating patients with MSI tumours with 5-FU 
based adjuvant treatment. Sargent et al (2010) carried out a large study examining a 
pooled data set of 1027 patients (n=165 with dMMR) with both stage II and stage III 




dMMR and exhibited an improved survival compared to the MSS tumours but showed 
no improved outcomes with adjuvant 5-FU treatment. The results of this study were 
validated by combining the data from an earlier study by Ribic et al consisting of 570 
patients, 96 of these patients had MSI tumours [106]. This study further confirmed that 
MSI tumours were associated with improved outcomes but that 5-FU based adjuvant 
treatment abrogated this improved outcome [107]. Furthermore, this part of the study 
confirmed a worse OS for stage II patients with MSI tumours that received 5-FU 
treatment versus surgery alone [106]. The commentary following these studies was that 
the small numbers of patients with MSI tumours meant that larger studies needed to be 
carried out before a definitive decision regarding dMMR and adjuvant chemotherapy 
could be reached and the difference in treatment between stage II and III MSI tumours 
established [110]. The role for adjuvant 5-FU chemotherapy in stage II CRC with MSI 
was also studied in the QUASAR trial where these patients were either randomized to 
receive 5-FU (n=1,483) or surgery alone (n=1,480). The improved outcome of patients 
with MSI tumours was again confirmed with the risk of recurrence being 11%  in this 
group compared to 26% in the MSS tumours. There was however no  benefit of 
adjuvant chemotherapy demonstrated in the MSI group (HR =0.97, P=0.92) [111] 
 
A more recent study in 2011 by Sinicrope et al was a large study involving 2141 stage II 
and III patients with CRC by including patients treated in several randomised studies of 
5-FU based adjuvant chemotherapy. In this study population, 344 patients (16.1%) had 
MSI tumours (164 stage II and 180 stage III tumours) and had an improved outcome in 
the treated and untreated group compared to patients with MSS tumours [108]. The MSI 
cohort (treated and untreated) had a reduced 5-year recurrence rate of 22% vs 33% 
(p=0.001), delayed time to recurrence (TTR) (p=0.001) and improved OS (p=0.004) 
[112]. This study showed a statistically significant increase in  DFS (p=0.47), TTR 
(p=0.016) and OS (p=0.041)  in both stage II and stage III MSI CRC compared to MSS 
tumours but upon carrying out univariate analysis in the MSI group treated with 5-FU 
based chemotherapy vs surgery alone or no 5-FU, the improved outcome was only 
significant for the stage III patients. In the patients with stage III cancers and dMMR, 
treatment with 5-FU resulted in a reduced distant recurrence rate of 11% vs 29%; ( P = 
0.11). This result confirmed that 5-FU treatment in patients with MSI does not abrogate 
the known improved survival in this group of patients. It is important to note that the 




untreated patients with MSS tumours. Interestingly, Sinicrope et al examined the 
difference in benefit from 5-FU between sporadic and germline (Lynch Syndrome) 
dMMR tumours and found that the benefit of treatment in the stage III MSI group is 
restricted to the tumours with germline mutations  with improved DFS after 5-FU-based 
treatment compared with sporadic tumors where no benefit was observed ( P = .006) 
[108]. Unfortunately the investigators did not examine the treatment effect in the  stage 
II MSI population in detail so no information regarding differences between germline 
and sporadic tumours in this setting is available. The criticism of this study is that 
despite the large study population, a stratified analysis by treatment group or stage was 
not performed therefore the unanswered questions from previous studies by Ribic et al 
[106] and Sargent et al [107] could not be answered. The control arm of the PETACC3 
clinical study contained 600 patients with stage II and III colorectal cancer treated with 
5-FU and this showed an improved 5-year DFS in patients with MSI tumours [113] 
 
The pressing question of the value of using MMR status as a tool to predict outcome of 
adjuvant chemotherapy has still not been definitively confirmed. Most importantly a 
clear answer about whether patients with stage II CRC have a worse outcome with 
chemotherapy needs to be addressed. In clinical practice currently the only widely 
accepted use for dMMR as a prognostic marker in guiding treatment decisions is in 
patients with dMMR and stage II CRC where the risk of recurrence is low [73, 76]. The 
clinical community feel better datasets with more detailed information are necessary to 
carry out  large studies examining the prognostic and predicative role of MSI in CRC. 
Furthermore, the recent study by Sinicrope et al has demonstrated that gene 
expression profiling, methylation studies and microRNA assessment will be necessary 
to elucidate clinically relevant biological subgroups [110].   
 
The most recent study, the AEGO study (2016) further examined the role for adjuvant 5-
FU in dMMR CRC . This study was set up to examine the  benefit of 5-FU in 
combination with Oxaliplatin (FOLFOX) versus 5-FU alone or no chemotherapy in CRC 
with MSI. This retrospective multicenter study included 433 patients with MMR deficient 
CRC who underwent curative resection for stage II and III disease between 2000-2011 
[83]. In comparison to surgery alone there was an improved DFS with Oxaliplatin based 




subgroup analysis revealed the benefit of combination chemotherapy was restricted to 
the patients with stage III disease [51, 83]. 
!
1.5.1.2!! Platinums!and!dMMR!
Several in vitro studies have confirmed that MMR deficient cancer cells are more 
resistant to the platinum based compounds Cisplatin and Carboplatin [114]. Aebi et al 
demonstrated that in vitro both MLH1 and MSH2 deficient cell lines were much less 
sensitive to Cisplatin than their MMR proficient matched cell lines [115]. This resistance 
is thought to be due to the DNA adducts produced by these agents which are normally 
recognized by an intact MMR system [85, 116]. Aebi et al. and several other groups 
have found that Cisplatin resistance is associated with loss of MMR proteins [115, 117]. 
From a clinical perspective there are contradictory studies and as yet MMR status is not 
used as a predictor for the response to chemotherapy with platinum based compounds.  
Resnick et al. evaluated data from 158 patients with endometrial cancer who had 
received adjuvant platinum based chemotherapy and found that the overall survival was 
not different in the group with MMR deficient cancers compared to those with MMR 
proficient cancers [82]. In a sub-group analysis however, the group with MMR deficient, 
stage III/IV disease had a worse progression free survival (p=0.031) [82]. Samimi et al 
ascertained a decreased expression of both MLH1 and MSH2 in paired ovarian tumour 
tissue after platinum based chemotherapy but did not find a correlation between MMR 
status and response to platinum based chemotherapy or overall survival (OS) [118]. 
Honecker et al examined the MMR status of 35 platinum resistant germ cell tumours 
(GCTs) compared to 100 controls. The authors found a correlation between dMMR 
(MLH1 and MSH2 loss) and the Cisplatin resistant tumours but found an improved OS 
in the MSI subgroup within the treatment resistant tumours [119]. Given the 
contradictory evidence regarding MMR status and response to platinum agents, larger 
scale prospective studies will be necessary to confirm whether there is a true 
relationship. 
 
The platinum agent, Oxaliplatin has not shown the same resistance in MMR deficient 
cells. This is thought to be due to the fact that the Oxaliplatin adducts are not 
recognised by the MMR system [114]. Oxaliplatin is part of the standard drug 




benefit of this combination in the setting of dMMR tumours had not been confirmed. The 
AGEO study carried out in 2016 has established the benefit of adjuvant Oxaliplatin 
based combination chemotherapy (FOLFOX) in stage III dMMR tumours [120].  
 
1.5.1.3!! Topoisomerase!inhibitors!and!anthracyclines!in!!dMMR!
To date there are preclinical studies showing both benefit [121], no additional benefit 
[122] and resistance [123] to topoisomerase inhibitors in MMR deficient cancer cell lines 
[85]. In vitro studies have shown impaired response of cells lines exposed to 
Doxorubicin, Epirubicin and Mitoxantrone in MSH2 and MLH1-deficient cell lines as well 
as an impaired sensitivity to Camptothecin and Topotecan in MHL1 deficient cells [123]. 
Jacob et al demonstrated an increased sensitivity of MLH1-deficient colorectal cancer 
cell lines to the drugs Camptothecin and Etoposide compared to MLH1-proficient cell 
lines [124]. It is thought that potential reasons behind these contradictory studies is due 
to differing secondary mutations in the cell lines used including MRE11 and RAD50. 
The clinical studies are confounded by the fact that Irinotecan is normally given with 5-
FU but one randomized phase III study which compared adjuvant 5-FU+Leucovorin to 
5-FU/leucovorin and Irinotecan (FOLFIRI) observed an improved 5 year disease free 
survival in the patients with MMR deficiency, in stage III CRC patients, who received 
Irinotecan based chemotherapy compared to the patients who had MMR proficient 
tumours [125]. A recent large prospective study (n=1254) which randomized patients 
with stage II and III CRC to receiving either 5-FU or FOLFIRI showed a contradictory 
conclusion to the study by Bertagnolli et al [125]. Klingbiel et al did not observe a 
significant advantage to giving adjuvant treatment to the patients with stage III disease 
and although there was an improved survival with chemotherapy in the stage II, setting 
there was no benefit in adding in Irinotecan [112].  
"
1.4.1.4!! Alkylating!agent!and!dMMR!
Alkylating agents including the drugs Temozolomide, Procarbazine and N-methyl-N'-
nitro-N-nitrosoguanidine (MNNG) are commonly used to treat lymphomas, brain 
tumours and sarcomas. They cause damage by modifying the N-7 and O-6 on guanine 
residues and this type of damage is repaired by several DNA repair pathways including 
the MMR pathway [126]. Most in vitro and in vivo studies have concluded that 




[127, 128].  Furthermore, MLH1-deficient cell lines have been shown to be resistant to 
treatment with MNNG [129].  
!
1.6.1!!The!mitochondrial!genome!
The mitochondrial genome is maternally inherited and present in multiple copies within 
a cell and in differing numbers per cell depending on the metabolic needs of the tissue 
type [130, 131]. Mitochondria have evolved to contain their own DNA (mtDNA), which is 
a small (16.6 kb), circular and encodes 37 genes. It has been established that on 
average mammalian cells contain 103-104 copies of mtDNA which undergo replication 
independently of nuclear DNA [132]. The majority of these genes (13 genes) are 
dedicated to producing components of the oxidative phosphorylation (OXPHOS) system 
and the remaining genes encode 22 tRNAs and two rRNAs [133]. The other proteins 
required for the proper functioning of the OXPHOS system come from nuclear encoded 
gene products of which there are in excess of 50 genes involved [4].  
!
1.6.2! Heteroplasmy!and!homoplasmy!
Studying mitochondrial genetics and mtDNA mutations is complicated by the fact that 
mitochondria can contain both mutant DNA in a situation known as heteroplasmy . The 
process of cell division results in a random distribution of mitochondria in daughter cells 
leading to either homoplasmy where there is majority wild type or mutant DNA or a 
mixture of both leading to heteroplasmy [134]. This concept was established as a 
consequence of the heterogeneity observed within families with mitochondrial diseases 
caused by the same mtDNA mutation.  Several studies have established the presence 
of mitochondrial mutations in human cancer but the significance of these mutations and 
their biological consequences are far from established and complicated by the presence 
of homoplasmy and heteroplasmy [132]. Park et al studied human cell lines carrying 
both homoplasmic and heteroplasmic mutations in the mitochondrial Complex I gene 
ND5 which have has previously been identified in a human CRC cell lines [5]. The 
authors established that there is a difference in tumour growth between the two cell 
lines with the heteroplasmic cell lines exhibiting enhanced growth and the homoplasmic 





The respiratory chain chain is located in the mitochondrial inner membrane and is 
compromised of five membrane bound enzyme complexes: Complex 1 (NADH–
ubiquinone oxidoreductase), Complex II (succinate- quinone oxidoreductase, CII), 
Complex III (cytochrome bc1, CIII), Complex IV (cytochrome c oxidase, CIV), Complex 
V ( F1FO-ATP synthase, CV) as well as two electron mobile carriers coenzyme Q and 
cytochrome C. The subunits of the respiratory chain are mainly encoded by nuclear 
DNA (approximately 70 subunits) with only 17 encoded for by mtDNA (Figure 1.5) [135]. 
These transmembrane complexes are able to undergo oxidation and reduction 
reactions because they have various oxidation-reduction centers, including quinones, 
flavins, iron-sulfur clusters, hemes, and copper ions. The transport of electrons between 
complexes takes place because of the mobile carriers coenzyme Q and cytochrome c 
[136]. The role of this system is to produce ATP by using the electrons from NADH2 and 
FADH2 produced during glycolysis, fatty acid oxidation and the citric acid cycle [137]. 
Glycolysis and the TCA cycle only yield approximately four molecules of ATP and the 
oxidative phosphorylation system produces the remaining 32 to 34 ATP molecules. The 
electrons from NADH initially enter Complex I and are then transferred to Complex III 
via flavin mononucleotide and the electron carrier coenzyme Q. Within Complex III the 
electrons are transferred from cytochtrome b to cytochrome c and finally to Complex IV, 
which ultimately transfers the electrons to molecular O2, which becomes reduced to form 
H2O . Complex II receives electrons from FADH2 rather than NADH and these electrons 
are also finally transferred to O2 via coenzyme Q, Complex III and Complex IV. The high 
energy electrons are transferred along the protein complexes within the electron 
transport chain in a series of redox reactions leading to the simultaneous pumping out 
of protons from the mitochondrial matrix and to the formation of an electro-chemical 
gradient [138]. Evidence suggests that the transfer of protons is either direct through 
protonation and de-protonation of  redox intermediates (Complex III and Complex IV 
use this method)  or indirect through conformational change of the complexes (Complex 
I and Complex V). It is estimated that approximately 10 protons are transported from the 








The! respiratory! chain! chain! is! composed! of! five! membraneFbound! complexes:! Complex! 1!
(NADH–ubiquinone!oxidoreductase),!Complex!II!(succinateF!quinone!oxidoreductase),!Complex!
III! (cytochrome!bc1),! Complex! IV! (cytochrome!c! oxidase),! Complex! V! (!F1FOFATP! synthase).!
These! OXPHOS! complexes! are! made! from! both! mitochondrial! and! nuclear! DNA! encoded!
subunits!apart! from!Complex! II! that! is!only!made!from!nuclear!DNA!encoded!subunits.!There!
are!two!electron!carriers!coenzyme!Q!(CoQ)! !and!cytochrome!c! (Cytc).!Electrons! from!NADH2!
and!FADH2!!(produced!during!glycolysis,!fatty!acid!oxidation!and!the!citric!acid!cycle)!undergo!a!
series! of! redox! reactions! leading! to! the! simultaneous! pumping! out! of! protons! from! the!
mitochondrial!matrix! across! the!mitochondrial! inner!membrane! (MM)! to! the! intermembrane!
space! (IMS)! forming! an! electroFchemical! gradient.! The! final! electron! acceptor! is! molecular!









The entire crystal structure of Complex I from the bacteria Thermus thermophilus at 3.3 
Å resolution was recently determined providing invaluable information about the 
organization and function of this indispensible respiratory enzyme in humans [140]. 
Complex I plays a vital role in the chain by enabling the transfer of two electrons from 
NADH to ubiquinone as well as coupling this to the translocation of four protons across 
the inner membrane [141, 142]. Complex I is the largest of the respiratory complexes 
and is made from at least 45 subunits of which 14 have been found to be ‘core’ subunits 
that are highly conserved from bacteria to humans strongly suggesting that the 
mechanism is also conserved [143-146]. These subunits are mainly coded for by 
nuclear DNA [147] and imported into the mitochondria [148] but there are seven 
mitochondrial encoded subunits [149].  
Bacterial and eukaryotic Complex I is an L shaped structure located within the 
mitochondrial inner membrane composed of a long hydrophobic transmembrane 
domain and a hydrophilic domain for the peripheral arm which protrudes into the 
mitochondrial matrix [150]. The structure of Complex I and our understanding of this 
complex enzyme has slowly been revealed through studies such as electron density 
mapping [151] and structural characterization at 3.8 Å of Yarrowia lipolytica [152], a 
cryo-EM map of bovine Complex I [152], a crystal structure of the membrane arm of E. 
coli at 3.0 Å [153, 154], a crystal structure of initially the  peripheral arm of T. 
thermophiles [155] and finally this year the entire crystal structure of Complex I at 3.3 Å 
resolution [140]. These studies have revealed that the key structures of Complex I is 
well preserved and therefore forms the basis of our understanding of the structure and 
function of the human form of the enzyme.  
 
The L shaped structure of Complex I comprises of the NADH-oxidizing dehydrogenase 
module (N module) which is connected to the Q module. The N nodule contains an 
NADH oxidation site with a FMN molecule, which accepts electrons and feeds them into 
a chain of Fe-S clusters. The Q module contains a ubiquinone reduction site and 
electrons from the N module are passed to this site [155]. The membrane arm consists 




in Thermus spp) which is the interface to the peripheral arm [156]. The two arms of 
Complex I are functionally and evolutionarily independent apart from the at their 










composed! of! a! peripheral! arm! and! a!membrane! arm.! The!membrane! arm! consists! of! the! P!
module!where!the!mitochondrial!encoded!core!subunits!are!situated!and!the!peripheral!arm!is!






Bacterial Complex I has 14 strictly conserved core subunits (Nqo1–Nqo14), which 
together are vital in effective Complex I function [140, 159]. The peripheral domain in T. 
thermophilus contains nine core subunits Nqo1-6, Nqo9, frataxin-like Nqo15 and 
possibly the chaperone Nqo16. The peripheral domain also contains FMN, 8-9 Fe-S 
clusters and finally quinone with its binding site at the junction with the membrane 
domain. The membrane arm is composed of seven subunits Nqo7, Nqo8 and Nqo1-14 
(Nqo12-14 are known as antiporter-like) [139].  
 
Bovine and human Complex I is made of 45 subunits and during the course of evolution 
30 additional supernumerary subunits were acquired resulting in a complex with a total 
molecular weight of 980kDa [143, 160]. There are seven mitochondrial encoded 
subunits ND1-6 and ND4L, all of which are core subunits [149]. There are 38 nuclear 
encoded subunits, which are transported into the mitochondria of which NDUFV1, 
NDUFV2, NDUFS1, NDUFS2, NDUFS3, NDUFS7 and NDUFS8 are core subunits. 
Over time, mammalian Complex I acquired 30 supernumerary subunits, the role of 
these has yet to be fully elucidated [147, 161] but is thought to involve biogenesis and 
stability of Complex I [147]. . Table 1.4 outlines the core subunits of Complex I in E.coli, 







Module Homo Sapiens E.coli T.thermophilus 
Peripheral arm 
N-module NDUFS1 NuoG Nqo3 
NDUV1 NuoF Nqo1 
NDUFV2 NuoE Nqo2 
Q-module NDUFS2 NuoD Nqo4 
NDUFS3 NuoC Nqo5 
NDUFS8 Nuol Nqo9 
NDUFS7 NuoB Nqo6 
Membrane arm 
    
P-module ND1 NuoH Nqo8 
ND2 NuoN Nqo14 
ND3 NuoA Nqo7 
ND4 NuoM Nqo13 
ND4L NuoK Nqo11 
ND5 NuoL Nqo12 
 ND6 NuoJ Nqo10 
Table!1.4!The!core!subunits!of!Complex!I!in!different!species.!






1.8.2! Electron! transfer,! proton! translocation! and! the! link! between! these!
processes!
The first step in T thermophilus oxidative phosphorylation involves NADH binding to a 
pocket in Nqo1 in the peripheral domain of CI allowing transfer of hydride ions to FMN 
followed by the transfer of one electron at a time to the Fe-S clusters and finally two 
electrons are transferred to the quinone binding site formed between subunits Nqo4, 
Nqo6, Nqo7 and Nqo8 at the interface between the peripheral domain and membrane 
domain [139]. The antiporter–like subunits in the transmembrane domain allow proton 
pumping due to the fact that they possess five helices which form a cytoplasmic half 
and periplasmic half channel [139].  
 
The mechanism that links electron transfer to proton translocation has not been 
elucidated and several models have been proposed including the direct model where 
there is direct binding through protein binding sites or the indirect model which proposes 
conformational changes to the enzyme [162]. The recent study solving the entire 
structure of Complex I in T thermophilus gave strength to the model that the mechanism 
most likely involves long-range conformational change. The proposed mechanism is 
that conformational changes at the interface of the matrix and membrane domains may 
drive proton translocation by moving the helical structure of the membrane domain into 
motion. [140, 163].  
 
The actual assembly of Complex I has been subject to numerous studies in many 
different types of organism but a conclusive model of how this takes place has yet to be 
established due to the complexity of the components that make up this enzyme and the 
fact that it is under both mitochondrial and genomic control [158]. A few studies have 
been conducted to ascertain the function of some of the Complex I subunits in the 
assembly process [164, 165]. For example, Yadava et al demonstrated in Chinese 
hamster cell lines the importance of the nuclear subunit NDUFA1 in the Complex I 
assembly process [165]. Experiments based on cell derived form Complex I deficient 
patients has revealed that the matrix and membrane arm of the complex are probably 
present together as intermediates early in the formation of the enzyme but this is in 
opposition to the model elucidated in N. crassa where the two arms are assembled 




Complex I deficiency is the most common of all respiratory chain defects [167]. Studies 
have revealed that mutations within all of the 14 core Complex I subunits, both 
mitochondrial and nuclear [168-170], can lead to Complex I deficiency and a 
heterogeneous group of clinical manifestations related to defects in energy metabolism. 
The most common mitochondrial disorder is the lethal infantile Leigh syndrome but 
other clinical presentations include adult-onset neurodegenerative disorders and 
myopathies [171, 172]. Ugalde et al examined fibroblasts from 15 patients with known 
mutations within nuclear encoded Complex I genes and demonstrated by isolating 
mitochondrial particles from these samples and carrying out BN–polyacrylamide gel 
separation of multisubunit complexes that these patients had decreased levels of intact 
Complex I and a corresponding decrease in Complex I activity using an in-gel activity 
assay. Furthermore, there was also a decrease in Complex III levels in patients with 
mutations in NDUFS2 and NDUFS4 [173]. Several other groups have described 
deficiencies in Complex I and III simultaneously in patients with specific mutations in 
Complex I genes [174]. The converse observation of Complex I deficiency in a patient 
with Complex III mutations has also been demonstrated [175]. Further analysis 
investigating Complex I and III deficiency have shown that there is likely a physical 
interaction between these complexes, which could explain why they can affect the 
stability of one another [174, 176].  The interaction of mitochondrial respiratory chain 
complexes has been investigated in several species and the concept of an association 
to form higher supramolecular structures called supercomplexes or respirasomes has 
been established. Schagger et al carried out experiments in bovine heart mitochondria 
and established the association of Complex I+III and Complex I+III+IV [177]. 
Furthermore, similar experiments in human mitochondria revealed supercomplexes of  
Complex I+III and I+III+IV but only Complex I+III was required for the stability of other 
respiratory complexes [178, 179].  
 
Although the role of the supernumerary complexes is unclear, mutations within these 
genes with a corresponding decrease in Complex I function have also been identified. 
Francis et al have demonstrated in a mouse model of Alzheimer’s disease that these 
mice had decreased expression of the supernumerary Complex I subunit NDUFB8 and 






A major challenge in cancer therapeutics is to develop specific therapies to target 
genetically distinct tumour types. The potential of therapy based on targeting the 
underlying genetic defects driving cancer is that it may cause selective killing of tumour 
cells while sparing normal cells, resulting in both increased efficacy and reduced 
toxicity. The identification of synthetic lethal interactions represents an attractive 
approach for targeting many of these defects. Two genes are said to have a synthetic 
lethal relationship if a mutation in either gene alone is compatible with viability but a 
mutation in both results in cell death [181]. The concept of synthetic lethality has been 
used in the clinical setting with PARP inhibitors in the treatment of BRCA deficient 
tumours. PARP1 is an important member of the BER pathway but PARP1-/- mice have 
been found to be viable [182, 183]. In the absence of PARP1 the increased formation of 
SSBs and collapsed replication forks has been shown to trigger the HR pathway to 
maintain genetic stability. Tumours deficient in the tumour suppressor genes BRCA1 
and BRCA2 which are key members of the HR pathway are highly sensitive to PARP 
inhibition [184]. The mechanism behind this synthetic lethal relationship has been 
established to be due to the fact that BRCA deficient tumours are unable to carry out 
DNA damage repair through the HR pathway when treated with PARP inhibitors leading 
to unrepaired collapsed replication forks and cell death [185]. In an analogous fashion 
to using inhibitors of the DNA repair protein, PARP, in the treatment of patients with 
germline mutations in the tumour suppressor genes BRCA1 and BRCA2, targeting 
genes that are synthetically lethal with MMR deficiency could result in selective killing of 
MMR deficient cells and therefore could be therapeutically beneficial.  
  
1.10.2! Synthetic!lethality!and!the!MMR!pathway!
Our group is interested in identifying synthetic lethal targets with MMR deficient cancers 
and have shown that silencing of the mitochondrial DNA polymerase POLG (involved in 
the repair of 8-oxoG lesions in the mitochondria) is synthetically lethal with MLH1 
deficiency [79]. This synthetic lethal interaction was associated with an increase in 
oxidative DNA lesions (8-oxoG) in the mtDNA only. Strikingly, MSH2 deficient cells 




nuclear polymerase POLB, which was associated with an increase in nuclear 8-oxoG 
(Figure 1.3) [186]. The authors also established that there was a decrease in mtDNA 
integrity in the MLH1-deficient cells compared to the proficient cell lines. Furthermore, 
by fractionating cellular protein into mitochondrial and nuclear components, MLH1 was 
found to be expressed in both the mitochondria and nucleus but MSH2 was only 
expressed in the nucleus [79]. Other mitochondrial proteins not involved in DNA repair, 
namely the kinases CKMT2, PCK2, and PINK1 (Figure 1.3) were also found to be 
synthetically lethal with deficiencies in a range of MMR genes (MLH1, MSH2 and 
MSH6) due to an accumulation of both nuclear and mitochondrial oxidative DNA 
damage [187]. Using a similar approach, our group screened a compound library and 
established that MSH2-deficient cell lines in vitro and in vivo are selectively lethal to 
treatment with the oxidative damage-inducing agent, methotrexate [188]. These findings 
have been taken into the clinic as a Phase II clinical trial (ClinicalTrials.gov Identifier: 
NCT00952016) in the metastatic colorectal cancer population, at the Royal Marsden 
Hospital, London.  
!
1.10.3! Synthetic!lethality!and!cancer!cell!metabolism!
The concept of using synthetic lethal approaches to target cancer cell metabolism is 
gaining an increasing amount of interest. Several metabolic enzymes with somatic 
mutations have been identified in cancer cells leading to research identifying targets to 
achieve selective cell death in these cells. The tumour suppressor fumarate hydratase 
has been found to be synthetically lethal with several genes in the heme biosynthesis 
pathway [189] as well as with adenylate cyclase [190]. Argininosuccinate synthase 1 
(ASS1) is the rate-limiting enzyme for arginine biosynthesis and is known to be deficient 
in a range of tumour types including approximately 50% of malignant pleural 
mesotheliomas (MPM) and malignant melanomas [191]. Synthetic lethal targeting of 
ASS1-deficient tumours with the arginine-depleting agent ADI-PEG20  has been found 
to be a useful therapeutic strategy in vivo and has been tested with promising results in 
metastatic melanoma [192] as well as in an ongoing study in MPM (ClinicalTrial.gov 
Identifier: NCT01279967) [193]. More recently Locke et al investigated resistance 
mechanisms in ASS1-deficient tumours and generated an MPM cell line resistant to 
ADI-PEG. The investigators identified that this cell line and serum from patient samples 




metabolism (decreased levels of acetylated polyamine metabolites and increased 
expression of polyamine biosynthetic enzymes) which could be exploited in ADI-PEG20 
resistance [194]. The AMPK agonist Metformin has been found to have a synthetic 
lethal relationship with glucose starvation in vitro highlighting the potential for exploiting 
this metabolic synthetic relationship [195]. The drug Dichloroacetate has been found to 
selectively kill cancer cells in solid tumours through enhancing tumour hypoxia by 
increasing pyruvate consumption in the mitochondria and total oxygen consumption 
[196]. Interfering with tumour bioenergetics by using a combined drug approach of 
treating cancer cells in a mouse xenograft model with metformin and the glycolysis 
inhibitor 2-deoxy-D-glucose (2DG) which both interfere with energy pathways causes 
selective cell death in these cells [197]. High throughput siRNA [190, 198], drug and 
genetic screens [199] have identified a range of potential metabolic targets in cancer 
cells including the metabolic enzymes isocitrate dehydrogenase 1 [200], fumarate 











Figure! 1.3:! Accumulation! of! oxidative!DNA!damage! causes! synthetic! lethality! in!MSH2! and!
MLH1Tdeficient!cells.""
(A)!Silencing!of!the!genes!PINK1,!POLB!or!treatment!of!cells!with!the!chemotherapeutic!drug,!
methotrexate! leads! to! selective! cell! death! in! MSH2! deficient! cell! lines! through! increased!
oxidative!DNA! damage! ! (8FoxoG! lesions! in! DNA)!which! can! be! successfully! repaired! in!MMR!
proficient! cells.! (B)! Silencing! of! PINK1! or! the! mitochondrial! gene! POLG! causes! selective! cell!
death!in!only!the!MLH1Fdeficient!cell!lines!and!not!the!MSH2!deficient!cells.!!More!specifically,!
in!MSH2!deficient!cell!lines!(A)!there!is!an!accumulation!of!nuclear!oxidative!DNA!lesions!and!in!









ROS is the term used for a group of molecules containing oxygen and are generally 
known to have reactive properties [203].  Cellular components, such as lipids, proteins 
and nucleic acids, are continuously exposed to endogenous and exogenous ROS, 
which potentially pose a threat to the stability of the genome. ROS are divided into two 
main groups: radicals and non-radicals. The radicals include the most reactive species, 
which is the oxygen-derived hydroxyl radical (HO•) as well as the intermediate or weakly 
reactive species, the superoxide anions (O2•-), hydroperoxyl radicals (HO2•), peroxyl 
radicals (RO2•), alkoxyl radicals (RO•), nitric oxide (NO•) and singlet oxygen (1ΔgO2) 
Nitric oxide is itself not reactive but can react with O2•- to form peroxynitrite (ONOO-) and 
eventually its protonated form peroxynitrous acid (ONOOH), which can in turn yield the 
highly reactive HO• or NO2• [204]. The main non radical is hydrogen peroxide (H2O2) 
which is generally weakly reactive but can react with transition metal ions to form the 
more reactive HO• [205] . 
 
The majority of ROS found in aerobic cells are generated during normal cellular 
metabolism in processes, which require oxygen, mainly in the mitochondria, 
peroxisomes and endoplasmic reticulum [203]. The mitochondria has been established 
to be the main site of ROS production since 2% of the oxygen used by the mitochondria 
becomes reduced to generate superoxides [203]. The tricarboxylic acid cycle (TCA) is 
composed of several enzymes in the mitochondrial matrix, which pass electrons from 
intermediary metabolites to the electron transport chain (ETC). The ETC has the 
potential to form ROS at several points in the pathway as electrons are passed through 
the series of enzymes using flavin adenine dinucleotide (FAD) or flavin mononucleotide 
(FMN) as carriers [206].  ROS is generated when electrons become ‘stuck’ on the flavin 
group. There are many mitochondrial proteins aside from those of the TCA cycle which 
use flavin containing groups and there is potential for ROS formation at all these sites 
[207]. Some enzymes also use iron-sulphur clusters as electron carriers and ROS can 
also be formed here in a similar manner to that described above with flavin containing 
groups [208]. The energy source for all cells, ATP, is generated in the mitochondria 




cycle and glycolysis being passed from NADH and FADH2 along a series of five protein 
complexes in the ETC [135]. The ETC is inherently leaky and electrons can escape and 
form O2• when they become trapped by O2. It is thought that the main sites of ROS 
generation are at Complex I, II and III since these are proton pumps [207]. Furthermore, 
Ubiquinone (coenzyme Q) is also a site for ROS generation since this inner membrane 
quinone transports electrons to Complex III from various sources including Complex I 
and II [207]. Certain enzymes can generate ROS as a result of the reactions they 
catalyze, these include NADPH oxidase, arachidonic acid and several metabolic 
enzymes including cytochrome p450 enzymes [203]. ROS can also be produced as part 
of the inflammatory response by neutrophils, eosinophils and macrophages [209]. In 
addition, ROS may also be generated by exogenous agents such as UV exposure, 
ionising radiation, carcinogenic compounds and redox-cycling drugs [210]. 
 
Maintaining optimum ROS levels is essential for cellular homeostasis since there is a 
fine balance between the levels of ROS required for cell signaling, proliferation, 
differentiation, activation of the inflammatory response and the excess ROS levels that 
are deleterious for DNA, protein and lipids [203].  
"
ROS species cause oxidative DNA damage which is a term used to describe the 
resulting damage when ROS alter DNA bases and sugar backbones resulting in DNA 
modifications [205]. The antioxidant defense system, which is the first line of defense 
protecting cellular components from ROS, is described in detail later in this introduction 
chapter. The majority of superoxide anions are converted into the less reactive H2O2 by 
superoxide dismutases (SOD) but a proportion may react with nitric oxide to form 
ONOO-, a very strong oxidant [211]. Superoxides which have managed to evade 
dismutation can form hydroxyl radicals through the Harber-Weiss reaction and H2O2 can 
also form the highly reactive hydroxyl species by reacting with Fe2+ [211]. Hydrogen 
peroxide is highly diffusible through different cellular compartments but possesses low 
chemical reactivity and therefore is only directly responsible for modifying proteins via 
thiol groups [209]. The HO• is the oxidant species that poses the biggest threat to DNA, 
given that it reacts with both purine and pyrimidine bases and the sugar moiety of the 
DNA backbone. Furthermore there are to date no known enzymes or other neutralizing 






The hydroxyl radical causes DNA damage by its ability to add to the double bonds of 
DNA bases as well as remove hydrogen from thymine and the C-H bonds of 2’-
deoxyribose [212]. Additional reactions with purines generate C4-OH-, C5-OH- and C8-
OH-adduct radicals of guanine and adenine [213] and reactions with the pyrimidines 
form C5-OH- and C6-OH-adduct radicals of thymidine and cytosine [214]. Thymidine 
can also form an allyl radical when a hydride anion (H•) is removed from its methyroup 
[215]. Downstream oxidation and reduction reactions of these radical intermediates 
result in a plethora of DNA lesions, including the most studied of oxidative lesions, the 
purine derivatives 8-oxoguanine (8-oxoG), 8-OH-Ade , 2,6-diamino-4-hydroxy-5-
formamido-pyrimidine (FapyGua), and the oxidised pyrimidines cytosine glycol and 
thymine glycol (Figure 1.4) [205]. The intermediary lesions resulting from oxidative DNA 
damage repair such as apurinic and apyrimidinic (AP) sites also pose a threat to the cell 
[216]. The hydroxyl radical can also attack all five carbons of 2’-deoxyribose and further 
processing of these lesions yields products incorporated within DNA, released from 
DNA or broken DNA strands bound to DNA. These lesions then have the potential to 
form DNA strand breaks [205, 209]. 8-oxoG is the most stable DNA lesion and can 
mispair with adenine [124,125] and less frequently it can pair with the original cytosine 
[217]  during DNA replication. Increased 8-oxoG levels have been reported in numerous 
in vitro and in vivo experiments when cultured cells and animals are exposed to 
oxidative stress [216].  The pairing of 8-oxoG and FapyGua with adenine has been 
shown to be pre-mutagenic and result in the mutagenic G:T transversions both in vivo 
[218, 219] and in vitro [220]. On the other hand, the less frequent event of  8-oxoG 
pairing with cytosine has not been shown to result in mutations [221]. Kalaman et al 
have shown that in Simian kidney cells FapyGua result in G:T transversions more 
frequently than 8-oxoG [217]. The other purine derived molecule 8-OH-Ade can pair 
with thymine as well as mispair with guanine and adenine [222] but the resulting 
mutations have been shown to be weakly mutagenic in simian kidney cells [217] and 
have been shown to cause A:G and A:C transversions mutations at a rate of 
approximately 1% [223]. Deamination and dehydration of the pyrimidine cytosine glycol 
to form 5-OH-Cyt and uracil glycol to form 5-OH-URa which can then mispair with 
adenine, have been found to result in C:T transitions [205]. Thymine glycol is much less 




frequently pair with guanine to result in T:C transitions [225]. Feig et al investigated the 
lesions that occur as a result of oxidative DNA damage by developing a ROS 
generating system and then inserting the formed products into DNA containing a target 
gene for scoring of mutations [226]. They found that the most frequently occurring 
mutagenic species as a result of oxidative damage was 5-hydroxy-2’-deoxycytidine and 
this caused C:T transversions in E.Coli at a rate of 2.5% [226]. It is clear that oxidative-
induced DNA lesions are mutagenic and therefore the antioxidant defense system, as 
well as DNA repair mechanisms has evolved to try and minimize the damage that ROS 

































Oxidative DNA damage is a very common event and therefore it is not surprising that 
this form of DNA alteration has been studied in relation to the aetiology and progression 
of cancer. Sequencing of a large range of cancer genomes over several tumour types 
showed that C:T transitions are the most commonly occurring mutation found in human 
tumours and in the tumour suppressor gene TP53 and a proportion of these mutations 
can be attributed to oxidative DNA damage [227, 228]. Chronic oxidative stress, 
especially in the context of chronic inflammation, has been linked to carcinogenesis. 
One of the most well-described causal relationships with cancer and oxidative stress is 
that between ulcerative colitis and colorectal cancer. The evidence suggests that 
cancer-causing genes are altered in this disease due to the production of ROS by 
inflammatory mediators [229, 230]. To date many studies examining oxidative DNA 
lesions in malignant cells or tissues from a wide variety of tumours compared to 
matched normal samples have found higher levels of 8-oxoG and other markers of 
oxidative stress in the cancerous samples [231-234]. More specifically, Gackowski et al 
illustrated that the levels of 8-oxoG by high performance liquid chromatography were 
significantly higher in lymphocytes from blood samples taken from 43 patients with 
colorectal cancer 55 control subjects [235]. Furthermore, the levels of (antioxidant 
vitamins (vitamin E (α-tocopherol), vitamin A (retinol) and vitamin C ) was lower in the 
colorectal cancer samples compared to controls [235]. Olinski et al have shown that the 
size of benign uterine myomas was positively correlated with levels of 8-oxoG lesions 
and it is well known that the larger the myoma the greater the risk of malignant 
transformation [231, 236]. Malins et al have also shown a positive correlation between 
metastatic potential and levels of oxidative DNA lesions in breast cancer [237].  
 
Nowsheen et al examined the levels of oxidatively induced clustered lesions (OCDLs) 
across several tumour types compared to match surrounding tissue [238]. In most 
cases there was an increase in OCDLs in the tumour tissues although the authors did 
remark on the fact that this was not always in a uniform manner across all samples from 
the same tumour type. The authors of this study discussed some limitations, which are 
key to the controversy surrounding the measurement of oxidative DNA lesions in cancer 
tissue and establishing a conclusive link between these lesions. The authors of this 




fact that tumour tissues may have endogenously high background levels of OCDLs due 
to factors such as impaired DNA repair, attenuated antioxidant capacity, increased 
cellular metabolism and higher ROS levels due to a chronic inflammatory 
microenvironment [238, 239]. Alterations within established tumours has been shown to 
induce an inflammatory environment and in some tumours this inflammatory 
environment is present before the malignant transformation occurs [240] leading to an 
accumulation of inflammatory cells and increases in ROS production and oxidative 
stress [241]. In breast cancer ROS levels have been found to be elevated because of 
exposure to oestrogen [242]. All the factors mentioned above mean that establishing a 
direct relationship between oxidative DNA damage and cancer in general is difficult. 
Investigators within the field of oxidative DNA damage have concluded that at the very 
least malignancy and oxidative DNA lesions exist in parallel and furthermore most 
evidence does point to a relationship between the two, but it seems to be context 
dependent rather than related to cancer as a whole [231].  
  
Furthermore, it is important to note that most investigators are cautious about potential 
inaccuracies in studies measuring levels of oxidative DNA damage due to the problems 
with measuring oxidative DNA lesions accurately. It has been estimated by various 
experimental studies that the background level of oxidative DNA lesions in normal 
human or animal cells and tissues is anywhere between 100-10,000 lesions/Gbp [241, 
243, 244] but controversy still exists about this topic [245]. The most obvious problem 
with measuring oxidative DNA damage lesions is that DNA extraction inevitably leads to 
some amount of unavoidable oxidation, which can result in unreliable results [231]. The 
European Standards Committee on Oxidative DNA Damage (ESCODD) examined the 
testing of 8-oxoG in various different types of samples in different laboratories using a 
variety of methods [245]. The main methods available for testing are chromatographic 
methods (GC-MS, HPLC with electrochemical detection (ECD) or HPLC-MS/MS) and 
immunoassays. They established that each method had its own weaknesses and 
strengths but some of the chromatographic methods displayed artefactual oxidation 
whilst the immunoassays lacked specificity. The study group concluded that there is still 







BER is largely responsible for the repair of oxidative DNA damage and to a lesser 
extent NER [209]. Both these pathways differ in the size of lesions that they repair and 
function by excising DNA lesions before instigating polymerase and ligase activity to fill 
in the resultant gap [246, 247].  
!
1.12.1! Base!excision!repair!(BER)!repair!of!nuclear!oxidative!DNA!damage!
Base excision repair is a highly conserved pathway that has evolved to repair non-bulky 
small nucleotide lesions such as bases that have been incorporated into DNA 
erroneously or damaged bases such as 8-oxoG [246]. The main steps involved in BER 
are: removal of the damaged base and creation of an abasic site as an intermediary 
molecule, end-processing of the DNA, filling the resulting gap with a polymerase and 
sealing the nick with a DNA ligase [248]. The repair of damaged DNA in BER is divided 
into short patch (SP) and long patch (LP) repair. The former is involved in the repair 
process if the removal of the damaged base results in a free 3’hydroxyl on one side 
which can be filled by a DNA polymerase and a 5’ phosphate on the other side to ligate 
to the new base [249]. Long patch repair is used in circumstances where a 5’ end is 
created, which cannot be ligated to the newly created base [249]. The first step in BER 
repair is the recognition of the damaged base by DNA glycosylases. The glycosylase 
will depend on the base to be excised. These include uracil-DNA glycosylase (UNG), 8-
oxoguanine DNA glycosylase (OGG1), MutY homolog (MUTYH), endonuclease three 
homolog 1 (NTHI) and NEI endonuclease VIII-like 1, 2 or 3 (NEIL1/NEIL2/NEIL3). 
These enzymes recognise different single base lesions (Figure 1.4). DNA glycosylases 
need to recognise damaged bases from undamaged bases to carry out their function 
[250]. Several mechanisms describing how glycosylases recognise DNA damage have 
been proposed including the fact that they can easily recognise damaged DNA double 
helix structures by moving along DNA slowly using a Phe residue as a wedge to look for 
damaged DNA [251]. However, it is still unclear how these enzymes recognise lesions 
such as guanine oxidation, which do not change DNA. Ultimately to actually reach the 
damaged base the glycosylases scan along and gently pinch the DNA causing it to 
bend at the site of a damaged base, which flips out of the double helix and enters the 




base and the 2’-deoxyribose is cleaved, generating an apurinic- or apyrimidinic- (AP) 
site [252]. For SP-BER the AP-sites must be further processed by an endonuclease, 
most commonly APE1, to create the correct 3’ and 5’ ends that allow DNA polymerase 
beta (Polβ) in the nucleus to remove the remaining sugar backbone of the damaged 
DNA base using its dRP lyase activity [246]. After this step de novo DNA synthesis can 
take place from the 3’ hydroxyl group and finally DNA ligase I (LIG1) can ligate the 
nascent base. SP-BER only allows the incorporation of a single nucleotide. The LP- 
BER allows the incorporation of multiple bases [249] and nucleotide synthesis occurs by 
Polβ, Pol δ and Polε in association with PCNA [253]. A substrate which can be ligated is 
created by these polymerases forming a ‘flap intermediate’ at the 5’ end of the DNA 
which is then removed by the nuclease flap endonuclease 1 (FEN1) resulting in a 
ligatable substrate [254]. There are numerous factors determining whether SP-BER or 
LP-BER takes place and these include the ATP concentration available after POLB has 
exerted its lyase activity since high concentrations usually lead straight to ligation but 
low concentrations of ATP are less likely to favour ligation Other factors include the 
initial type of lesion, stage of the cell cycle and certain lesions are resistant to Polβ 
activity [249]. The nick in the DNA is sealed by LIGI in the case of LP-BER and 
LIGIIIα/XRCC1 in SP-BER [205, 248, 255]. 
!
1.12.2! Nucleotide!excision!repair!(NER)!and!nuclear!oxidative!DNA!damage!
Whilst BER acts to repair individual nucleotides, the NER system generally removes 
large DNA-distorting lesions such as intra-strand crosslinks, tandem lesions and bulky 
adducts [205]. NER has been described to repair certain single nucleotide oxidatively-
induced lesions such as thymine glycol [256], 8-oxoG [257] and 8,5’-cyclopurine-2’-
deoxynucleosides [258, 259], the latter of which cannot be repaired by BER due to the 
8,5’-covalent bond. Nucleotide excision repair has two main mechanisms by which it 
carries out repair: global genome repair (GGR-NER) which is associated with repair of 
the entire genome and transcription coupled repair (TCR-NER) for the repair dedicated 
to transcribing repair strands. This occurs either during normal surveillance of the 
genome or specifically on transcribing DNA strands [260]. The primary step in NER is 
the recognition of the site of damage and this is carried out in the GGR-NER pathway 
by the protein complex composed of XPC-hHR23B together with XPE. In TCR-NER the 




DNA lesion and when the Cockayne syndrome proteins (CSA and CSB) are present 
[261].  The subsequent steps in both the GGR-NER and TCR-NER pathways are 
similar. Once the section of damaged DNA has been identified the XPC-hHR23B 
complex brings TFIIH to the site of DNA damage. Also, for both pathways a protein 
complex of XPA-RPA is formed and is necessary for recruiting the downstream protein 
necessary for NER repair. XPA-RPA in association with TFIIH and its two helicase 
subunits XPB and XPD enable the unwinding of the DNA helix around the damaged 
lesion[262]. Two incisions either side of the lesion are made by the endonuclease 
activity of XPG cutting 3’ to the lesion and a complex composed of XPF-ERCC1, XFG 
and XPA-RPA cutting 5’ to the lesion [263]. In a similar fashion to BER, the final steps 
of excision and DNA synthesis to fill the single strand gap is carried out by polymerases 
(δ and /or ε) and the resulting gap at the 3’ is filled by DNA ligase I [205, 264]. The 
single base lesions repaired by BER and NER are highlighted in Figure  1.4 
 
The DNA glycosylases involved in oxidative DNA damage repair have been shown to 
target specific oxidative DNA lesions [248] . Various in vitro and in vivo studies have 
shown that the nuclear human OGG1 and the mitochondrial targeted β-hOgg1 have a 
major role in the recognition of 8-oxoG. Although studies in E.Coli demonstrated that 
OGG1 also recognises FapyGua lesions, this was not found to be the case in 
eukaryotes [265]. Mambo et al investigated 8-oxoG levels in 18 lung cancer and three 
control cell lines and found overexpression of this hOGG1 in most cases but two of the 
eighteen tumour samples had decreased protein and mRNA expression of OGG1 
compared to the normal samples [266]. Furthermore the two samples with low levels of 
OGG1 displayed a significant attenuation of 8-oxoG removal in both nuclear and 
mitochondrial extracts. Despite these findings, Ogg1-/- mice did not exhibit tumour 
formation even though the levels of 8-oxoG and G:T transversions were increased 
[266]. The DNA glycosylases NEIL1 and NTH1 were investigated by developing Neil1-/-, 
Nth1-/- and double mutant mice. During the second year of the experiment up to 16% of 
the Neil1-/- and Nth1-/- mice developed tumours and in the double mutant, mice 75% 
developed tumours [266]. Furthermore, when oxidatively induced lesions were 
measured in these animals, the levels of FapyAde (in the liver, kidney and brain) and 
FapyGUA (liver and kidney) but not 8-oxoG was raised in the the Neil1-/- and double 
mutant animals. The Nth1-/- mice only displayed an accumulation of FapyAde in the  




cancer has not been studied in detail [205]. Mice that lack the DNA glycosylase Ape1 
are characterised by early embryonic lethality and the Ape1 heterozygotes exhibit 
increased oxidative stress, carcinogenesis and decreased survival pups [268-270]. 
Several studies have demonstrated the overexpression of APE1 in tumour tissue and 
furthermore its association with treatment resistance [271-273]. Many variants of APE1 
exist and there are some studies suggesting that certain variants are associated with 
cancer [274, 275] but to date there is no conclusive evidence linking carcinogenesis to a 
particular variant [276, 277]. Mutations in the nuclear DNA polymerase Polβ have been 
shown to present in a range of human tumours [278-280].  Structural studies of Polβ 
have revealed that it binds to 8-oxoG at its active site. It has been found to insert both 
cytosine and adenine depending on the sequence context [281]. There is a paucity of 
studies looking at the role of Polβ with other oxidative DNA lesions. Several 
polymorphisms of Polβ have been linked to certain types of cancer [280, 282] and to OS 
in pancreatic adenocarcinoma. Li et al demonstrated an improved survival (35.7 months 
versus 14.8 months) for patients carrying at least one of the two homozygous variant 
Polβ GG or CC genotypes compared with those carrying the AA/AG or TT/TC 
genotypes in 378 human pancreatic adenocarcinomas[283].   
!
1.13! MMR!and!oxidative!DNA!damage!
It is widely accepted that BER and NER are the primary DNA repair pathways 
responsible for the repair of oxidative DNA damage [205]. There is however a growing 
body of evidence implicating the MMR system in the repair of oxidative DNA damage 
and this is possibly linked to carcinogenesis due to an accumulation of oxidative DNA 
damage in the context of MMR deficiency [284, 285].  
  
An early study in 1998 in mice demonstrated that mouse embryonic stem (ES) cells 
deficient in MSH2 (Msh2+/- and Msh2 -/-) had much higher levels of genomic 8-oxoG 
both at baseline and in response to low-levels of ionizing radiation, compared to wild-
type controls [286]. A subsequent study by Colussi et al showed that baseline and H202-
induced 8-oxoG levels were much higher in extracted DNA from MSH2 deficient mouse 
embryo fibroblasts (MEFs), MSH2 deficient cells lines and MLH1-deficient cell lines 




oxoG from the oxidised dNTP pool incorporated into DNA. Furthermore, overexpressing 
the hydrolase MTH1 that normally sanitizes the dNTP pool of 8-oxoGTP, reduced the 
levels of oxidative DNA lesions in the MMR-deficient mouse cells, in comparison to the 
proficient cells. MTH1 over expression also resulted in a decrease in the mutator 
phenotype in MSH2 deficient MEFs [287]. 
 
Another study that adds to the current evidence implicating the MMR pathway in the 
repair of oxidative DNA damage was carried out in Helicobacter pylori (H. pylori) since 
the inflammatory stress response that occurs after infection by this organism in the 
gastric mucosa results in an increase in ROS [205]. The investigators showed that mutS 
mutant variant H.pylori were more sensitive to ROS inducing drugs including H2O2 and 
had increased 8-oxoG accumulation when exposed to oxidative stress, in comparison to 
wild type mutS [288]. Mazurek et al. further elucidated the distinct roles of the MMR 
proteins in oxidative repair by showing that MutSα, but not MutSβ is activated by the 
presence of a mismatched 8-oxoG lesion [289]. Furthermore, MutSα was able to bind 
different mismatches with differing affinities: 8-oxoG/T>8-oxoG/G>8-oxoG/A>8-
oxoG/C≈G/C. This finding illustrated that in the context of oxidative DNA damage, 
MutSα is only activated by mismatched DNA. They also demonstrated that this 
activation occurred because binding of the mismatched DNA caused ATP-ADP 
exchange due to ATPase activity of MutSα.  Given the observed variations in the ability 
of MutSα to recognize different mismatch lesions, it is thought that the MMR system will 
continually excise an 8-oxo-G lesion and re-synthesise new DNA until a C is inserted 
opposite the lesion because MMR is not activated by an 8-oxo-G/C pair [289]. 
 
As mentioned above, we have observed a synthetic lethal interaction upon increased 
oxidative DNA damage in MMR deficient cells, further suggesting a role for the MMR 
proteins in the repair of oxidative damage [79, 187] 
 
1.13.1! BER!and!MMR!
Studies in yeast and in vivo work have shown that both the BER and the MMR pathway 
contribute to the repair of oxidative DNA damage. The experiments in S. cerevisiae by 
Ni et al identified increased mutation rates due to G:C-to-T:A transversions in combined 




Russo et al found increased 8-oxoG lesions in the spleen, liver, heart, lungs, kidneys 
and small intestine of Msh2−/− mice compared to their wild-type controls [285]. A more 
recent study conducted by the same group aimed to investigate whether MUTYH (a 
BER protein) and MSH2 have overlapping or independent roles found a disparity in in 
vitro compared to in in vivo models. There was no difference in the levels of 8-oxoG 
lesions in double mutant MEFs in vitro but there was a synergistic increase in 8-oxoG in 
some of the organs of double mutant animals compared to single mutants. The authors 
concluded that in vivo, MSH2 and MUTYH act independently and both contribute 
significantly to the repair of oxidised lesions. They proposed that the disparity seen in 
vivo compared to in vitro is due to the higher percentage of proliferating cells in vitro. Gu 
et al conducted a study to allow a more in-depth understanding of how the MMR system 
and BER may be working together which concluded that MUTYH physically associates 
with MutSα via MSH6. In addition, they demonstrated that the role of MutSα is to 
enhance the BER mediated excision of 8-oxoG/A mismatched lesions.  The authors 
speculate that protein-protein interactions may be how the BER and MMR make contact 
to reduce replicative errors caused by oxidative damage [291]. 
 
1.13.2! MMR!and!oxidative!damage:!relevance!to!carcinogenesis!
Given the dual function of MMR in removing both incorrectly placed bases and 
oxidatively damaged nucleotides, it is inherently difficult to dissect a separate impact of 
these two roles upon cancer development. The mutator phenotype is clearly the driving 
force behind carcinogenesis in many MMR deficient tumours but does reduced 8-oxoG 
removal also contribute, either via increased MSI or independently?  
 
Few studies have examined the specific role of oxidative damage repair by the MMR 
pathway in relation to tumourigenesis. Colussi et al. tested to what extent oxidative DNA 
damage played a role in the MMR mutator phenotype by expressing MTH1 in MSH2 
deficient MEFs; the resulting decrease in DNA 8-oxoG levels translated into a decrease 
in the mutator effect [287]. Glaab et al. reported that growing the MLH1-deficient CRC 
cell line HCT116 in the antioxidant ascorbate, both with and without H2O2 treatment, 
significantly reduced mutation rates and reduced MSI by 30% [292]. Conversely, it has 
been suggested that MLH1-deficient, HCT116 cells are less sensitive to H2O2 than their 




impaired apoptotic response in the HCT116 cells, suggesting that MMR is required for 
the recognition of severe oxidative damage and subsequent signalling to the apoptotic 
machinery. Our data suggest that MSH2 deficient cells are more sensitive to treatment 
with H2O2 [188]. It has recently been shown in a model for oxidative damage-induced 
tumours that loss of MSH2 significantly increased the formation of epithelial tumours in 
the small intestine [294]. Upon treatment with potassium bromate, Msh2 -/- mice 
displayed a 22.5-fold increase in tumour incidence [85, 294].  
 
The evidence thus far suggests that the MMR system may suppress carcinogenesis in 
the context of oxidative damage by directly repairing ROS induced DNA lesions or 




Mitochondrial BER is similar to the nuclear pathway described above but there are 
some important differences that need to be noted. The majority of nuclear proteins 
involved in BER are soluble and after the activation of DNA damage response pathways 
they move to sub-nuclear foci. In the mitochondria the BER proteins are located in the 
inner mitochondrial membrane so DNA has to localise to this membrane to be repaired 
[295]. The BER proteins do not localise to the inner membrane in a DNA related fashion 
and studies have shown that the BER components are still present even in 
mitochondria with no DNA [295]. The four known glycosylases in the mitochondria that 
participate in BER are OGGI, NTHI, NEIL1 and NEIL2 [250]. Gap filling and DNA 
synthesis in the mitochondria is thought to be carried out by Pol γ and more specifically 
Pol γ1 for single nucleotides. This polymerase like Polβ has dRP lyase activity and can 
change 5’dRP residues to 5’phosphate which are ligatable [296]. In mitochondrial-LP-
BER it is thought that the nuclease helicase DNA2 stimulates the DNA synthesis activity 
of Pol γ [248]. 
 
No definitive role for the NER pathways has been established in the mitochondria to 
date. A recent study by Pohjoismaki et al carried out genome wide transcriptional 




DNA repair proteins including the NER proteins XPA and RAD23A in relation to 
increased oxidative damage during cardiac mitochondrial biogenesis [297]. 
 
1.14.2! DNA!break!repair!in!the!mitochondria!
DNA strand breaks occur in DNA as a consequence of endogenous and exogenous 
damage including oxidative DNA damage. Single strand breaks are known to be the 
result of oxidative damage to sugar moieties, erroneous BER repair and collision of 
topoisomerase I with RNA polymerases and DNA polymerases during transcription and 
replication. This form of damage in the nucleus is repaired by PARP and reports 
suggest that this repair protein in much smaller amounts, may be present in the 
mitochondria and forms a complex with mtDNA [298]. The proteins involved in SSB 
repair are similar to those involved in BER: APE1, PNKP and PolΥ [248]. Tyrosyl-DNA 
phosphodiesterase 1 (TDP1) is involved in the repair of SSBs formed during DNA 
replication and cells deficient in this enzyme have been found to have high levels of 
mitochondrial oxidative DNA damage [299]. Aprataxin which removes AMP from DNA 
has been shown to repair SSBs in the mitochondria which have formed as a result of 
abortive DNA ligase activity [300] 
!
1.14.3! Double!strand!break!repair!in!the!mitochondria!
There are more SSBs than double strand breaks DSBs as a consequence of single 
stranded DNA (ssDNA) being more vulnerable to attack. The nucleus has a complex 
network of three main pathways to repair DSBs: NHEJ, microhomolgy-mediated end-
joining (MMEJ) and HR. The mitochondrial system for repair of DSBs is nowhere near 
as developed probably due to the fact that there are numerous copies of the genome in 
each mitochondria and therefore it is less imperative to repair all DSBs. Nevertheless, 
studies have shown that when DSBs are introduced into the mitochondrial genome they 
are most likely to be repaired by NHEJ [301]. Although the exact proteins involved in 
mitochondrial NHEJ are yet to be elucidated the evidence suggests that these are 
similar to the nuclear proteins involved in NHEJ [248]. For example, the expression of 
KU70 and KU86 have been detected in mitochondrial lysates and MRE11 has been 
found to co-localize with mtDNA [302]. It is thought that some form of HR takes place in 




is required for homology-dependent repair the evidence points to the fact that 
recombination between different mtDNA molecules is unlikely to take place [303, 304]. 
The link between deletions and re-arrangements of mitochondrial DNA and disease has 
now long been established. It is thought that a version of MMEJ is likely to be 
responsible for this given that there are often repeat sequences present at areas of 
deleted mitochondrial DNA [305].  
!
1.14.4! mtDNA!degradation!
Mitochondrial DNA is more prone to attack than nuclear DNA especially by oxidative 
DNA damage so it is fortuitous that there are typically hundreds to thousands of copies 
of the mitochondrial genomes per cell. This means that if the DNA damage to mtDNA 
cannot be repaired, as is often the case with oxidative or alkylating damage, the DNA 
can be degraded without affecting mitochondrial function [248]. Shokolenko et al have 
shown that under high levels of oxidative stress the number of DNA strand breaks far 
outweighs the formation of oxidatively induced pre-mutagenic DNA lesions [306]. These 
strand breaks and abasic sites if left unrepaired lead to mtDNA degradation. It is 
thought that strand breaks are likely to occur as a consequence of stalled replication or 
transcription [306]. The most abundant nuclease in the mitochondria, Endonuclease G 










The PGC1- family of co-activators which are composed of three main members; PGC1-
α, PGC1-β and PGC-related-co-activator (PRC). The first member to be discovered was 
PGC1-α, which was found in brown fat for its role in interacting with the protein PPARγ 
[308]. PGC1-β has been identified to be most closely related to the first identified 
member of the PGC1- family, PGC1-α [309]. These two family members are similar in 
many key sequences including the N-terminal activation domain, a C-terminal RNA 
binding domain and a central regulatory domain. PRC on the other hand does not share 
as many similarities to PGC1-α in its sequence structure compared to PGC1-β [310]. 
 
The most pertinent characteristic of the PGC1- family is their ability to activate a wide 
range of transcription factors allowing them to carry out the role of ‘master co-
regulators’ of mitochondrial biogenesis. The PGC1- family are responsible for a key 
cellular function; alterations in metabolism through a diverse array of transcription 
factors as a result of changes in the environment [308]. Leone et al carried out a study 
investigating the phenotype that PGC1-α  null mice exhibit and found a range of 
metabolic abnormalities including growth retardation of organs with high energy 
demands, high body fat, decreased numbers of mitochondria and respiratory capacity 
and a blunted thermogenic response [311].  
!
1.15.2! Mitochondrial!biogenesis!and!the!PGC1T!family!
Mitochondrial biogenesis is a process, which has evolved to compensate for the 
depletion of damaged mitochondria. The term encompasses several functions: 
formation of the mitochondrial phospholipid double membrane [312], importing the large 
number of nuclear encoded mitochondrial proteins, translation of the mitochondrial 
encoded respiratory genes [313] and replication of mitochondrial DNA and translational 
machinery [314]. The PGC1- family achieves its role in  mitochondrial biogenesis by 
interacting with a wide range of nuclear receptors (NRs) and transcription factors (TFs) 
to enable the expression of the mitochondrial proteome compromised of approximately 




PGC1-α is known to be cold activated in brown muscle and fat and through activation of 
a range of transcription factors it induces mitochondrial biogenesis and uncoupled 
respiration leading to adaptive thermogenesis [308]. PGC1-β on the other hand is not 
cold induced in brown fat and muscle [316] and has been found to share many but not 
all of its target genes with PGC1-α . A study by Leone et al investigated differences in 
PGC1-α and PGC1-β function using an adenoviral expression system in cell culture 
(hepatocytes) and in vivo [311] . The authors discovered that these two family members 
are similar in their metabolic function and both are able to induce a range of genes 
involved in oxidative metabolism but PGC1-β did not induce genes involved in hepatic 
glucose metabolism. The authors concluded that this difference was partly due to the 
fact that PGC1-β cannot interact with and co-activate hepatic nuclear receptor 4alpha 
(HNF4alpha) and FOXO1 [317]. St Pierre et al investigated the differences in 
mitochondrial respiration between cells expressing PGC1-α and those expressing 
PGC1-β [318]. They showed that these two cell types are able to induce similar 
mitochondrial genes but PGC1-β expressing cells had increased mRNA levels of 
glutamyl cysteine synthetase light and heavy subunit, both of which are known as 
activators of UCP2 and UCP3 which detoxify ROS [318]. Lin et al established from gain 
of function analysis that although PGC1-α and PGC1-β are able to activate similar 
genes, PGC1-β loss cannot completely compensate for PGC1- α loss [317] 
"
Co-activators like the PGC1- members are multi-protein complexes which alter gene 
expression by allowing the downstream processes necessary for gene expression or 
repression. The most well known targets of the PGC1- family are the nuclear DNA 
binding transcription factors NRF1 and NRF-2alpha [319] which are discussed further in 
section 1.15.3 . There are a multitude of TFs and NRs that have been found to interact 
with the PGC1- family to control mitochondrial biogenesis including the cAMP response 
element binding protein (CREB) [320] thyroid receptors [321], glucocorticoid receptors 
[322], estrogen related receptor (ERRα) [323], estradiol (ERα) [324] and peroxisome 
proliferator–activated receptor (PPARα and PPARγ). Furthermore, some of the proteins 
involved in mitochondrial biogenesis are governed by a much wider group of 
extracellular and intracellular signalling pathways involving cellular lipid and 





1.15.3! Mitochondrial!biogenesis!and!NRF1!and!!NRFT2alpha ! 
The transcription of mitochondrial genes is mainly controlled by nucleo-mitochondrial 
interactions and the two main systems that are involved in this process are a few  
nucleus encoded transcription factors that bind directly to the mtDNA: transcription 
Factor A (Tfam), mitochondrial transcription Factor B (mtTFB) isoforms TFB1M and 
TFB2M) [326] and a set of transcription factors (including NRF1 and NRF-2alpha, 
stimulatory protein 1 (Sp1), oestrogen related receptor α (ERRα), and yin yang 1 
transcription factor (YY1) that activate nuclear genes upstream that are required for 
respiratory chain expression [327, 328]. NRF1 and NRF-2alpha  were first discovered 
through an effort to find TFs which could induce the respiratory genes cytochrome c and 
cytochrome oxidase [329, 330]. NRFI recognition sites were later identified in several 
promoter regions of genes involved in expression of respiratory chain complexes [331]. 
NRF1 has been identified as a positive regulator of transcription and binds as a 
homodimer to a palindromic recognition site in the cytochrome c promoter. Gugneja et 
al established that in mammalian cells NRF1 is a phosphoprotein and its 
phosphorylation at serine residues results in a conformational change in the NRF1 
dimer enhancing its ability to bind DNA [332]. Several studies have established the key 
role that NRF1 plays in regulating respiratory chain complexes through both direct 
regulation of nuclear encoded subunits and indirectly to control the mitochondrial 
encoded subunits by regulating Tfam [333], tTFB and mitochondrial RNA polymerase 
[334]. The promoter regions of a large number of genes involved in mtDNA transcription 
and replication have been found to contain NRF1 and NRF-2alpha  binding sites [335]. 
NRFI also controls several genes, which indirectly effect respiratory function through 
their genes products such as enzymes of the heme biosynthetic pathway [336], 
cytochrome c assembly factor and members of the protein import  (TTOM20, TOM70 
and COX17) and assembly system (ribosomal proteins and tRNA synthetases) [327, 
337]. NRF1 null mice display embryonic lethality and have been shown to have reduced 
levels of mtDNA and have deficiencies in maintaining a mitochondrial membrane 
potential [338]. Hoppeler et al have shown that exercise results in upregulation of 
PGC1- and NRF1 proving their role in regulating OXPHOS gene expression [339].  
 
NRF-2alpha  was later discovered through it specific binding in the cytochrome oxidase 




contain the GGAA motif [335]. Experiments have revealed NRF-2alpha to have a role 
not only in COX subunit expression but also in the expression of all 10 cytochrome 
oxidase subunits encoded by nuclear DNA [340] and NRF-2alpha  binding sites have 
been found in a multitude of genes related to the respiratory chain [335]. Furthermore, 
Verbasius et al have shown that both NRF1 and NRF-2alpha  indirectly control mtDNA 
expression through activation of the mtTFA promoter TFB1M and TFB2M [341]. Glezer 
et al have shown that in fibroblasts that are stimulated with growth factors, the mRNA 
levels of three NRF target genes encoding mitochondrial transcription factors TFB1M, 
TFB2m and COXII are upregulated in preparation for increased growth [334]. NRF-
2alpha like NRF1 also has a role in driving the expression of proteins involved in protein 
import and assembly [342]. 
 
1.15.4! Mitochondrial!copy!number 
Estimating the number of mtDNA molecules per cell is fraught with difficulty due to the 
fact that unlike the fixed copy number of the nuclear genome, there are numerous 
copies of the mitochondrial genome per cell [134]. Mitochondria are subject to fusion 
and fission leading to fluctuations in the number of mitochondrial  genomes present 
within each mitochondria [343]. The most frequently used estimate to overcome this 
problem is measuring mtDNA copy number per cell. D’Erchia et al  examined six 
different tissues from three different human individuals and found that there was a 
strong correlation between mtDNA copy number and mitochondrial gene expression 
levels, mitochondrial mass and respiratory function [344].  
 
Hori et al have shown that ROS is involved in regulating mitochondrial copy number in 
yeast [345]. Holt et al propose that in mammalian DNA p53, ROS and the availability of 
the components necessary for biogenesis are all likely to play a role in deciding the fate 
of defective mitochondrial DNA. Several studies have shown that p53 associates with 
mtDNA and mtDNA binding proteins including POLG1 [346], TFAM (mtDNA 
maintenance protein) [347] and single stranded DNA binding protein [348]. Achanta et 
al have shown that the well known inhibitor of mitochondrial respiration Rotenone, 
causes increased ROS levels and promotes the translocation of p53 into the 
mitochondria [346]. Based on the studies described and the established role of p53 in 




mitochondria the role of p53 could be to decide whether the mtDNA should be retained 
or rejected under conditions of high ROS levels. It has been shown that when the levels 
of ROS are increased, p53 translocates to the mitochondria and that there is a 




The antioxidant system is the essential first step in combating ROS and there are two 
main types of antioxidant: non-enzymatic and enzymatic. The non-enzymatic 
antioxidants include Vitamins C and E, carotenoids, natural flavonoids, melatonin and 
thiol antioxidants (glutathione, thioredoxin and lipoic acid). The enzymatic antioxidant 
include superoxide dismutase (SOD), catalase and glutathione peroxidase.  The gene 
expression of many of these antioxidants are controlled by several regulators including 
NF-E2-Related Factor 2 (NFE2L2 and also known as NRF2), FOXO and p53 [212] . 
 
1.16.1! NRF2!and!the!antioxidant!defense!system!
NRF2 (NFE2L2) is known as the master regulator of the antioxidant defense pathway. 
This key transcription factor detects signals activated due to cellular stress and  
activates the downstream genes necessary to respond to these signals. NRF2 is itself 
controlled by its inhibitor the Kelch-like ECH associated protein 1 (KEAP1)-Cullin 3 
(CUL3) which ensures through binding with NRF2 that it remains inactive under normal 
physiological conditions [350]. This ensures that ROS levels are maintained at a level 
that allows for normal cell signalling but if ROS levels exceed a threshold then NRF2 
can respond to counteract this. KEAP1 is composed of several cysteine residues and it 
is the 20 free sulphydryl (-SH) groups within this that carry out the role of sensing cell 
stress including oxidative stress [351]. ROS modify the cysteine residues such that a 
conformational change prohibits the degradation of NRF2 and allows its translocation to 
the nucleus [352]. This allows it to carry out its role as a transcription factor that controls 
over 100 genes involved in the antioxidant response including glutathione production 
and regeneration, NADPH, thioredoxins, quinones, catalase and enzymes involved in 
iron sequestration (Figure 1.6). NRF2 regulates these genes by binding to the 




The expression of the enzymes controlling the most abundant antioxidant, glutathione 
(GSH), is under the sole control of NRF2 [350]. GSH is readily available in the cytosol, 
nuclei and mitochondria. Glutamine cysteine ligase (GCL) is responsible for driving the 
reaction between glutamate and cysteine. GCL is composed of two subunits the 
modifier (GCLM) and the catalytic subunit (GCLC) both of which are under the control of 
NRF2. The substrate which limits the production of GSH is cysteine and NRF2 also 
regulates the availability of this molecule through the expression of solute carrier family 
7 member 11 (SLC7A11) which in turn drives the transcription of the cysteine/glutamate 
transporter XCT [354]. Furthermore, by governing the expression of several other 
antioxidant enzymes (GPX2, glutathione-s-transferases), NRF2 dictates the use of GSH 
since these enzymes detoxify ROS through GSH. This ROS detoxification results in the 
formation of the oxidised from of glutathione GSSG which is ultimately used to 
regenerate GSH using glutathione reductase and NADPH [203, 353] . 
 
NADPH is produced by several metabolic pathways but NRF2 is able to modulate the 
expression of all NADPH-generating enzymes. NRF2 is also involved in the production 
and regeneration of thioredoxin  and peroxiredoxins through controlling the expression 
of Thioredoxin 1 (TXN1) and peroxiredoxin 1 (PRDX1) as well as the fact that NADPH 
is required for the regeneration of thioredoxin via thioredoxin reductase (TXNRD) [203, 
355].  
 
The role of NRF2 in free Fe(II) homeostasis indirectly implicates it in ROS modulation 
through the Fenton reaction where H2O2 is converted to OH! [356]. NRF2 encourages 
ROS detoxification because it controls the transcriptional upregulation of HMOX1[357] 
as well as the ferritin complex which deters the ROS producing fenton reaction taking 
place by converting Fe(II) to Fe(III) [203].  
 
There are several other components apart from the main components of the antioxidant 














NRF2:! Glutamine! cysteine! ligase! (GCL)! (composed! of! glutamate–cysteine! ligase! complex!
modifier! subunit! (GCLM)! and! the! GCL! catalytic! subunit! (GCLC))! the! cysteine/glutamate!
transporter! XCT! and! glutathione! reductase! (GSR).! GSH! utilization! is! controlled! by! the!
glutathione!SFtransferases!(GSTA1,!GSTA2,!GSTA3,!GSTA5,!GSTM1,!GSTM2,!GSTM3!and!GSTP1)!
and!glutathione!peroxidase!2! (GPX2).!Thioredoxin!synthesis,! regeneration!and!ultilization,!are!
regulated! by! NRF2! through! TXN1,! thioredoxin! reductase! 1! (TXNRD1)! and! peroxiredoxin! 1!
(PRDX1).! NADPH! production! is! under! the! control! of! NRF,! which! controls! the! production! of!
glucoseF6Fphosphate!dehydrogenase!(G6PD),!phosphoglycerate!dehydrogenase!(PHGDH),!malic!
enzyme! 1! (ME1)! and! isocitrate! dehydrogenase! 1! (IDH1).! GSH! and! TXN! require! NADPH! to!
regenerate! them! once! they! have! reduced! ROS.! NRF2! also! controls! NAD(P)H:quinone!






The tumour suppressor and forkhead box O (FOXO) family of transcription factors, 
mainly FOXO3a, have an essential role in controlling the expression of several 
antioxidant defense genes even though this is not one of their more well known roles. 
The main role of the FOXO transcription factors in the antioxidant pathway is in 
controlling the transcription of superoxide dismutases (SOD) [358], catalase and Sestrin 
3 [359]. FOXO also plays a role in the control of several other antioxidants including 
glutathione, glutathione peroxidase and HMOX1 despite not directly controlling the 
transcription of these enzymes[203].  
 
The tumour suppressor p53 is known to have both pro-oxdiant and antioxidant roles. Its 
pro-oxidant role relates to the fact that it promotes ROS production as a response to 
pathways resulting in apoptosis. The mechanism by which p53 acts as an antioxidant 
by increasing the transcription of NRF2, sestrin 2 , sestrin 3, GPx1 . Furthermore, it also 
has two other target important targets; TP53-induced glycolysis and apoptosis regulator 
(TIGAR) and glutaminase 2 (GLS2). TIGAR encodes a protein that blocks glycolysis 
and encourages a shift towards pentose phosphate pathway mediated NADPH 
production. GLS2 is essential for GSH synthesis since it converts glutamine to 
glutamate and this leads to the production of GSH via GCLC and GCLM [203, 360]. 
 
1.16.2.1! Superoxide!dismutases!(SOD)!
The role of the superoxide dismutases is to convert the highly toxic OH! to the less toxic 
H2O2 which can finally be reduced to H2O by catalase [361]. There are several different 
isoforms of SOD differing in several ways including the metal center and amino acids 
they are made from. The three human isoforms are the cytosolic form Cu, Zn-SOD 
(SOD1), the mitochondrial form Mn-SOD (SOD2) and the extracellular isoform EC-SOD 
[362]. This family of antioxidants carry out their function by utilizing the metal ion at their 
center to for successive oxidation and reduction reactions. Superoxide dismutase 1 
which is composed of copper and zinc ions at its center carries out the dismutation of 
superoxide anions to hydrogen peroxide and water . Superoxide dismutase 2 is 
composed of one manganese atom per subunit and it undertakes a two-stage 




Mn(III) to Mn(II) and then back to Mn (III) [363]. EC-SOD does not directly detoxify ROS 
but is a glycoprotein which is under the regulatory control of cytokines [212]. 
 
1.16.2.2! Catalase!
Catalase is one of the most efficient antioxidant enzymes being capable of detoxifying 6 
million H2O2 into H2O and O2 each minute [212] : 
 
 
            Catalase                       





The glutathione peroxidase enzymes are responsible for counteracting low levels of 
oxidative stress. They are divided into two main forms: the selenium-independent form 
glutathione-s-transferase (GST) and the selenium-dependent GPx. The transcription 
factor FOXO also plays a role in glutathione metabolism although it is not one of its 
main functions, it controls the transcription of two of the gluthathione peroxidase family 
members, glutathione peroxidase 1 (GPx1) and glutathione-s-transferase (GSTM1). 
The GPx enzymes act as antioxidants by reducing peroxides to form selenoles (Se-OH) 
which have detoxifying properties because they stop peroxides from taking part in the 
Fenton reaction. GPx and glutathione metabolism is closely linked because it uses H2O2 
or an organic peroxide ROOH and coverts this substrate to water (or alcohol) whilst 
oxidising glutathione at the same time. Catalase and GPx both use H2O2  as a substrate 
and compete for this molecule [203, 212]. 
 
                         GPx                       
2GSH +  H2O2                      GSSG  + 2H2O 
 
                            GPx                       






The sestrin family have been shown to exert their ROS detoxifying activity by restoring 
the activity of peroxiredoxins through their ability to reduce these enzymes when they 
have become over-oxidised. Sestrin 3 specifically is controlled by FOXO mediated 
transcription whereas sestrin 1 and sestrin 2 are controlled by p53 [364].  
!
1.16.3! The!role!of!PGC1T!family!as!antioxidants!
PGC1-α and PGC1-β have been found to be activated by ROS induction and have 
been found to induce several antioxidant defense enzymes [318, 365, 366]..The 
mechanism by which the PGC1 family controls these antioxidant has not been studied 
extensively but Kukidome et al have shown that PGC1-α decreases ROS levels and 
increases the mRNA levels of NRF1 and mitochondrial transcription factor A (mtTFA) 
[367]. St Pierre et al have recently demonstrated that when 10T1/2 cells are treated with 
H202 the expression of PGC1-α and PGC1-β and a host of antioxidant genes (SOD1, 
SOD2, catalase, GPx1, ANT1, UCP2 and UCP3) are increased. This study found that 
the expression of PGC1-α was consistently much larger than the corresponding 
increase in PGC1-β mRNA. The investigators also demonstrated that PGC1-α null mice 
were much more sensitive to oxidative stress and damage as indicated by increased 8-








We have previously shown that MLH1 localises to the mitochondria [186] supported by 
a proteomic analysis of the mitochondria which identified MLH1 as a mitochondrial 
protein [368]. MLH1 deficiency has been found to be synthetically lethal with silencing of 
a number of mitochondrial genes [186, 187] 
 
Therefore the preliminary data strongly suggest that targeting mitochondrial function 
may be a potential therapeutic strategy for the treatment of MLH1-deficient tumours. 
 
In addition there is a an unmet clinical need to try and identify targeted drugs to treat 
these groups of MLH1-deficient cancers, given that there is evidence to suggest that 
these tumours are resistant to the commonly used therapeutics. Bearing this in mind, 
the main aims for my project are as follows: 
 
1, Validation of mitochondria-targeted compounds in a range of MLH1-deficient and 
proficient cell lines 











The human colorectal isogenically-matched cell line HCT116 and HCT116+chr3 were a 
kind gift from Dr. A. Clark (NIEHS). The human ovarian cancer cell line SKOV3 were 
obtained from Cancer Research UK Cell Services (Clare Hall, South Mimms, 
Hertfordshire, UK) and the human ovarian cancer cell line IGROV were acquired from 
NCI-Frederick, MD, USA. The human ovarian cancer cell lines A2780 and A2780cp70 
were a kind gift from Prof. Robert Brown (ICR, UK). The human colorectal cell lines 
SW620, HT29, SW480, SW48 and the human endometrial cell lines MFE296 and 
MFE280 cell lines were obtained from American Type Culture Collection (ATCC) 
!
3.1.2! Cell!growth!methods!
The cell stocks were made from early passage cells and stored in 10 % Dimethyl 
sulfoxide (DMSO)/FBS in liquid nitrogen or at -80˚C for short-term storage. The 
HCT116, HCT116+chr3, HT29, A2780cp70, A2780, SW480, MFE-296, MFE-280 and 
SW48 cells were cultured in Dulbecco’s modified eagle medium (DMEM) (Sigma) and 
the SKOV3 and IGROV cells were grown in the Rosewell Park Memorial Institute 
medium (RPMI 1640). The RPMI and DMEM media was supplemented with fetal bovine 
serum (FBS; Gibco® Life Technologies, 10% v/v), L-glutamine, sodium pyruvate, 
penicillin (5X v/v) and Streptomycin (5X v/v). Cell lines were maintained at 37°C in a 
humidified atmosphere with 5% CO2 in T75 flasks (Corning). Cells were split 1:10-1:15 
when confluency of 80%-90% was reached. The cells were washed with phosphate 
buffered saline (PBS) and then incubated for up to five minutes at 37°C with 5mls of 1x 
trypsin-EDTA (Gibco®, Life Technologies). Once the majority of cells had detached 
from the flask, the trypsin-EDTA was quenched by the addition of double the volume of 
media. Cells were collected and then pelleted by centrifugation for 3 min at 1200 rpm. 




in section 3.1.3) and seeded in T75 flasks for further experiments. No cell line was cultured 
at passage higher than 10. All cell lines were authenticated on the basis of STR-profile, 
viability, morphologic inspection, and were routinely mycoplasma tested.  
!
3.1.3! !Cell!seeding!conditions!!
All experiments were performed in both biological and technical triplicate unless stated 
otherwise. Cells from flasks that were 80-90 % confluent and were seeded in either 
96,12 or 6-well plates or 10 cm petri dishes (Corning) depending on the experiment. 
The cells were pelleted (as described in section 3.1.2) and re-suspended in fresh 
media. To establish the number of cells present per ml accurately, the cells were 
quantified using a Cell counter (TC20, BioRad) and plated at the appropriate density 
depending on cell type, the plate used and the experiment, as detailed throughout. 
!
3.2! Compounds!
All compounds were diluted in water or DMSO to a concentration of between 10mM-








Compounds Cat number Company 
Antimycin A SC202467A Sigma-Aldrich 
Betulinic acid CAS 472-15-1 Abcam 
β-Lapachone SC200875A Santa Cruz Biotechnology 
2-Deoxy-D-Glucose D8375 Sigma-Aldrich 
Dichloroacetate D6399 Sigma-Aldrich 
Fccp SC203578 Santa Cruz Biotechnology 
Lonidamine L4900 Sigma-Aldrich 
Menadione M9429 Sigma-Aldrich 
N-Acetyl-Cysteine SC202232A Sigma-Aldrich 
Oligomycin O5001 Sigma-Aldrich 
Parthenolide SC3523 Sigma-Aldrich 






A panel of MLH1-deficient (SKOV3, IGROV, HCT116, A2780cp70, MFE-296) and -
proficient (HCT116+chr3, HT29, SW480, SW620, MFE-280) cell lines were plated at a 
density of between 1000-2000 cells/well in 96 well plates. The following day, cell 
medium was removed and replaced with either media containing vehicle (DMSO or 
water (0.01%)) or increasing concentrations of drug (10 µM-100 µM). Cell viability was 
estimated five days later using the CellTiter-Glo assay (Promega) according to the 
manufacturer’s instructions (as described in section 3.3.2). The effect of each 
compound was determined by comparing luciferase readings from drug treated wells 
with those from wells treated with the compound vehicle to determine the surviving 





Cell viability was measured using the ATP based luminescent CellTiter-Glo assay 
(Promega), which is based on the following reaction: 
 
Beetle luciferin + ATP + 02  " Oxyluciferin 
 
The CellTiter-Glo reagent was thawed from -20°C and diluted at a ratio of 1:4 with 1X 
PBS, prior to use. The diluted reagent (100 µL) was added to each 96-well, after 
removing the drug containing media from the well. The 96-well plate was placed on a 
plate shaker (Grant-bio) and mixed for 2 minutes followed by an incubation period of 10 
minutes at room temperature. Luminescence was estimated using a Wallac 1420 plate 
reader (PerkinElmer). To obtain the surviving fraction, the luminescence reading of 
each of the drug treated wells was normalized to the average luminescence reading of 





For preparation of whole cell protein lysates, cells in 6 well plates were washed in 
1xPBS and plates were then placed on ice, to prevent evaporation and reduce protein 
degradation. The cells were lysed in NP-40 lysis buffer (20 mmol/Tris (pH 8), 1 mmol/l 
EDTA, 0.5% (v/v) NP40, 10% (v/v) glycerol) and protease inhibitors (Roche) and kept 
on ice for 10 minutes. The lysed cells were then harvested using a cell scraper (BD 
Flacon, UK) and transferred to 1.5ml tubes and kept on ice for a further 15 minutes. The 
cells were then centrifuged to remove cell debris at 12,000 rpm for 20 minutes at 4°C 
and the supernatant removed and either used fresh or stored at -80°C.   
!
3.4.2!!Protein!concentration!determination!
The protein concentration was determined using Pierce BCA Protein Assay Kit 




derived from the albumin stock provided in the kit was made by carrying out serial 
dilutions to give concentrations ranging from 125-2000 µg/ml. A sample of the dd H2O 
used to produce these dilutions was also set aside to be kept with the standards. The 
standards were kept at -20°C. All standards and samples were plated out in duplicate in 
a 96-well plate. 10µl of double distilled water, standards and samples of unknown 
concentration were plated out in wells of a 96-well plate in duplicate. Reagent A and 
Reagent B from the Pierce BCA Protein Assay Kit were then diluted at a ratio of 1:50 
and 200 µl of the mixture was added to each well containing either standard or sample 
using a multichannel pipette. The plate was placed on a plate shaker (Grant-Bio) for 1 
minute, kept in the dark and incubated at 37°C for 30 min. The absorption at 562 nm of 
each well was measured using the Wallac 1420 plate reader (PerkinElmer). A standard 
curve was plotted using the mean absorption readings for the standards. A scatter 
graph was plotted in Excel with protein concentration as the dependent variable on the 
Y-axis and absorbance as the independent variable on the X-axis. A polynomial trend 
line (2nd order regression) was added and the equation of the line was displayed, of the 
format y = ax2 + bx + c. The protein concentration was represented by y, therefore the 
equation and hence the protein concentration could be solved for each protein sample 
by entering the known mean absorbance value for that sample (x). 
!
3.4.3!!Western!Blotting!
The same amount of protein was used for each sample (30-50µg- depending on the 
concentration of all the samples) and prepared with LDS loading buffer at a final 
concentration of 25mM DTT and incubated at 95°C for 5 minutes to denature the 
protein. The samples were then incubated on ice for 1 min and centrifuged at 
12,000rpm for 30 seconds to ensure adequate mixing. 
 
Protein lysates were eletrophoresed on 4-12% Bis-Tris Novex precast gels (Invitrogen, 
UK) in 1X MOPS running buffer (Invitrogen). Molecular weight full-range rainbow 
markers (GE Healthcare Life) were loaded alongside the protein samples to allow size 





Proteins were transferred onto nitrocellulose membranes (GE Healthcare) at 20 V for 45 
min using a semi-dry transfer apparatus (Bio-Rad) and transfer buffer. The membrane 
was equilibrated in transfer buffer (9.6mM glycine, 1.2mM Tris base, 10% methanol in 
distilled water). All Extra ThickBlot Paper (Bio-Rad) used for the transfer was previously 
soaked in transfer buffer and the negative electrode of the transfer apparatus was wet 
with transfer buffer.  
 
Following transfer, the membrane was blocked in blocking solution (5% (w/v)) milk 
powder in 0.1% PBS-Tween) for 1 hour at room temperature. The membrane was then 
incubated in primary antibody diluted in blocking buffer (normally 5% milk powder 
unless the manufacturer’s instructions specified) overnight at 4°C on a roller mixer. The 
primary antibodies used and the dilutions at which they were used are listed in Table 2.  
 
The primary antibody was removed by washing the membrane three times with 0.1% 
PBS-Tween for 10 minutes, each wash. The membrane was then incubated with the 
appropriate horseradish peroxidase (HRP) conjugated secondary antibody (Table 3) 
diluted at a concentration of 1:5000 in 5% milk and incubated for 1 hour at room 
temperature.  
 
The membrane was then washed with three, 15 minute washes with 0.1% PBS-T as 
before. Protein expression was detected by chemiluminescence (SuperSignal West 
Pico Chemiluminescent substrate, Pierce, UK). Reagents 1 and 2 were mixed 1:1 and 
used to completely cover the membrane, followed by 5 minutes incubation at room 
temperature. Excess reagent was removed from the membrane and the resulting 
chemiluminescence signal was detected with Amersham Hyperfilm™ ECL (GE 






Antibody Rasied in Cat Number Company Concentration 
MLH1 Rabbit 4256 Cell Signalling 1:1000 
MSH2 Rabbit sc-365052 
 
Santa Cruz 1:1000 










NRF2 Rabbit ab62352 
 
Abcam 1:1000 










NDUFB8 Mouse ab110242 Abcam 1:1000 
Anti-Oxphos Mouse ab110411 Novex 1:1000 






Antibody Cat Number Company Concentration 
Anti-rabbit IgG 7074 Cell Signalling 1:5000 









Complex I activity was measured using the Complex I activity ELISA assay (Abcam) 
The assay contains a pre-coated microplate with capture antibodies specific to complex 
I. Samples were prepared as in Section 3.5.2 and added to the pre-coated microplate 
wells. After the target has been immobilized in the well, Complex I activity is determined 
by following the oxidation of NADH to NAD+ and the simultaneous reduction of the 
provided dye (ε = 25.9/mM/well) which leads to increased absorbance at OD 450 nm. 
The Complex I activity measured here is the NADH-dependent activity of Complex I 
which is not dependent on the presence of ubiquinone. This means that inhibitors, such 
as rotenone, which bind at or near the ubiquinone binding site do not inhibit this assay 
but assembly deficiencies of Complex I can affect this activity assay. 
!
3.5.2! Sample!preparation!
Cells were grown in 6 well plates until they had reached 80-90% coluency and two wells 
were plated per cell line. A cell pellet was obtained as described in section 3.1.2 using 
250µl of trypsin per well. The final cell pellet for each cell line was re-suspended in 
500µl of PBS. The protein was extracted from the cell by adding 10X non-ionic native 
detergent solution (n-dodecyl-b-d-maltoside Aka lauryl maltoside) provided in the kit (to 
a final dilution of 1/10) which fully lyses mitochondrial membranes (followed by 
incubating the samples on ice for 30 minutes. The samples was then centrifuged for 20 
minutes at 4°C at 12,000rpm. The supernatant was collected and protein concentration 
determined using the BCA assay described previously in section 3.4.2. The samples 
were diluted in the provided incubation solution (made by diluting 10X blocking solution 
with wash buffer) to a concentration of 200µg/200µl. 
!
3.5.3! Experimental!procedure!
Equal amounts of protein (200µg) were loaded in the provided pre-coated 96 well 
microplate containing the enzyme NADH dehydrogenase. For the background wells, 




room temperature for 3 hours. The contents of the plate was then removed by turning 
the plate over onto a paper towel and blotting the plate face down onto it. To wash the 
plate, 300µl of 1X wash buffer was added to each well and removed by blotting on to a 
paper towel. This was step was repeated once more. The following assay solution was 
then prepared and the final volume made was dependent on the sample size.  
 
 
No of strips (8 
well per strip) 
1X Buffer (ml) 20XNADH (µl) 100XDye (µl) 
1 1.57 84 17 
 
Two hundred microliters of the assay solution was added to each well and any bubbles 
formed in this process were popped immediately using a fine needle. The microplate 
was then placed on the plate reader (Wallac 1120) and the following program applied to 
measure the activity of Complex I over time by measuring the oxidation of NADH to 
NAD+ and the simultaneous reduction of the dye, leading to increased absorbance at 
450 nm over time.   
 
Wavelength    450nm 
Time     120 minutes 
Interval between readings  1 minute 
Temperature    room temperature 
Shaking    Shake between readings 
 
!
3.6! Quantitative! reverse! transcriptaseTpolymerase! chain! reaction!!
(qRTTPCR)!"
3.6.1! RNA!extraction!and!cDNA!synthesis!
Before any RNA work was conducted, all surfaces, Eppendorf racks and pipettes were 
cleaned with RNaseZAP (Ambion) to remove any traces of RNase enzymes, which 
could contaminate samples and lead to RNA degradation. Total RNA was extracted 




Once the RNA extraction had been completed, the amount and purity of the RNA was 
determined by measuring absorbance at 260 nm (A260) and 280 nm (A280) with a 
NanoDrop-1000 Spectrophotometer. RNA absorbs light at 260 nm, solvents at 230 nm 
and proteins at 280 nm. A solvent contamination of our samples was observed by a 
ratio 260/230 lower than 1.6. A protein contamination of our samples was observed by a 
ratio 260/280 lower than 1.6.   
 
A volume with a total concentration of 1µg of RNA was used to synthesize cDNA using 
the Omniscript Reverse Transcriptase System for RT-PCR (Qiagen) with oligo dT 
primers, per the manufacturer's instructions.  
 
3.6.2  Experimental procedure 
 
Quantitiative RT-PCR (qRT-PCR) was performed using either SYBR Green (Applied 
Biosystems) or Taqman® Assay-on-demand primer/probe assays (Applied Biosystems) 
and the primers used are listed below (Table 3.4). qRT-PCR was performed on the ABI 
Prism 7500 Sequence Detection system Instrument and software (PE Applied 
Biosystems). The qRT-PCR reactions for each biological repeat was carried out in 
triplicate and in duplicate for the patient samples due to a limited quantity of RNA. All 
qRT-PCR reactions were carried out in MicroAmp® Optical 96-Well Reaction Plates 
(Applied Biosystems, Life Technologies) sealed with MicroAmp® Optical Adhesive 
Films (Applied Biosystems, Life Technologies). The reaction conditions were as follows: 
95°C for 10 min to activate the DNA polymerase, followed by 40 cycles of 95°C for 15 
sec and 60°C for 1 min. Fluorescence readings were taken at the end of the 60°C 
incubation. All qRT-PCR experiments contained negative controls consisting of the 
mastermix and nuclease free water instead of cDNA. 
 
3.6.2.1!! TaqMan®!Gene!Expression!Assay!!
qRT-PCR was carried out using the TaqMan® Universal PCR Master Mix (PE Applied 
Biosystems) . 
 
Each well contained the following reagents to make up a total volume of 20µl: 
 




7µl DEPC H20  
1µl Sample cDNA 
1µl Probe/primer assay for gene of interest 
1µl Probe/primer assay for β-actin 
 
The cycling program consisted of 10min at 95°C followed by 40 cycles of 95°C for 15 
sec and 1 min at 60°C. 
  
3.6.2.2!! SYBR!Green!
The primers used for qRT-PCR with SYBR Green (NDUFA and TUBB) were a kind gift 
from Professor Gyorgy Szabadkai’s laboratory (Department of Cell and Developmental 
Biology, UCLH) and The primers were used at a concentration of 0.15µM  
 
Each well contained 10µl of the SYBR® Green PCR Master Mix (Applied Biosystems, 
Life technologies), forward and reverse primers (volume dependant on concentration 
used) and nuclease free water was added to make up a final reaction volume of 20µl.  
 
The reaction conditions were as outlined above in section 3.6.2 but for primer 
optimization, an additional dissociation step was added at the end of the PCR program 
which consisted of 95°C for 15 sec, 60°C for 20 sec, a 19 min 59 sec ramping step and 








































Target mRNA was normalised (∆CT) to β-actin by subtracting the cycle threshold (Ct) of 
the β-actin sample from the cycle threshold (Ct) of each target gene of interest for each 
sample. The expression level of each target gene was determined relative to the MLH1 
proficient cell line or in the case of the patient samples the cDNA from normal 
surrounding MMR proficient tissue. 
 
∆∆CT = ∆CT MLH1 deficient - ∆CT MLH1 proficient 




Fold change = 2-∆∆CT 
3.7! Measurement! of! oxidative! consumption! rate! (OCR)! and! spare!
respiratory!capacity!!
3.7.1! Day!1:!cell!plating!
Oxidative consumption rate (OCR) and spare respiratory capacity (SPR) were 
measured using the Seahorse extracellular flux analyser (XFe24; Seahorse Bioscience). 
Cells were plated in a 24 well plate designed for use with the XFe24 in appropriate 
media as in section 3.3.1. The number of cells plated was calculated with the aim to 
achieve 80-90% confluency the following day and 100µL of cell suspension was used 
per well. No cells were plated in the designated temperature control wells as shown in 










Calibration plates were obtained specifically designed for use with the XFe24 and one 
plate was required for every cell culture plate used. The calibration plate is composed of 
two seperate parts: a sensor cartridge with ports to allow addition of drugs which is 
placed on top of a 24 well calibration plate (Figure 3.2). The sensor cartridge was 
hydrated by adding 1ml of XFe24 calibrant solution (Seahorse Bioscience) to each well 
of the calibrant plates. The plate was wrapped in parafilm to prevent evaporation and 
incubated overnight (37°C and 0% CO2).  
  












The media from the XFe24 cell culture plate was removed and replaced with 500µL for 
each well (including temperature control wells) of XF assay media (Seahorse 
Bioscience, 102365-100) supplemented with L-glutamine (5% v/v), sodium pyruvate 
(5% v/v), penicillin (5X v/v) & streptomycin (5X v/v), glucose 4.5gr/L and the pH of the 
media was adjusted to 7.4. The cell culture plate was incubated at 37˚C in a non-CO2 
incubator for at least 60 minutes.  
 
3.7.4! Day!2:!preparing!and!running!the!calibration!plate!
The ports in the sensor cartridge (labelled A-D) were loaded with the indicated drugs 
(Table 3.5) at 10X concentration so that the final desired concentration would be 
achieved once the drug mixes with the 500µl of XF assay media that is in each well of 




to achieve a full bioenergetic profile. The calibration plate with the loaded sensor 
cartridge on top is placed in the XFe24 machine and the automated calibration 





































65µl of 10µM 
(port C) 












65µl of 10µM 
(port C) 



















The cell culture plate is loaded immediately after optimal calibration has occurred and 
the calibration plate is ejected. The machine retains the sensor cartridge with the loaded 
drugs and the cell culture plate is then inserted and the machine places the sensor 
cartridge on top of the cell culture plate so that the appropriate drugs can be added. The 
following programme was then set up and run to determine the OCR: 
  





Further Calibration and Mixing 15 min 
Measure   2min 
Mix    2min  
Wait    2min  
Measure baseline  2min 
 
Mix    2min 
Wait    2min 
Inject (Port A)  2min    
Measure   2min  
 
Mix    2min 
Wait    2min 
Inject (Port B)            2min     
Measure   2min 
  
 
Mix    2min 
Wait    2min 
Inject (Port C)            2min 
Measure   2min    
 
Mix    2min 
Wait    2min 
Inject (Port D)                     2min 




The spare respiratory capacity was calculated by taking away the basal OCR 
(measured prior to addition of any drugs) from the maximal respiration (measured after 











      Cellular ROS levels were measured using the MitoXpress (Luxcel Biosciences) 
instrument, which allows high throughput fluorescence microscopy. The cells were 
plated in a 96 well black/clear bottom plate (BD Falcon) in DMEM or RPMI as described 
in section 3.3.1. The following day, media was removed and replaced with media 
containing either DMSO, Antimycin (positive control, 1 µM, 10 µM and 100µM) or 
Parthenolide (10µM) and incubated for 30 minutes at  5% CO2. After this 30 minute 
incubation the  drug-containing media was aspirated and 100µL of media containing the 
dye dihydroethidium (DHE), (Invitrogen,10µM) was added to each well. Cytosolic DHE 
exhibits blue fluorescence but once it reacts with superoxide anions it becomes oxidized 
to 2-hydroxyethidium, it intercalates with DNA, and stains the cell with a red 
fluorescence (Excitation⁄Emission 530/380 (nm)) [370]. The fluorescence was measured 
in the same number of sites and cells per well by the MitoXpress instrument. Each 
experiment was carried out in triplicate. The data was analysed by Zhi Zhao 
(Department of Cell and Developmental Biology, UCLH) by obtaining the fluorescence 
values from the MitoXpress instrument measured at 530nm (W3) and 380nm (W3) for 
each sample and calculating a ratio between these values and then taking the average 
increase rate of the ratio.    








The mitochondrial genome of the HCT116 and HCT116+chr3 cell lines was sequenced 
on the Illumina®MiSeqTM platform as per the manufacturers guidelines [371]. The main 













The HCT116 and HCT116+chr3 cell lines were grown in T75 flasks and when cells 
reached 80-90% confluency, they were trypsinised as in section 3.1.2. One million 
(1X106) cells were counted for each cell line and pelleted. Three biological repeats were 
used for each cell line for this experiment and the experiment was carried out in 
duplicate for each repeat. Genomic DNA was extracted from these cell pellets using the 
using the QIAmp DNA Mini Kit (Qiagen). The concentration and quality of DNA samples 




The aim of this step was to obtain two long overlapping PCR amplicons spanning the 
entire human mtDNA genome as described in the TakaRa LA Taq PCR kit (TaKaRa). 
The forward and reverse primers used were MTL1 and MTL2 (Table 3.6). The amount 
of template DNA used was 1.0ng per reaction. The volume of reagents and total PCR 
reaction volume used was half of that described in the manufacturers protocol (20μl 
total volume). The PCR master mix outlined below (Table 3.7) and DNA were plated in 








MTL!F1 5’! AAA GCA CAT ACC AAG GCC AC 
!3’ 
MTL! F2 5’! TAT CCG CCA TCC CAT ACA TT !
3’ 
MTL! R1 5’! TTG GCT CTC CTT GCA AAG TT 
!3’ 












Reagent Volume (µl) 
2.5 mM dNTP mix 1 
10X LA PCR Buffer II (25 mM MgCl2) 2.5 
 




Diluted Reverse Primer (e.g., MTL!R1 
or MTL!R2) 
1 
Nuclease!free water 11.25 
 








 Amplification was performed on a thermal cycler (Bio-Rad, Tetrad 2) machine using the 
following parameters:  
 
94°C for 5 minutes 
30 cycles of: 
-- 98°C for 15 seconds 
-- 68°C for 10 seconds (slow ramp from 68°C to 60°C at 0.2°C per second) 
-- 60°C for 15 seconds 
-- 68°C for 11 minutes 
72°C for 10 minutes 
Hold at 10°C 
 
The amplified product was held at 10°C overnight and at 4°C until it was required. The 
following day, the DNA products were checked for the correct size and quantified for 
subsequent normalisation to 0.2ng/µL using a 2200 TapeStation instrument (Agilent, 
Stockport, UK). The MTL-F1 and MTL-R1 primer pairs generated 9065bp and a single 
peak in the range of 7705-10425bp. The MTL-F2 and MTL2-R2 primer pair generated 




diluted in RSB buffer (Nextera XT DNA Sample Preparation Kit, Illumina) to a final 
concentration of 0.2ng/µl and the entire volume was transferred to a PCR plate. 
 
3.9.3! Tagment!amplified!DNA!
The next step tags and fragments the input DNA using the human mtDNA genome 
sample prep transposome (Nextera XT DNA Sample Preparation Kit, Illumina) which 
both fragments the DNA and adds adapter sequences to the ends to allow amplification 
by PCR. The following reagents were used for this step to make the Nextera XT 
Tagment Amplicon (NTA) plate . 
 
Nextera XT DNA Sample Preparation Kit reagents: 
 
ATM (Amplicon Tagment Mix)                                      
TD (Tagment DNA Buffer)                                   
NT (Neutralize Tagment Buffer)                            
Input DNA (0.2 ng/µl) 5 µl per sample (1 ng total)          
 
After thawing the reagents the following mix was prepared in a PCR plate per well. 
"
Table!3.8!
Reagent Volume (µl) 
TD Buffer 10 






After centrifuging the plate to 280 x g at 20° C for 1 minute the plate is placed in a 





55°C for 5 minutes 
Hold at 10°C 
The samples were neutralized by adding 5 µl of NT Buffer to each well of the NTA plate. 
The plate was centrifuged at 280 X g at 20°C for 1 minute and then placed at room 
temperature for 5 minutes. 
 
3.9.4! LimitedTCycle!PCR!Amplification!
The rationale behind this step was to amplify the tagmented DNA. In addition this step 
also adds the index 1 (i7) and index 2 (i5) primers, which are required for cluster 
formation. 
 
The following reagents were required for this step   
 
Nextera XT DNA Sample Preparation Kit contents: 
 
NPM (Nextera PCR Master Mix)                                 - 
Index 1 primers (N7XX) 1 tube each index ‐   
Index 2 primers (S5XX) 1 tube each index   
TruSeq Index Plate Fixture 1        
     
After the above reagents were thawed and mixed the primers were arranged as below 










A=Index Primer 1 (i7) (Orange Caps) 






The dual indexing approach uses two 8 base indices: Index 1 (i7) and Index 2 (i5) 
(Table 3.9). These indices allow unique indexing of samples by adding one adapter 

















The NTA plate was placed in the TruSeq plate fixture and the following reagents are 
added to each well (Table 3.10). The primers were added in different combinations as 
shown in the diagram below (Table 3.11) 
"
Table!3.10!
Reagent Volume (µl) 
NPM 15 
Index 2 primers (White Cap) 5 





Index 1 (i7) Sequence Index 2 (i5) Sequence 
N701 TAGATCGC S501 TAGATCGC 
N702 CGTACTAG S502 CTCTCTAT 
N703 AGGCAGAA S503 TATCCTCT 
N704 TCCTGAGC S504 AGAGTAGA 
N705 GGACTCCT   










The plate was then sealed and centrifuged at 280 X g at 20°C for 1 minute. The plate 
was then placed on a thermal cycler (Bio-Rad, Tetrad 2) and the following program 
applied: 
 
95°C for 30 seconds 
12 cycles of: 
95°C for 10 seconds 
— 55°C for 30 seconds 
— 72°C for 30 seconds 
72°C for 5 minutes 
Hold at 10°C 
 
3.9.5! ! LimitedTCycle!PCR!cleanTup!
This step purifies the library DNA using AMPure XP beads and removes very short 
library fragments from the population. The following reagents were used for this step 
 
AMPure XP beads          












































































RSB (Nextera XT DNA Sample Preparation Kit contents)      ‐ 
 
The library DNA was purified by adding 30µl of mixed AMPure beads to each well of the 
NTA plate, which contained 50µl PCR amplified library. The plate was then 
subsequently placed on a magnetic stand and the supernatant discarded. Two ETOH 
washes were then carried out on the magnetic stand as per manufacturers instructions. 
The NTA plate was then left to air dry on the magnetic stand and a pellet obtained, 
which was re-suspended in 52.5µl of RSB and then placed on the magnetic stand. The 
supernatant from each well of the NTA plate was transferred to the corresponding well 
of a plate named LNP (Library Normalization Plate).  
!
3.9.6! Bead!Based!Normalization!
This step aims to normalize the quantity of each library so that there is an even 
distribution of each library in the pooled sample. 
 
The following reagents are required for this step  
 
Nextera XT DNA Sample 
Preparation Kit contents: 
 
LNA1 (Library Normalization Additives)             
 
LNB1 (Library Normalization Beads 1)    
     
LNW1 (Library Normalization Wash 1)       
 
LNS1 (Library Normalization Storage Buffer 1)    
0.1 N NaOH          
     
After all the reagents were thawed and LNA1 was mixed with LNB1 45ul of the 
LNA1/LNB1 was added to each well of the LNP plate (see section 3.9.5), which 
contains sample and libraries. The plate was sealed and placed on a microplate shaker 
at 1800rpm for 30 minutes. The LNP plate was then placed on a magnetic stand and 
80µl of supernatant removed. The plate was then removed from the magnetic stand and 





A SGP (StoraGe Plate) barcode label was applied to a PCR plate and this was now 
known as the SGP plate. 
 
The LNP plate was again removed from the magnetic stand and 30µl of 0.1 N NaOH 
added to each well to elute the sample. The plate was sealed and placed on a 
microplate shaker at 1800 rpm for 5 minutes. LNS1 (30µl) was added to each well to be 
used in the SGP plate. After the 5 minute elution, the LNP plate was again placed on 
the magnetic stand for 2 minutes or until the liquid was clear. The supernatant form the 
LNP plate (30µl) was then transferred to the SGP plate. 
!
3.9.7! Pool!and!load!from!beadTbased!normalization!
This part of the method prepares for cluster generation and sequencing, equal volumes 
of the bead based normalized library is combined, diluted in hybridization buffer and 
heat denatured for Miseq sequencing 
 
The following reagents are require for this step 
 
Nextera XT DNA Sample 
Preparation Kit contents: 
HT1 (Hybridization buffer)      
MiSeq reagent cartridge       
PhiX Control v3       
 
An eppendorf tube was labeled PAL (Pooled Amplicon Library) and a second, DAL 
(Diluted Amplicon Library). All reagents were thawed. From the SCP plate  5µl of each 
library to be sequenced was transferred column by column, to a PCR eight‐tube strip.  
PhiX control (5% 2nm ) was added to the library in the eight tube strip. 
 
The contents of the PCR tubes were combined and transferred to the tube labeled PAL. 
Following this, 576ul of HT1 was transferred to the DAL tube and then 24ul of the PAL 
tube was transferred to the DAL tube that contains HTI.  The DAL tube was then 




miSeq reagent catridge in the load samples reservoir. The SGP plate was sealed and 




Sequencing reactions were carried out using the MiSeq v2 (150bp) chemistries 
(Illumina) according to the manufacturer’s recommendations. The MiSeq re-sequencing 
protocol for small genome sequencing was followed according to the manufacturer's 
recommendations. On-board software (i.e., Real-TimeAnalysis and MiSeq Reporter) 
converted raw data to Binary Alignment/Map (BAM) and Variant Call Format (VCF) v4.1 
files using Genome Analysis Toolkit (GATK). During this process, the sequenced region 
of interest (ROI) was aligned to the revised Cambridge Reference Sequence (rCRS). 
Each nucleotide position (np) was interrogated and variations from the reference were 
annotated by base difference.  
!
3.9.9! Analysis!
Analysis was carried out by Dr. Jun Wang (Department of Bioinformatics, Dr Claude 
Chalala’s lab) using the MiSeq Reporter software and Variant Analyzer software. 
!
3.10! Measuring!mitochondrial!copy!number!changes!




β2-microglobulin and mitochondrial tRNA forward and reverse primers were designed 
and the sequences are described below (Table 11). Plasmids containing the β2-
microglobulin (β2M) gene and mitochondrial tRNA gene were a kind gift from Professor 
Chris Boschoff’s lab (UCLH). The plasmid concentrations were determined using the 
Nanodrop. These were then linearized by digesting the plasmids using the BAMH1 
(New England Biolabs) restriction enzyme as detailed in the manufacturers instructions. 




manufacturers instructions. The linearized plasmids were quantified using the Nanodrop 




The β2M plasmid is known to be 4000bp long and the tRNA plasmid is 3650bp long. 
 
For example, for the β2M linearized plasmid: 
Copies/µl =  [5.1(ng/µl) x 6.022x1023] = 1181238462 copies/µl  









Mitochondrial tRNA-F CACCCAAGAACAGGGTTTGT 





A cell pellet was obtained by the method described in section 3.3.2 and either frozen 
down at 80°C for later use or DNA extracted immediately. The DNA was extracted using 
the Qiagen DNeasy Blood and Tissue DNA extraction kit protocol and quantified using a 
Nanodrop. DNA samples were then diluted to 1ng/µl using clean ddH2O. 
!
3.10.3! Preparing!qPCR!plate!
The β2M and tRNA primers were diluted 1/10 in ddH2O to give 10µM working solutions. 
The following qPCR master mix per well was prepared, one each for   β2M and tRNA 
(Table 3.13) 





Table!3.13! ! ! !
Reagent Volume (µl) 
Sybr Green 6.5 
ddH2O 12.5 
Forward primer (10µM) 2.5 
Reverse primer (10µM) 2.5 
!
Table! 3.13.! Reagent! used! and! volumes! per! well! for! qPCR! to! ascertain!mitochondrial! copy!
number.! !
 
To each well of an Optical 96-Well Reaction Plate, 24µl of the master mix and 1µl of the 
relevant standard or diluted genomic DNA was added. Each biological repeat of the 
samples and the standards was carried out in triplicate. The reaction conditions were as 
follows:  
 
95°C for 10 min  
40 cycles of  
-- 95°C for 15 sec and  
-- 60°C for 1 min.  
Fluorescence readings were taken at the end of the 60°C incubation.   
To calculate the exact number of mitochondrial copies in our sample, the Ct values 




Standard curves of both tRNA and β2M were generated by plotting the mean Ct value 
of the standards against concentration of the standard. A logarithmic regression was 
performed on excel and the resulting equation was used to calculate the copy number 




equation generated (as below). The standard curves were only used if the efficiency 
was ≥ 99%.  
 
Ct = m*ln(x) + b, where  
M= slope,  
b = y intercept and  
x = sample’s genome copy number 
 
This allowed determination of the log copy number and 10X (where X is the log copy 
number) determined the actual number of nuclear (for β2m) and mitochondrial genomes 
(tRNA). For β2M, the nuclear copy number/cell was calculated by dividing the copy 
number by two. Finally the mitochondrial DNA copy number was normalized to nuclear 
DNA copy number by dividing the number of mitochondrial genomes by the average 
number of nuclear genomes/cell to derive the mitochondrial copy number/genome/cell. 
Initially values were calculated for each replicate and a final mean value was calculated 
and used as a measure of mtDNA copy number.  
 
3.11! Experiments!with!patient!samples!
RNA from 12 MSI and seven MSS tumours with RNA from matched surrounding tissue 
was obtained as a kind gift from Professor Andrew Silver’s laboratory (Centre for 
Genomics and Child Heath, Blizzard Institute, QMUL). Characteristics of the patient 
samples are listed in Table 3.14. The RNA was quantified and cDNA synthesised as 
described in section 3.6.1. The expression of the antioxidant enzymes in these samples 
was measured using qRT-PCR as described in section 3.6.2 and using the primers 
detailed in Table 3.4. The data was analysed as described in 3.6.3. For each sample 
the experiment was carried out twice and samples were plated in duplicate for each of 








Code MSI/MSS Gender Age at 
diagnosis 
TNM Dukes' Site 
303 MSI M 47 T2N2Mx C Proxiaml 
colon 
312 MSI F 54 T3N1Mx C Proximal 
colon 
323 MSI F 82 T3N0Mx B Proxiamal 
colon 
325 MSI M 77 T3N0Mx B Proximal 
colon 
334 MSI M 76 T3N1Mx C Proximal 
colon 
339 MSI F 79 T4N0Mx B Proximal 
colon 
340 MSI M 73 T3N1Mx C Proximal 
colon 







362 MSI F 83 T3N1Mx C Proximal 
colon 
371 MSI M 83 T3N0Mx B Distal 
colon 
375 MSI M 65 T3N0Mx B Proximal 
colon 
383 MSI M 20 T3N0Mx B Proximal 
colon 










131 MSS M 27 T3N0Mx B Rectum 
347 MSS M 58 T4N2Mx C Proximal 
colon 
353 MSS F 36 T2N0Mx A Rectum 
389 MSS M 78 T3N0Mx B Rectum 
390 MSS F 60 T3N2Mx C Proximal 
colon 
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4.1.1! The! ROS! inducing! agent! Parthenolide! is! selectively! lethal! with! MLH1Tdeficient! cell!
lines! !
With the aim of identifying compounds that are selectively lethal with MLH1 deficient cell 
lines, our lab have previously screened the MLH1-deficient human colorectal cell line 
HCT116 and its isogenetically matched MLH1-proficient cell line HCT116+chr3, with the 
Prestwick chemical library (120 small molecules, 90% marketed drugs and the 
remaining 10% bioactive alkaloids). Cell viability was estimated using a luciferase-
based ATP assay (CellTiter-Glo) and the effect of each compound on viability was 
estimated by comparing luciferase readings from drug treated wells with those from 
wells treated with the compound vehicle, DMSO. “Hit” compounds were identified if 
treatment caused selective lethality in MLH1-deficient cells, in comparison to MLH1-
proficient cells. The top hits included Menadione, Podophyllotoxin and Parthenolide. 
Strikingly, upon analysis, all of these hit compounds have been shown to target 
mitochondrial function.  
 
Preliminary data previously carried out in our lab outlined above, using synthetic lethal 
compound screens suggest that the MLH1-deficient cell line, HCT116 is selectively 
lethal with mitochondrial-targeted agents (Menadione, Parthenolide and 
Podophyllotoxin), when compared to the isogeneticallymatched MLH1-proficient cell 
line, HCT116+chr3. Based on this data I initially aimed to validate the drugs identified in 
these previous screens, in addition to a range of agents known to target various aspects 
of the mitochondria, in a panel of MLH1-deficient and -proficient cell lines.  To this end, I 
first confirmed the MLH1 status of a panel of cell lines (Table 4.1) (HCT116, 
A2780cp70, IGROV, MFE-296, SKOV3, SW48, HCT116+chr3, A2780, HT29, MFE-280, 







Cell line Tumour type MLH1 status 
HCT116 Colorectal Deficient 
A2780cp70 Ovarian Deficient 
AN3CA Ovarian Deficient 
MFE296 Endometrial Deficient 
IGROV Ovarian Deficient 
SKOV3 Ovarian Deficient 
SW48 Colorectal Deficient 
HCT116+chr3 Colorectal Proficient 
A2780 Ovarian Proficient 
HT29 Colorectal Proficient 
MFE280 Endometrial Proficient 

















Protein! lysates! were! isolated! from! a! panel! of! MLH1Fdeficient! (HCT116,! A2780cp70,! AN3CA,!
MFE296,!SKOV3!and!SW48)!and!proficient! (HCT116+chr3,!A2780,!HT29,!MFE280!and!SW620)!
cell! lines! and! analyzed! by! western! blotting! using! MLH1! and! βFactin! primary! antibodies.! (A)!
Western!blotting!to!confirm!the!MLH1!status!of!a!panel!of!MLH1Fdeficient!cell!lines.!The!MLH1F







I next treated our panel of MLH1-deficient and MLH1-proficient cell lines using short-
term cell viability assays with increasing concentrations of the ‘hit’ compounds 
(Parthenolide, Menadione and Podophllotoxin)  identified in the drug screen which all 
target mitochondrial function. Five days post drug treatment, cell viability was estimated 
using a luciferase-based ATP assay (CellTiter-Glo; Promega). The effect of each 
compound was determined by comparing luciferase readings from drug treated wells 
with those from wells treated with the compound vehicle (DMSO). These experiments 
validated that the ROS inducing drug Parthenolide exhibited the most consistent 
selective toxicity between MLH1-deficient and -proficient cell lines in both the 
isogenetically matched cell lines HCT116 (MLH1-VE) and HCT116+chr3 (MLH1+VE) 
(Figure 4.2) as well as in a panel of genetically diverse MLH1-deficient and -proficient 














Figure! 4.2.! The! ROS! inducing! agent! Parthenolide! is! synthetically! lethal! with! the! MLH1T
deficient!cell!line!HCT116!compared!to!its!isogenetically!matched!MLH1Tproficient!cell!line.!
!(AFC)! ShortFterm! survival! curves! are! shown! upon! continuous! exposure! to! increasing!
concentrations!of!Parthenolide.!After!5!days!cell! viability!was!estimated!using! the!ATP!assay,!
CellTiterFGlo.! The! isogenetically! matched! cell! lines! HCT116! which! is! MLH1Fdeficient! and!
HCT116+chr3! which! is!MLHL1F! proficient! were! treated! with! increasing! concentrations! of! (A)!
Parthenolide! (B)! Podophyllotoxin! (C)!Menadione.!Graphs! shown!here! are! one! representative!















Figure!4.3.!The!ROS! inducing!agent!Parthenolide! is! synthetically! lethal!with!MLH1Tdeficient!
cell!lines!in!a!panel!of!cell!lines!from!a!range!of!tumour!types.!!
(AFC)! The! MLH1Fdeficient! cell! lines! HCT116,! SKOV3,! IGROV,! MFEF296,! A2780cp70! and! the!
MLH1Fproficient!cell!lines!HCT116+chr3,!SW480,!SW620!and!HT29!under!continuous!exposure!







4.1.1.2!! MLH1Tdeficient! cell! lines! are! only! synthetically! lethal! with! Parthenolide! and!
not!other!drugs!targeting!mitochondrial!function!
 
To determine, whether mitochondrial-targeted drugs in general are selective for loss of 
MLH1, the same panel of MLH1-proficient and -deficient cell lines was treated with a 
range of mitochondrial-targeted compounds including Betulinic acid, Dichloroacetate, 2-
Deoxy-D-glucose, ABT 737, and Lonidamine (Figure 4.4A-4.4E), (Table 4.2). These 
drugs act on a variety of mitochondrial functions (Table 4.2) but did not show selectivity 








Drug Mechanism of Action 
Parthenolide ROS inducing agent 
Activates NADPH oxidase 
Inhibits SOD1 and 
catalase 
 
Menadione ROS inducing agent 
Futile redox cycling 
B-lapachone NQO1 dependent ROS 
induction 
2-Deoxy-D-Glucose Inhibitor of hexokinase 
(HK) 
Dichloroacetate Inhibitor of pyruvate 
dehydrogenase kinase 
(PDK) 
Podophyllotoxin Inhibitor of Topoisomerase  
II 
ABT-737 Modulator of BCL-2 
protein family 
Lonidamine Adenine nucleotide 
translocase ligand (ANT) 
Betulinic acid Interacts with permeability 




















glucose,! Lonidamine,! Betulinic! acid! and! Dichloroacetate! in!MLH1Fdeficient! cell! lines.! ! ShortF
term!survival!curves!are!shown!under!continuous!exposure!to!increasing!concentrations!of!the!
mitochondrialFtargeted! agents.! After! 5! days! of! exposure! to! the! drugs,! cell! viability! was!
estimated!using!the!ATP!assay!CelltireGLo.!Short!term!cell!viability!curves!of!the!MLH1Fdeficient!
cell! lines! HCT116,! SKOV3,! IGROV,! MFEF296,! A2780cp70! and! the! MLH1Fproficient! cell! lines!
HCT116+chr3,! SW480,! SW620!and!HT29!under! continuous! exposure! to! (A)! Betulinic! acid,! (B)!
Dichloroacetate,! (C)! ABT! 737,! (D)! Lonidamine,! (E)! 2FDeoxyFDFglucose! (5! days).! Error! bars!





4.1.2! Investigating! the! mechanism! behind! the! synthetic! lethal! relationship!
between!Parthenolide!treatment!and!MLH1!loss.!
4.1.2.1!! Increased! ROS! production! in! MLH1Tdeficient! cell! lines! treated! with!
Parthenolide!
 
Parthenolide has been established to be a ROS inducing agent and I observed a 
synthetic lethal relationship with Parthenolide and MLH1-deficient cell lines. Therefore I 
next investigated whether this selectivity was due to ROS induction.  To this end, I used 
the dye Dihydroethidium (DHE) to measure ROS production in MLH1-deficient 
(HCT116) and -proficient (HCT116+chr3) cell lines treated with vehicle control (DMSO) 
and Parthenolide (10 µM). The cell lines were treated with either DMSO, Parthenolide 
or three different concentrations of the Complex III inhibitor Antimycin which is known to 
induce ROS (positive control). Cellular ROS levels were measured using the dye DHE 
which becomes oxidized to ethidium in the presence of ROS and emits red 
fluorescence. This increased fluorescence was measured on a high-throughput 
fluorescent microscope (MitoXpress). We observed a gradual increase in fluorescence 
with increasing concentrations of Antimycin (Figure 4.5A) confirming that this method 
for measuring ROS was robust. Our results indicated that there was no significant 
difference in baseline ROS levels between MLH1-deficient and -proficient cell lines 
treated with DMSO (Figure 4.5B) but upon addition of Parthenolide, we observed a 
significant increase in ROS production in the MLH1-deficient cell line HCT116 
compared to the MLH1-proficient cell line HCT116+chr3 (Figure 4.5C). To further 
investigate this, I also carried out short-term cell viability assays using the same cell 
lines treated with Parthenolide, with and without the ROS scavenger, N-acetylcysteine 
(NAC; Figure 4.5D). I observed that addition of NAC (1mg/ml) rescued the selective 
lethality of Parthenolide in the HCT116 cells and rescued cell viability to approximately 
the level of the MLH1-proficient cell line, HCT116+chr3 This observation confirmed that 
Parthenolide induces selective lethality in MLH1-deficient cell lines through 
accumulation of ROS.  
 
Taken together, these experiments displaying increased ROS production in the MLH1-




NAC is able to rescue this selectivity strongly suggests that the mechanism of selectivity 
of Parthenolide with MLH1-deficient cell lines is at least in part likely to be related to 
ROS. These experiments highlighted that ROS metabolism could in some way be 



















The!MLH1Fdeficient! HCT116! cell! line! and! its! isogenetically!matched!MLH1Fproficient! cell! line!




between! the! baseline! (DMSO! treated)! ROS! levels! in! MLH1Fdeficient! and! proficient!
isogeneticallymatched!cell! lines.! (B)!There! is!a! significant! increase! in!ROS! levels! in! the!MLH1F
















Thus far my results suggest that the mechanism of selectivity of Parthenolide with 
MLH1 loss is related to ROS and possibly due to ROS accumulation, so I decided to 
investigate whether MLH1 loss is selectively lethal with other ROS inducing drugs. I 
treated the isogenetically matched cell line HCT116 (MLH1-deficient) and HCT116+chr3 
(MLH1-proficient) with increasing concentrations of the ROS inducing agents 
Menadione and β-lapachone with and without the addition of the ROS scavenger NAC 
and compared the surviving fraction from short term cell viability assays (Figure 4.6A 
and 4.6B). Overall there was no selective toxicity of these ROS inducing agents with 
MLH1 loss. Of note, there were several experiments where MLH1 loss was selectively 
lethal with Menadione and β-lapachone but my overall conclusion is based on the fact 
that I did not observe this selectivity in a reproducible manner across several 
experiments. The non-selective cell death seen in these experiments was rescued by 
NAC confirming that the ROS agents used in these experiments did indeed induce ROS 
and kill the cells by producing ROS. Similar cell viability assays were also carried out in 
a panel of MLH1-proficient and deficient cell lines (Figure 4.6C and 4.6D) and again 
overall there was no selective toxicity across all the MLH1-deficient cell lines when 
treated with Menadione and β-lapachone. It is worth noting that the majority of MLH1-
deficient cell lines amongst a panel of cell lines did result in selective toxicity with 
Menadione and β-lapachone. These results could be attributed to the different ways in 

















(AFD)! Investigation!of!the!ROS! inducing!drugs,!Menadione!and!βFlapachone! in!MLH1Fdeficient!
and! –proficient! cells.! Short! term! survival! curves! are! shown! under! continuous! exposure! to!
increasing!concentrations!of!the!ROS!inducing!agents!After!5!days!cell!viability!was!estimated!
using! the! ATP! assay! CelltireGLo.! (A,! B)! ShortFterm! cell! viability! curves! of! the!
isogeneticallymatched!cell!lines!HCT116!(MLH1Fdeficient)!and!HCT116+chr3!(MLH1FVE)!treated!
with!(A)!Menadione!+/F!NAC!and!(B)!βFlapachone!+/F!NAC.!(C,D)!ShortFterm!cell!viability!curves!









4.2! Functional! investigation! to! study! the! differences! between!
mitochondrial!function!in!MLH1Tdeficient!and!proficient!cells!lines!
4.2.1! Investigating!the!antioxidant!defense!system!in!MLH1!deficiency!
4.2.1.1!! Decreased!gene!and!protein!expression!of! the! transcription! factor! !NRF2!and!
the!downstream!antioxidant!defense!enzymes!
 
Thus far I observed that MLH1-deficient cells were sensitive to Parthenolide due to 
ROS induction but the same sensitivity was not observed with other ROS inducing 
agents,. Parthenolide is known to act on members of the antioxidant defense system 
therefore I next investigated whether the cellular antioxidant response could be different 
upon MLH1 loss.. 
 
To this end I measured the gene expression of the transcription factor NRF2 (NFE2L2), 
which is responsible for coordinating the antioxidant defense system of cells, as well as 
several downstream antioxidant enzymes (SOD1, catalase, and GPX1 by qRT-PCR 
(Figure 4.7A-4.7D). I observed a significant decrease in the expression of NRF2, SOD1, 
Catalase and GPX1 (Figure 4.7A-4.7D) in the MLH1-deficient cell line HCT116 
compared to its isogenetically matched pair HCT116+chr3 Next, I validated these 
observations by western blotting observing decreased protein levels of NRF2, catalase 





























(AFC)! Western! blot! analysis! to! investigate! expression! of! several! antioxidant! enzymes! in! the!
absence! of!MLH1! expression.!Protein! lysates!were! isolated! from! the!MLH1Fdeficient! HCT116!
and! the! MLH1Fproficient! HCT116+chr3! cell! lines! and!analyzed!by! western! blotting! using! an!!
antiFNRF2,! antiFcatalase!or! an! antiFGpx1,!in! addition! to!MLH1! and! βFactin! primary!
antibodies.!Decreased! expression! of! the! transcription! factors! (A)! NRF2! ! as! well! as! the!
downstream! antioxidant! enzymes! (B)! Gpx1! and! (C)! catalase! was! observed! in! the! MLH1F








Thus far I observed a difference in ROS metabolism and the antioxidant response 
between MLH1-deficient and proficient cell lines but to get a full understanding of why 
these differences may be present it was imperative to investigate mitochondrial function 
since this is where most ROS is produced.   
 
To investigate mitochondrial function, we initially investigated the OXPHOS system 
since this is one of the main functions of the mitochondria.  We isolated protein from our 
MLH1-deficient and MLH1-proficient cells and performed western blotting to determine 
the expression of the five respiratory chain complexes. Our data showed decreased 
expression of Complex I in the MLH1-deficient HCT116 cell line compared to its 
matched MLH1-proficient cell line HCT116+chr3, using an antibody cocktail targeting all 
five membrane-bound complexes of the respiratory chain (Figure 4.9A). We validated 
our observation using the primary antibody NDUFB8 (Figure 4.9B), which detects an 
accessory subunit of Complex I and observed decreased NDUFB8 expression. 
Furthermore we also analysed NDUFB8 expression in our panel of genetically diverse 
MLH1-proficient and deficient cell lines, however we did not observe consistent 
decreased NDUFB8 in our MLH1-deficient cells (Figure 4.10A) across this panel. This 
may be due to the fact that this is a panel of isogenetically diverse cell lines with 
potentially a range of other mutations that could affect NDUFB8 expression. Another 
important fact to consider is that Complex I is made up of 45 subunits so there may be 
mutations in other subunits.  
 
To further investigate deficiencies in Complex I, we analysed gene expression of two 
mitochondrial-encoded core Complex I subunits MTND1 and MTND2 (Figure 4.11A-
4.11B) as well as a further nuclear encoded accessory subunit NDUFA (Figure 4.11C) 
in the MLH1-deficient cell line HCT116 compared to the MLH1-proficient cell line 
HCT116+chr3 Our data suggests that MTND1, MTND2 and NDUFA expression was 











(AFB)! Western! blot! analysis! to! investigate! expression! of! Complex! I! in! the! absence! of!
MLH1.!Protein! lysates!were! isolated!from!the!MLH1Fdeficient!cell! line!HCT116!and!the!MLH1F
proficient! cell! line!HCT116+chr3! cell! and!analyzed!by!western! blotting! using! (A)! antiFOXPHOS!
(cocktail!antibody!detecting!all!five!oxidative!phosphorylation!complexes)!and!(B)!antiFNDUFB8!
(accessory! subunit! of! Complex! I),!in! addition! to!MLH1! and! βFactin! primary! antibodies.! (AFB)!













Figure! 4.10.! Decreased! expression! of!mitochondrial! encoded! Complex! I! subunits! in!MLH1T
deficient!cell!lines.!!
(AFB)!qRTFPCR!was!used!to!measure!the!expression!of!several!mitochondrial!encoded!Complex!I!













(A)! Western! blot! analysis! to! investigate! expression! of! Complex! I! in! the! absence! of!
MLH1.!Protein! lysates! were! isolated! from! the! MLH1Fdeficient! cell! lines! cell! lines! HCT116,!








Given that the panel of cell lines have a diverse genetic makeup, aside from their 
differences in MLH1 status and the fact that Complex I is made up of multiple subunits, 
we decided to measure Complex I activity since this may be more biologically relevant. 
Complex I activity was measured using an ELISA assay assessing the oxidation of 
NADH to NAD+, which in turn leads to reduction of a dye and increased absorbance at 
OD 450 nm. We observed a significant decrease in the activity of Complex I in the 
MLH1-deficient cell line HCT116, compared to the MLH1-proficient HCT116+chr3 cells 
(Figure 4.12A). We also observed a statistically significant decrease in the activity of 
Complex I in our panel of MLH1-deficient cell lines compared to the MLH1-proficient cell 
lines. (Figure 4.12B). We hypothesized from these results that the decrease in Complex 
I activity in the absence of MLH1, may have a role to play in the selectivity we observe 
with Parthenolide.  
 
Given that I had observed the selectivity of MLH1 with Parthenolide in a panel of cell 
lines I also looked at the expression of NDUFB8 in this panel of cell lines to see whether 
deficiencies in Complex I might explain the mechanism of selectivity. I did not see a 
similar trend in my panel of genetically diverse MLH1-deficient and proficient cell lines 
(Figure 4.11). However when I examined Complex I activity which is more biologically 
relevant, a significant difference in Complex I expression became apparent between the 
MLH1-deficient and proficient cell lines in my panel of cells (Figure 4.12B)  
 
Given how integral Complex I is to oxidative phosphorylation, I hypothesized that my 


















quantified!and!equal!amounts!of!protein!were! incubated! in! the!ELISA!plate! to!determine!the!






duplicates! performed! in! three! independent! experiments.! (A)! The! graph! shown! here! is! a!










Thus far, we identified significant differences in the expression and activity of Complex I 
in MLH1-proficient and -deficient cell lines. Given that Complex I is the biggest Complex 
In the oxidative phosphorylation chain, we wanted to examine whether there was a 
difference in oxidative phosphorylation and mitochondrial metabolism in general 
between the MLH1-deficient and -proficient cell lines using the Seahorse XF analyzer. 
The XF analyzer measures the rate of oxygen consumption in a given sample providing 
a measure of oxidative phosphorylation. The basal oxidative consumption rate (OCR) 
when no drugs are added to the sample allows a measure of basal respiration.  The 
addition of the uncoupling agent FCCP provided a measure of the cells maximal 
respiratory capacity and when the basal OCR is taken away from the maximal 
respiration a measure of spare respiratory capacity (SRC) is obtained. The XF analyzer 
was used to measure the difference in the OCR as a measure of oxidative 
phosphorylation in the HCT116 and HCT116+chr3 cell lines as well as in a panel of 
MLH1-proficient and -deficient cell lines. Our experiments have shown a significant 
decrease in the basal OCR (Figure 4.13A+4.13B) and a decrease in the SRC (Figure 
4.13C) in the MLH1-deficient HCT116 cells compared to the MLH1-proficient 
HCT116+chr3 cells. We also observed a statistically significant decrease in the basal 
OCR in the panel of MLH1-deficient cell lines (figure 4.13D), compared to the MLH1-
proficient cell lines. These results confirm that not only is Complex I deregulated in 
MLH1-deficient cells; there is also decreased oxidative phosphorylation in general, in 


















Figure!4.13.!Reduced!basal!OCR!and! spare! respiratory! capacity! in!MLH1Tdeficient! cell! lines.!
(AFD)!The!XF!analyzer!was!used!to!analyze!the!OCR!as!a!measure!of!oxidative!phosphorylation.!
The! basal! OCR! was! determined! prior! to! the! addition! of! drugs! to! ascertain! the!
full!bioenergetic!profile.!The!addition!of!Oligomycin!(1um)!inhibits!complex!V!and!approximates!
leak! of! the! inner! mitochondrial! membrane.!! The! addition! of! FCCP! (0.25um)! allows! for!
measurement! of! maximal! respiration.!! Mitochondrial! respiration! is! then! inhibited! by! the!
addition! of! the! Complex! I! inhibitor! Rotenone! (1um)! and! the! Complex! III!
inhibitor!Antimycin!(1um)! to!ascertain!nonFmitochondrial! sources!of!oxygen!consumption.! (A)!
An! example! illustrating! the! results! of! the! full!bioenergetic!profile! from!one! experiment! using!











4.2.4! Investigating! differences! in! the! mitochondrial! genome! between! MLH1T
proficient!and!deficient!cell!lines!
4.2.4.1!! There! are! no! significant! differences! in! mutations! within! Complex! I! genes! in!
MLH1Tdeficient!and!proficient!cell!lines!
To explore the reasons behind the deficiencies in Complex I that I observed I 
hypothesized that there may be an increased number of mutations within microsatellites 
in mitochondrial encoded Complex I genes between MLH1-deficient and proficient cell 
lines. Increased mutations within microsatellites, due to the nature of these repetitive 
sequences has been extensively described in CRC with MMR deficiency. [374, 375]. 
Similar observations of MSI in the mitochondrial genome have been suggested but this 
concept has not been as well established as MSI in the nuclear genome.  One study by 
Habano et al discovered that out of 45 sporadic colorectal cancers, 44% had mutations 
within microsatellites in the non-coding D-loop region of the mtDNA and tumours also 
had mutations within mitochondrial encoded Complex I genes [76]. This study was the 
first indication that MMR deficient tumours may harbour mutations within Complex I 
genes. More recently, Mishra et al proved that MLH1 deficiency (as a result of retinal 
endothelial cells exposed to high glucose) leads to increased sequence variants in the 
mitochondrial D-loop region and decreased OCR. All of these finding were ameliorated 
when MLH1 was overexpressed [78].   
 
To investigate if MSI may account for the deficiencies in Complex I that I had observed, 
I carried out experiments using the Illumina MiSeq platform to carry out next generation 
sequencing on the mitochondrial genome of the isogenetically matched cell lines 
HCT116 which is MLH1-deficient and HCT116+chr3 which is MLH1-proficient. 
Interestingly I did not observe a difference in mutations within the seven known 
mitochondrial encoded Complex I genes as well as the non-coding D-loop regions 









My results thus far have displayed a mitochondrial phenotype with a deregulated 
antioxidant response, deficiencies in Complex I and decreased oxidative 
phosphorylation in MLH1-deficient cell lines. Therefore I next investigated the possible 
reasons to explain this. We initially examined the expression of the nuclear 
transcriptional co-activator PGC-1β in my MLH1-deficient and proficient cell lines since 
this co-activator is known as the master regulator of mitochondrial biogenesis and has 
been described to mediate the transcription of a multitude of nuclear encoded 
mitochondrial genes [325]. Significantly, we observed a decrease in the expression of 
PGC-1β (Figure 4.14A) in our MLH1-deficient cell line compared to the isogenetically 
matched MLH1-proficient cell line HCT116+chr3 suggesting that the MLH1-deficient cell 
lines were likely to have decreased mitochondrial biogenesis compared to the MLH1-
proficient cell lines. I also analysed the expression of NRF1, which is downstream of 
PGC-1β and co-activates mitochondrial transcription factor A, which in turn regulates 
mitochondrial biogenesis and function [333]. In concurrence with our previous results, 
NRF1 protein levels (Figure 4.14B) and gene expression (Figure 4.14C).  was reduced 
in the MLH1-deficient cell line HCT116 compared to the MLH1 proficient cell line 
HCT116+chr3. I also carried out qPCR experiments to determine the mitochondrial 
copy number of my samples by determining the ratio of the expression of mitochondrial 
tRNA to nuclear β2M. There was a striking decrease in the mitochondrial copy number 
of the MLH1-deficient HCT116 cell line compared to proficient cell line HCT116+chr3 
(Figure 4.14D). Both these findings demonstrate that MLH1-deficient cell lines have 
decreased mitochondrial biogenesis and taken together with my other findings in this 


















cell! lines.! (A)! qRTFPCR!was! used! to!measure! the! expression! of! PGC1β.! There!was! decreased!
expression! of! pgc1β! in! the! MLH1Fdeficient! cell! line! HCT116! compared! to! its! isogenetically!
matched! MLH1Fproficient! cell! line! HCT116+chr3! (B)! Western! blot! analysis! to! investigate!
expression!of!NRF1!in!the!absence!of!MLH1!expression.!Protein!lysates!were!isolated!from!the!
MLH1Fdeficient! HCT116! and! the! MLH1Fproficient! HCT116+chr3! cell! lines! and!analyzed!by!
western!blotting!using!an! !antiFNRF1,!MLH1!and!βFactin!primary!antibodies.!NRF1!expression!
was! significantly! decreased! in! the! MLH1! deficient! cell! line! HCT116! compared! to! the! MLH1!
proficient!cell! line!HCT116+chr3! (C)!qRTFPCR!was!used! to!measure! the!expression!of!NRF1! in!
the!same!cell!lines!and!there!was!!a!significant!reduction!in!the!gene!expression!of!NRF1!in!the!
MLH1! deficient!HCT116! cell! line! compared! to! the!MLH1! proficient! cell! line!HCT116+chr3! (D)!
Mitochondrial! copy! number! was! also! determined! in! the! same! cell! lines! using! qPCR! with!
genomic!DNA.!There!was!a!significant!decrease! in! the!average!mitochondrial!copy!number! in!










4.3.1.1!! There! is!no!significant!decrease! in!expression!of!antioxidant!defense!genes! in!
MLH1Tdeficient!and!MSI!patient!tumour!samples!
 
In order to determine whether a similar phenotype may be present in tumours from 
MLH1-deficient patient samples I decided to examine the gene expression of the 
antioxidant defense enzymes using qRT-PCR using RNA from MMR-deficient and 
MMR-proficient patient tumour samples  and comparing it to RNA from adjacent normal 
tissue (for characteristics of patient samples see Table 3.14). I carried this experiment 
out in tumour samples known to be MSI positive and determined whether they were 
MLH1 negative by qRT-PCR. Similar experiments were also carried out in MSS tumour 
samples in order to compare MSI tumours with MSS tumours. I did not see the same 
decreased expression of the antioxidant defense enzymes (NRF2, SOD1, Catalase and 
GPX1) or genes involved in mitochondrial biogenesis (PGC1β and NRF1) in the MLH1-
deficient tumours compared to normal tissue (Figure 4.15A-4.15F). Furthermore there 
was no significant difference in the fold change (compared to matched normal tissue) in 
expression of the antioxidant defense enzymes in MSI tumours compared to MSS 
tumours (Figure 4.16A-4.16F and Figure 4.17).  
 
Upon comparing the expression of PGC1β, NRF1 and the antioxidant defense genes in 
the patient samples, I did not observe a consistent difference in expression in these 
genes between the tumour samples and matched normal tissue in the MLH1-deficient 
tumours. There was also no significant difference in the expression of these genes 




























































The! average! fold! change! in! expression! of! the! antioxidant! genes! compared! to! surrounding!






Average fold change 
Gene MSS MSI 
PGC1β 2.07569247 2.007241727 
NRF1 2.11204977 2.276021 
NRF2 4.21932991 2.190205071 
Catalase 2.07029845 2.040376571 
GPx1 2.35512133 2.098196083 




4.3.2! Analysis! of! mitochondrial! phenotypes! in! other! MMRTdeficient! cells!
Examining!!
4.3.2.1!! Deficiencies!in!Complex!I!in!MSH2!and!MSH6!deficient!cell!lines!
Taken together my data conclusively demonstrates that MLH1-deficient cell lines have a 
deregulated mitochondrial phenotype. Therefore, I next investigated whether other 
MMR-deficiencies display a similar phenotype or whether my observations are specific 
to deficiencies in MLH1 only. Initially, we analysed Complex I protein expression in the 
MSH2- and MSH6-deficient and -proficient matched cell lines using the antibody 
targeting NDUFB8 (Figure 4.18A-C) Protein was isolated from the MSH2-deficient cell 
line HEC59 and its isogenetically matched cell line HEC59+chr2 and the MSH6 
deficient cell lines DLD1 and U251.TR3 and their matched MSH6 proficient cell lines 
DLD1+chr2 and U251, respectively. Upon western blotting for NDUFB8 expression, we 
observed a decrease in NDUFB8 expression in the MSH2-deficient HEC59 cells (Figure 
4.18A) and in the MSH6 deficient DLD1 cell line (Figure 4.18B), in comparison to their 
MMR-proficient matched cell lines. However, a slight decrease in NDUFB8 expression 
was observed in the MSH6-deficient U251.TR3 (Figure 4.18C) cell line in comparison to 
the U251 cells. The fact that the MSH6 deficient cell line DLD1 displayed a more 
pronounced decrease in NDUFB8 expression compared to U251.TR3 could be 
explained by the fact that these matched cell lines are generated by different methods 
leading to different cell models. U251.TR3 is made by exposure to Temozolomide and 
therefore acquires secondary mutations whereas the addition of chromosome 2 to 
DLD1 cells results in the addition of other genes carried on this chromosome which may 






















MSH6! proficient! cell! lines! DLD1+chr2! and! U251.! These! cell! lines! were! analyzed!by! western!
blotting!using!antiFNDUFB8!(accessory!subunit!of!Complex!I),!MSH2,!MSH6!and!βFactin!primary!






To further investigate the decreased Complex I expression in the MSH2 and MSH6 
deficient cells, we next measured the activity of Complex I activity, as before. Measuring 
Complex I activity would allow me to see if there are differences in Complex I as a 
whole as opposed to a single subunit. Upon carrying out the ELISA to measure 
Complex I activity, I did indeed see a decrease in activity in all the MMR-deficient cells 
analysed (Figure 4.19A-4.19C). Given that Complex I activity is likely to be more 
biologically relevant than examining the expression of the individual Complex I subunits, 
this result displaying decreased Complex I activity in all my MMR-deficient cell lines 
lead me to further investigate whether these cell lines displayed deficiencies in 








(AFC)! An! ELISA! was! used! to! measure! Complex! I! activity.!Protein! lysates! were! isolated! and!
quantified!and!equal!amounts!of!protein!were! incubated! in! the!ELISA!plate! to!determine!the!
activity! of! Complex! I! by!measuring! the! oxidation! of! NADH! to! NAD+! and! the! simultaneous!
reduction!of! a!dye! leading! to! increased!absorbance!at!450!nm,!over! time.!Complex! I! activity!
was! measured! using! the! ELISA! described! with! protein! lysates! from! the! (A)! MSH2Fdeficient!
HEC59! and!MSh2F! proficient!HEC59+chr2! cell! lines.! (B)! The!MSH6Fdeficient!DLD1! and!MSH6F






4.4.2.2!! MSH2! deficient! cell! lines! have! decreased! mitochondrial! copy! number! and!
decreased!expression!of!the!antioxidant!defense!enzymes.!
"
I wanted to investigate if MMR deficient cell lines have the same mitochondrial 
phenotype as I had shown in MLH1-deficient cell lines so I carried out similar 
experiments as previously mentioned to determine expression of PGC1β, antioxidant 
defense genes and mitochondrial copy number in my panel of MMR deficient and 
proficient cell lines. Our results suggest that only the MSH2 deficient cell lines HEC59 
displayed decreased expression of the antioxidant defense genes (Figure 4.20A-4.20F) 
and decreased mitochondrial copy number (Figure 4.21A) compared to its matched 



















































Given the mitochondrial phenotype I had observed in my MLH1-deficient cell lines I 
wanted to investigate if a similar phenotype was present in other MMR deficient cell 
lines. I used western blot analysis to look for the expression of Complex I (NDUFB8 
subunit) in a panel of MMR-deficient and proficient isogenetically matched cell lines. I 
observed a decrease in the expression of NDUFB8 in the MSH2 deficient cell line, 
HEC59 as well as one of the MSH6 deficient cell lines, DLD1 compared to their 
respective matched MMR proficient cell lines, HEC59+chr2 and DLD1+chr2, 
respectively. In a similar fashion to my previous experiments, I carried out an ELISA in 
these cell lines to examine the activity of Complex I. There was a corresponding 
decrease in activity of Complex I in all the MMR deficient cell (DLD1, HEC59 and 
U251.TR3) lines compared to the corresponding MMR proficient cell lines (DLD1+chr2, 
HEC59+chr2 and U251). Furthermore I observed a similar mitochondrial phenotype with 
decreased mitochondrial copy number as well as decreased expression of PGC1β and 
NRF1 and decreased expression of the antioxidant defense enzymes NRF1, NRF2, 
catalase, GPx1 and SOD1 in the MSH2 deficient cell line HEC59 compared to its 










MMR deficiency is involved in the pathogenesis of a significant proportion of several 
common cancers and MLH1 loss specifically is one of the most common causes for 
MMR deficiency in these tumours. Several studies have shown that MMR-deficient 
tumours are resistant to commonly used chemotherapeutics, so there is an unmet 
clinical need to identify new agents to treat this group of cancers [85]. Numerous lines 
of evidence  including a preliminary screen that identified mitochondrial drugs to be 
selectively lethal with MLH1 deficiency, have suggested that targeting the mitochondria 
in MLH1 deficient disease might be a useful novel strategy [79, 187]. There is little 
known about the MMR pathway and its role in the mitochondria. With the recent move 
in clinical practice towards personalized cancer care, using a synthetic lethal approach 
has proved successful in identifying drugs and targets that affect tumour cells whilst 
sparing normal body cells [84, 188, 376]. To this end, the overall aim for this PhD 
project is to employ a synthetic lethal approach and identify drugs that target 
mitochondrial function, which are synthetically lethal with MLH1 deficient cancers. This 
line of investigation will allow me to explore the relationship between the MMR pathway 




To identify drugs that target mitochondrial function that are synthetically lethal with 
MLH1 deficient cell lines, I tested several drugs identified as hit compounds from a 
previous drug screen carried out by our lab in MLH1 deficient and proficient cell lines. 
Several other drugs were identified from a review by Fulda et al [373] on targeting the 
mitochondria for cancer therapy. Short term cell viability assays were carried out with all 




deficient and HCT116+chr3 which is MLH1 proficient  as well as in a panel of MLH1 
deficient and proficient cell lines from a variety of tumour types (Table 4.1).  
 
The isogenic matched paired models used in this study are generated by using a 
parental cell line harbouring a mutation in one of the MMR genes (HCT116, DLD1, 
HEC59) and the matched proficient cell line is generated by the stable addition of a 
chromosome (HCT116+chr3, DLD1+chr2, HEC59+chr2) [129]. An alternative method 
widely used to establish matched cell lines is to expose the parental cell line which is 
MMR proficient (U251) to a particular drug for a period of time so that an acquired 
mutation is established (U251.TR3 made by exposure to TMZ). The resulting MMR 
deficient cell lines made by this method not only differ in their MMR status but also differ 
with regards to secondary mutations. The matched cell lines result in cells with an 
identical genetic background whereas the panel of cell lines I used have diverse genetic 
backgrounds. 
 
I feel the strategy I employed for testing these drugs is robust since they were all tested 
in an isogentically matched cell line to confirm that the selectivity is due to MLH1 
deficiency and then tested in a panel of isogenetically diverse cell lines to see if my 
results are generalizable to a range of tumour types.  
 
The obvious advantage of using a matched cell line made by the addition of a 
chromosome harboring the MMR gene of interest is that it allows more accurate 
identification of synthetic lethal interactions with MMR genes. Conversely, the criticisms 
directed towards using this approach is that the chromosome contains numerous other 
genes aside from the MMR gene of interest. One could argue that matched cell lines 
generated by an acquired mutation are more clinically relevant since the secondary 
mutations they possess are thought to drive the oncogenic process .  
 
5.1.2! The! ROS! inducing! agent! Parthenolide! is! selectively! lethal! with! MLH1T
deficient!cell!lines!
MLH1 deficient cell lines were found to be synthetically lethal with the ROS inducing 
agent Parthenolide both in the matched cell lines HCT116+/-chr3 (Figure 4.2A) and in a 




MLH1 deficient cell lines was not apparent with agents that target various other aspects 
of the mitochondria (Table 4.2) (Figure 4.4A-4.4E).  
 
The fact that Parthenolide was selectively lethal with MLH1 deficiency in both the 
isogenetically matched cell lines and the panel of cell lines strongly suggests that the 
reason behind the selectivity is MLH1 deficiency. Furthermore, the fact that only 
Parthenolide showed selectivity and not the other mitochondrial-targeted agents 
suggests that the selectivity of Parthenolide is not merely because it is a mitochondrial-
targeted agent. 
 
Parthenolide is a sesquiterpene lactone found in the plant Tanacetum parthenium. It is 
most well known for its anti-inflammatory activity but several studies have recently 
shown it to be an effective chemotherapeutic through ROS generation via activation of 
NOX and inhibition of several FOXO3a target antioxidant enzymes including 
manganese SOD2 and catalase.[377, 378]. A recent study by D’Anneo et al in triple 
negative breast cancers illustrated that Parthenolide and its soluble analogue 
dimethylamino (DMAPT) caused cell death by a strong induction of ROS through 
activation of NOX, depletion of thiol groups and glutathione, activation of JNK and down 
regulation of nuclear factor NF-kB [379].  
 
!
5.2!! Investigating! the! mechanism! behind! the! synthetic! lethal!
relationship!between!Parthenolide!treatment!!and!MLH1!loss!
5.2.1! Increased! ROS! production! in! MLH1Tdeficient! cell! lines! treated! with!
Parthenolide! !
To confirm that the selectivity of Parthenolide with MLH1-deficient cell lines is due to 
ROS production I carried out experiments using the dye DHE to measure ROS levels in 
the MLH1-deficient cell line HCT116 and the MLH1-proficent cell line HCT116+chr3 on 
the the MitoXpress machine. DHE is dye which is widely used to detect superoxide 
anions by the fact that it becomes oxidized and fluoresces upon reacting with these 




in the first 5 hours and that this progressively increases to a maximum from 8-16 hours 
[363].  Upon optimizing this experiment I actually decided to measure ROS levels 
shortly after Parthenolide was added since there was significant cell death  when the 
cells were left for an extended period of time in Parthenolide which could also affect 
ROS levels. Carlisi et al used flow cytometry to measure fluorescence but I used a high 
throughput fluorescent microscope, which may be more sensitive and  therefore detect 
ROS levels earlier. [363]. I observed that the cytosolic ROS levels at baseline  (DMSO  
treated  cells)  were  not  significantly  different  between   the MLH1-deficient and 
proficient cell lines (Figure 4.5B) but increased ROS levels in the  MLH1- deficient cell 
lines became apparent upon treating the cells with the ROS inducing agent 
Parthenolide (Figure 4.5C). The addition of NAC to the same cell lines treated with 
Parthenolide was able to rescue the selectivity (Figure 4.5D). These experiments 
established that ROS was likely to play a significant role in the selectivity of 




I did not observe as robust a selective toxicity with MLH1 deficient cell lines using two 
other ROS-inducing agents; Menadione and β-lapachone (Figure 4.6A-4.6B) compared 
to Parthenolide. This may be due to the different methods in which these drugs induce 
ROS.  
 
Menadione (Vitamin K3)  is a quinone that is metabolized by the reductive enzymes 
NADPH-cytochrome p450 and NADH-ubiquinone oxidoreductase by one electron 
reduction. This process initiates futile redox cycling when the resulting semiquinones 
enter the electron transport chain causing ROS generation [365, 366]. Many pre-clinical 
studies have shown Menadione, through its ability to generate ROS to be a potential 
treatment for cancers. The study by Yang et al found CR108 (a novel vitamin K3 
derivative) to cause cell death in human breast cancer cells by causing ROS 
production, apoptosis and mitochondrial dysfunction [367]. β-lapachone (clinical form, 
ARQ761), induces ROS by also undergoing  futile redox cycles on the respiratory chain 





5.3! Functional! Investigation! to! study! the! differences! between!
mitochondrial!function!in!MLH1Tdeficient!and!proficient!cell!lines!
5.3.1!Investigating! the! antioxidant! response! in! MLH1! deficient! and!
proficient!cell!lines!
I decided to investigate the antioxidant defense system in my cell lines given the vital 
role of this system in the control of ROS levels and the fact that this system is one of the 
targets of Parthenolide. I observed a significant decrease in both the gene expression 
(NRF2, SOD1, Catalase and GPX1) (Figure 4.7A-4.7D) and protein levels (NRF2, 
catalase and GPx1) (Figure 4.8A-4.8C) of several key members of the antioxidant 
defense system in the MLH1-deficient cell line HCT116 compared to its isogentically 
matched pair HCT116+chr3.  
 
The transcription factor NRF2 (NFE2L2) through its interactions with the antioxidant 
response element (ARE) is probably the most well established regulator of several 
enzymes within the antioxidant defense system [113]. Some studies have shown NRF1 
to have a role independent of NRF2 in activating ARE-driven genes but its part in 
controlling the antioxidant system is less well defined [369]. Unlike the other ROS 
agents used in this study, Parthenolide has been shown  to inhibit members of the 
antioxidant defense system which is likely to explain why only Parthenolide showed 
selectivity with MLH1-deficient cell lines which already have an attenuated antioxidant 
response. Furthermore a recent study  by Hassane et al supports our finding since they 
identified NRF2 through a  gene signature analysis to be upregulated as a protective 
mechanism when primary human acute myeloid leukemia (AML) cells are treated with 
Parthenolide [370]. With this Parthenolide gene expression signature they carried out 
chemical genomic screening of the Connectivity Map database and found that 
compounds acting along the phosphatidylinositol 3-kinase and mammalian target (PI3K) 
and mammalian target of rapamycin pathway (mTOR) inhibited this cytoprotective 
responses. The authors used the drug Temsirolimus for their experiments which is a 
known mTOR inhibitor and they were able to show that Temsirolimus inhibits NRF2 and 
its downstream activation of the antioxidant enzymes. They carried out in vitro 




alone and in vivo experiments in murine xeno transplantation models using DMAPT 
(water soluble analogue of Parthenolide) with Temsirolimus or DMAPT as a single 
agent. Compared with Parthenolide alone, the combination treatment was synergistic 
and significantly decreased viability of AML cells and decreased tumour growth in vitro 
[370]. From this study we gain further evidence that cell lines deficient in NRF2 and the 
antioxidant defense enzymes, as is the case with my MLH1 deficient cell lines, are more 
sensitive to the ROS inducing agent Parthenolide due to its mechanism of action. 
 
As mentioned previously, the ROS levels at baseline (DMSO treated cells) between the 
MLH1-deficient HCT116 cell line and the MLH1-proficient cell line HCT116+chr3 were 
not significantly different and the difference only became apparent upon ROS induction. 
It has been established that ROS levels are tightly controlled since they play an 
essential role in cell signaling and maintaining cell function. The electron transport chain 
is known to be one of the main sites of ROS production and deficiencies of the 
complexes involved in this system are known to alter ROS levels. The redox status of 
the electron transport chain is one of the main determinants of ROS production and 
typically deficiencies in the chain are likely to increase ROS levels. It is thought that 
baseline ROS levels are maintained to allow cellular functions but following the 
introduction of stress these levels may change [371]. In this study the baseline ROS 
levels are similar in the MLH1-deficient and proficient cell lines despite an attenuated 
antioxidant defense system, this finding is likely to be due to the tight control of baseline 
ROS levels to allow normal homeostasis. 
"
5.3.1.1"" The"antioxidant"response"in""cancer"
The expression of antioxidant enzymes have been found to be altered in many cancers 
but the evidence thus far does not seem to point to a specific pattern in which the 
antioxidant enzymes are altered in all cancers. Several small studies have been carried 
out examining the difference in expression between cancer tissue and surrounding 
normal tissue. Botwick et al examined the expression of SOD1, SOD2, catalase and 8-
hydroxydeoxyguanosine as a marker of oxidative stress in human prostate carcinoma 
tissue, high grade prostatic intraepilethial neoplasia (PIN) and benign epithelium [410]. 
The authors found decreased expression of all the antioxidant enzymes in PIN and the 




levels  of the DNA adduct 8-hydroxydeoxyguanosine in any of the different types of 
samples, eluding to the fact that oxidative stress occurs early in the development of 
cancer [410]. Chung-man Ho et al looked at the expression of the antioxidant enzymes 
in 16 lung tumour samples (adenocarcinoma and squamous cell) and 24 tumour free 
samples [411]. The authors examined both protein and mRNA expression and found 
decreased total levels of the SODs, decreased catalase expression and similar levels of 
glutathione and glutathione peroxidase in tumours compared with tumour-free lung 
tissues [411]. Studies have also shown that the environmental context can affect 
antioxidant expression as shown in the study conducted by Skrzycki et al which showed 
decreased levels of total SOD in CRC cell lines (SW480 and SW620) in hypoxia 
compared to atmospheric normoxia [412]. Recently a study by Govatati et al examined 
the mitochondrial D loop region of 35 CRC patient  samples  compared to normal tissue 
examining for the incidence of mitochondrial MSI (mtMSI) in this region and then 
correlated the findings to SOD2 expression [413]. The authors concluded that there was 
a significant increase in the incidence of mtMSI in tumour samples and that this had a 
positive correlation with SOD2 overexpression [413]. 
 
I possibly would have expected to observe similar results to the study by Govatati et al 
displaying mtMSI and upregulation of antioxidant enzymes in my MMR deficient cell 
lines. I did not observe an increased incidence of mtMSI in the D-loop region of these 
cells compared to the MMR proficient cell lines. However, one potential reason for this 
is that I was comparing MMR proficient and deficient CRC cell lines and not normal 
tissue compared to CRC tissue. To ultimately determine whether MLH1 deficient 
tumours have increased mtMSI compared to normal tissue, an extensive in-depth 
analysis of fresh tissue is required. Furthermore, the main obstacle with investigating 
mitochondrial mutations is related to the consequences of mitochondrial heteroplasmy 
where there are multiple mitochondrial genotypes within one cell making it difficult to 
detect low level mutations. The use of more high depth sequencing may also help 
determine the precise differences in mtMSI 
 
5.3.2! Investigating!Complex!I!in!MLH1!deficiency!
To investigate if there are functional differences in mitochondrial function between 




bound oxidative phosphorylation complexes.  I established that the MLH1 deficient cell 
line HCT116 has decreased protein expression of Complex I (Figure 4.9A-4.9B) 
(Complex I subunit NDUFB8) and decreased gene expression of both mitochondrial 
(Mt-ND5, Mt-ND2) (Figure 4.10A-4.10B) and nuclear encoded (NDUFA) (Figure 4.10C) 
Complex I subunits compared to its isogentically matched cell line HCT116+chr3. 
Furthermore I observed a significant decrease in the activity of Complex I in the MLH1 
deficient cell line HCT116 compared to its isogenetically matched MLH1-proficient cell 
line HCT116+chr3 (Figure 4.12A). There was also a similar decrease in Complex I 
activity in a panel of MLH1 deficient cell lines compared to a panel of MLH1 proficient 
cell lines (Figure 4.12B). 
 
As described above, Mendione and β-Lapachone produce ROS through a similar 
mechanism which is different to the mechanism of action of Parthenolide. After 
examining the differences in mitochondrial function between my MLH1 deficient and 
proficient cell lines it became apparent that the reason why only Parthenolide is 
selectively lethal with MLH1 deficient cell lines may be due to its mechanism of action 
involving the antioxidant defense system in MLH1 deficient cells which already posses  
deficiencies in Complex I and the antioxidant defense system. 
 
I did not observe a difference in the expression of NDUFB8 between a panel of MLH1-
proficient and deficient cell lines (Figure 4.11A)  which could potentially have explained 
the observed selectivity of this panel of MLH1-deficient cell lines with Parthenolide. 
Given that Complex I is the biggest complex in the oxidative phosphorylation chain and 
composed of thirty seven subunits it is not surprising that I did not see a difference in 
expression of one of the subunits in a genetically diverse panel of cells. When I 
examined complex I activity which is more biologically relevant, a significant difference 
in Complex I expression became apparent between the MLH1-deficient and -proficient 
cell lines in my panel of cells (Figure 4.12B). 
 
5.3.2.1!! Complex!I!and!MMR!deficient!cancer!cell!lines!
The first potential link between Complex I and the MMR system is that of Habano et al 
who examined 45 sporadic colorectal samples and identified mutations within 




the microsatellites in the Complex I genes ND1 and ND5 [247]. More recently, Mori et al 
examined coding region frameshift mutations within 46 MSI-H tumours and identified 
that in 28% of these tumours, there was a mutation in the nuclear encoded B14.5B 
Complex I subunit [380]. 
 
Complex I deficiencies have clearly been demonstrated in a multitude of studies and the 
concept of deficiencies in this complex in the context of cancer is now widely accepted. 
Furthermore there is already some evidence linking complex I deficiencies with MMR 




I used the XF analyzer to see whether the deficiencies I had observed in Complex I 
expression resulted in changes in the basal OCR and SRC. The basal OCR gives a 
measure of basal oxidative phosphorylation whilst the spare respiratory capacity allows 
a measure of the ability of the cells to respond to stress and the resulting increased 
energy demands[88]. Birsoy et al harecently   shown   that   both   defects   in   glucose   
utilization  and  oxidative phosphorylation have an impact on spare respiratory capacity. 
Particularly relevant to my study, the authors demonstrated that cell lines with known 
mutations in Complex I subunits (but no defects in glucose transporters) were unable to 
sufficiently increase their OCR to meet increased demands when grown in low glucose 
media. To further prove that the defect in SRC was due to Complex I the investigators 
demonstrated an increase in the OCR (and SRC) in low glucose conditions in these cell 
lines when the Complex I gene NDII from s. cerevisiae was expressed [372]. 
 
I observed a significant decrease in both the OCR and SRC in my MLH1- deficient cell 
line HCT116 compared to the MLH1-proficient cell line HCT116+chr3 (Figure 4.13A-
4.13C). On carrying out similar experiments in my panel of cell lines  there was a 
decrease in the basal OCR in my panel of genetically diverse MLH1-deficient cell lines 
compared to the MLH1-proficient cell lines (4.13D). These results suggest that MLH1-
deficient cell lines have decreased oxidative phosphorylation and have a decreased 
capacity to respond to increased energy demands and this is likely due to the 






Within the context of cancer, mutations in the mitochondrial encoded respiratory 
complex genes has been shown in various tumour types affecting mainly CI,CIII and 
CIV [505]. It is still unclear what the definitive course of events is within these tumours; 
the main question is whether these mutations cause cancer or arise due to the high 
levels of oxidative stress in the tumour compounded by the fact that mtDNA replication 
and repair occurs with poor fidelity. It is also paramount to remember that any definitive 
conclusions about mtDNA are affected by the fact that there are multiple copies of the 
mitochondrial genome within the numerous mitochondria in each cell. This could lead to 
heteroplasmy where there are multiple mitochondrial genotypes within one cell or 
homoplasmy where all the DNA within all the mitochondria in one cell are the same 
[505]. There is evidence that some mitochondrial mutations even when present in a 
homplasmic state may be merely due to unbiased mtDNA replication and cell division 
alone [506]. Ishikawa et al however carried out a very important study in 2008, which 
showed that when mtDNA in a non- metastatic mouse tumour was replaced by mtDNA 
from a metastatic tumour, there was a significant transformation in the metastatic 
potential of the non- metastatic cell lines [507]. Furthermore, when the reverse 
experiment was carried out the metastatic potential of the aggressive cell lines was 
blunted [507]. Several studies have been carried out with the aim of investigating the 
consequences that mitochondrial respiratory complex mutations, especially Complex I, 
have on tumours. Park et al [5] developed rotenone resistant clones harbouring 
homoplasmic and heteroplasmic mtDNA mutations with a resulting abnormality in 
oxidative phosphorylation. They developed C8T and C9T cells with a frame-shift 
mutation in the ND5 gene which was present in nearly all mtDNA (72% mutant in C8T 
and near homoplasmic DNA in C9T). The mutation that was found in ND5 by this 
method had previously been found by Polyak et al. [508] in human colorectal cancers. 
Cybrids were then created by transferring the mitochondria from the C8T and C9T cells 
to the human osteosarcoma cell line 143B. The authors found that increasing mutant 
ND5 was associated with decreased oxidative phosphorylation, increased ROS, 
increased glycolysis  and tumour growth. Bonora et al. [509] and Ishikawa et al. [507] 
have also shown that mutations in mitochondrial encoded Complex I subunits, ND1 and 
ND6 respectively, resulted in a decrease in Complex I activity and increased ROS 




small cell lung cancer cell line A549 resistant to Cisplatin by exposing them to low 
concentrations of the drug for a prolonged period of time, resulted  in the transformation 
of a mutation in the MT-ND2 gene which was present in a heteroplasmic state in the 
control cells into a homoplasmic mutation in all the Cisplatin resistant cells. These cells 
harbouring a mutation in one of the core subunits of Complex I resulted in a 50% 
decrease in Complex I activity with maintained oxidative phosphorylation and increased 
expression of some of the nuclear encoded subunits of CI-CIV and of mtDNA encoded 
COXI (subunit of CIV). The authors investigated how these cells were able compensate 
for the decrease in Complex I activity and implicated the nuclear co-activators PGC-1α 
and PGC-1β evidenced by an increase in their mRNA levels[510]. 
 
5.3.4!!Investigating! differences! in! the! mitochondrial! genome! between! MLH1T
proficient!and!deficient!cell!lines!
I carried out sequencing of the mitochondrial genome to investigate if the deficiencies in 
Complex I that I observed may be due to MSI within Complex I genes in the 
mitochondria. A study by Habano et al discovered that out of 45 sporadic colorectal 
cancers, 44% had mutations within microsatellites in the non-coding D-loop region of 
the mtDNA and tumours also had mutations within mitochondrial encoded Complex I 
genes [247]. This study was the first indication that MMR deficient tumours may harbor 
mutations within Complex I genes. More recently, Mishra et al proved that MLH1 
deficiency (as a result of retinal endothelial cells exposed to high glucose) leads to 
increased sequence variants in the mitochondrial D-loop region and decreased OCR. 
All  of these finding were ameliorated when MLH1 was overexpressed [249]. I did not 
observe any differences in mutation rates between MLH1-deficient and proficient cell 
lines but it is important to discuss a few experimental considerations  that  may  have  
led  to  this  result.   
 
One of the challenges of sequencing the mitochondrial genome and diagnosing 
mitochondrial disease is the fact that the mitochondria within each cell could be 
heteroplasmic where there are multiple genotypes within one cell or homoplasmic 
where all the mtDNA within one cell is the same. To complicate the scenario further, 
heteroplasmy is not a static situation and mutational load can change during mitotic and 




biochemical change depends on the amount of mutant DNA present and the threshold 
of the affected tissue before symptoms or a phenotype become apparent. It is widely 
understood from numerous studies  that mitochondrial DNA is constantly acquiring 
mutations and that homoplasmy in the true sense is unlikely to exist but the most likely 
situation is that these mutations are present at a low level and cannot be detected [375, 
376]. My experiment allowed for a depth of 18,000 bp which is the average number of 
reads that cover known reference bases and this value gives an indication of  the 
degree of certainty with which a variant is detected. 
 
King et al carried out NGS on the Illumina MiSeq™ platform using DNA from 283 blood 
samples and found that one of the problems they encountered is that the coverage was 
not equal across the mitochondrial genome within individual genomes especially in a 
portion of the ND1 gene (Complex I) [377]. This type of error may have affected my 
results. Furthermore, it is difficult to know at what point after the addition of 
chromosome three bearing MLH1 (HCT116+chr3) do the mutations that were present in 
the MLH1-deficient parental cell line (HCT116) become repaired. The investigators who 
constructed this matched cell line carried out experiments approximately fourteen days 
after chromosome three was transferred to the MLH1-deficient parent cell line HCT116 
examining whether a mutation within a specific microsatellite had been repaired. They 
reported that after the addition of chromosome three, 8 of 80 HCT116 (MLH1- deficient) 
sub-clones carried the mutation in comparison to none of the 225 HCT116+chr3 (MLH1-
proficient) sub-clones confirming restoration of MMR activity. Furthermore, this was 
accompanied by changes in response to drug  treatment [93] Although I did not observe 
any significant differences in mutations within mitochondrial encoded Complex I genes, 
it is worth bearing in mind that I did observe a decreased expression of several 
mitochondrial encoded Complex I subunits in my MLH1-deficient cell lines. These 
finding suggest that there are likely to be mutations within Complex I genes in the 
MLH1-deficient cell lines  but these may be low levels of heteroplasmic mutations we 
did not observe due to experimental constraints or possibly due to alterations in 
translational and post translational modifications. An alternative explanation is that there 
may be increased mutations in the MLH1-deficient cell lines in nuclear genes  essential 






Experiments investigating mitochondrial biogenesis in the MLH1-deficient cell line 
HCT116 and the MLH1-proficient cell line HCT116+chr3 revealed decreased 
expression of the nuclear transcriptional co-activator PGC-1β (Figure 4.14A) and its 
downstream transcription factor NRF1 (Figure 4.14B-4.14C)  as well as decreased 
mitochondrial copy number in the MLH1-deficient HCT116 compared to MLH1-proficient 
HCT116+chr3 cell lines (Figure 4.14B).   
 
We measured mitochondrial copy number using qPCR to examine the expression of the 
mitochondrial tRNa relative to the expression of the nuclear housekeeping gene β2M. 
Since mitochondrial DNA codes for the respiratory genes that are essential for the cell’s 
energy processes; the replication, transcription and expression of these genes are 
known to be strictly regulated to match the energy requirements of the cell [380]. 
Mitochondrial copy number is not only a product of mtDNA itself but also the numerous 
nuclear proteins involved in control of mtDNA..  
 
The PGC-1 family of co-activators are often described as the master co-regulators of 
mitochondrial biogenesis since they have diverse roles in controlling mitochondrial 
biogenesis and function. The mitochondrial phenotype which I have established is 
present in MLH1-deficient cell lines could be explained by the decreased expression of 
PGC1-β seen in these cell lines. The key processes involved in mitochondrial 
biogenesis include transport of nuclear encoded mitochondrial proteins, translation of 
mitochondrial encoded respiratory chain proteins and replication of mtDNA. PGC1-β 
through its interactions with a multitude of transcription factors including NRF1 and  
NRF-2alpha controls the expression of the respiratory chain and the supporting 
machinery which is needed for the expression of a wide range of mitochondrial and 
nuclear encoded genes with key functions in the mitochondria [325]. Several in vitro and 
in vivo studies have shown that overexpression of members of the PGC-1 family 
including PGC1-β results in increased mitochondrial biogenesis [310]. In this study I 
have demonstrated decreased expression of not only PGC1β but also NRF1 which are 
involved in Complex I expression and function, oxidative phosphorylation (OCR and 
spare respiratory capacity) and mitochondrial biogenesis and therefore could explain 




been shown to have a role in controlling the antioxidant defense enzymes and therefore 
the decreased expression of PGC1-β that I observed in my MLH1-deficient cell lines is 
also in keeping with the deficiencies in the antioxidant enzymes in these cell lines. The 
mechanism behind decreased PGC1β levels in MLH1-deficient cell lines needs to be 
explored further but given the key role of MLH1 in post replicative repair it is possible 
that this could be due to mutations in the PGC1-β gene. 
 
Several studies have established that MLH1 is likely to have a role in the repair of 
oxidative DNA damage both in the nucleus and the mitochondria. Colussi et al showed 
that the baseline levels of the oxidative lesion 8-oxoG was higher in MSH2 and MLH1-
deficient cell lines [287]. We have previously shown that silencing of the mitochondrial 
DNA polymerase POLG is synthetically lethal with MLH1-deficient cell lines due to an 
increase in oxidative DNA lesions in the mitochondria only and not the nucleus [79]. 
Silencing of several other nuclear encoded mitochondrial genes PINKI, CKMT2 and 
PCK2 was synthetically lethal with several MMR genes including MLH1 due to an 
increase in ROS levels and both nuclear and mitochondrial oxidative DNA lesions [187]. 
In this study I have shown that MLH1-deficient cell lines are selectively lethal with the 
ROS inducing agent Parthenolide due to the fact that they have deregulated 
mitochondria, decreased expression of PGC1β, NRF1 and an attenuated antioxidant 
defence system. It is important to remember that I found only Parthenolide to be 
selectively lethal with MLH1-deficient cell lines and not all ROS inducing agents most 
likely due to the mechanism in which Parthenolide induces ROS. Treatment with 
Parthenolide results in higher ROS levels in the MLH1-deficient cell lines, which is likely 
to result in oxidative DNA damage.  It is likely that the ultimate reason for decreased cell 
viability in MLH1-deficient cell lines is due to their inability to repair the oxidative DNA 
damage in the mitochondria which has occurred due to increased ROS levels compared 
to MLH1-proficient cell lines. The fact that the MLH1-deficient cell lines have decreased 
mitochondrial copy number at baseline without the addition of ROS gives a potential 
insight into the fact that the mitochondrial DNA in these cell lines may already be 
compromised due to lack of MMR activity. Studies mentioned above support the fact 
that with increased ROS levels and increased oxidative DNA damage (caused by 
Parthenolide), MLH1-deficient cell are less able to repair the resulting mitochondrial 
oxidative DNA damage resulting in decreased cell survival in these cell lines compared 





Based on the fact that there are numerous copies of the mitochondrial genome within 
each cell and that mitochondria undergo constant fusion and fission the most 
established way of estimating the number of mitochondrial genomes is to measure 
mitochondrial copy number per cell. Mitochondrial copy number alterations have been 
observed in numerous human cancers with both increased [416-419] and decreased 
copy number alterations [420-422]. Chen et al carried out a large study examining 
mtDNA copy number in a Chinese cohort of patients and observed an increase in copy 
number when compared to matched surrounding normal tissue [419]. Van Osch et al 
compared mtDNA copy number between normal tissue, adenoma and carcinoma tissue 
and observed  a  significantly  lower  copy  number  in  both  the  cancer  tissue  and 
surrounding normal tissue compared to the earlier resected adenoma tissue. 
 
Furthermore, decreased mtDNA copy number was established to be present in the MSI 
tumours compared to MSS tumours [423]. 
 
There is an increased interest in investigating the clinical implications of these copy 
number changes. Resnik et al studied mitochondrial copy number in cancers by looking 
at 22 different types of tumours and examining the impact of mitochondrial copy number 
on expression of metabolic genes [424]. They established that nearly half of the 
tumours exhibited a reduced copy number compared to adjacent normal tissue. To 
validate that mitochondrial copy number was a true reflection of mtDNA content the 
investigators correlated mtDNA copy number with specific gene sets and found that 
mitochondrial metabolic pathways and the transcription factor TFAM (essential for 
transcription and replication of mtDNA) were positively correlated to mtDNA copy 
number across all tumour types. . The investigators explored this further and found that 
the ‘TCA Cycle and Respiratory Electron Transport’ gene set was the most frequently 
correlated to mtDNA copy number (1st out of 674 gene sets) and the other highly 
scoring sets were mitochondrial metabolism related including mitochondrial beta 
oxidation of fatty acids and branched chain amino acid catabolism [424]. Gene sets with 
functions related to mRNA processing,  the cell cycle and immune pathways showed a 
negative correlation with mtDNA copy number. Although in the majority of cancer cases 




number, there were a few tumour types such as bladder cancer samples where this was 
not apparent [50]. 
!
5.3.5.2!! Some! cancers! upregulate! respiratory! genes! to! compensate! for! decreased!
mitochondrial!copy!number!
The concept that in some tumours depletion of mtDNA can actually lead to a 
compensatory increase in respiratory activity has previously been described. For 
example, Siedel-Rogol et al demonstrated that when partially mtDNA- depleted cells are 
cultured there is an upregulation in transcription and replication of mtDNA [425]. Kim et 
al investigated lipoatrophy due to HIV treatment which is thought to be due to mtDNA 
depletion. The investigators used  samples  from  the  subcutaneous  fat  of  patients  
with  lipoatrophy   and compared the DNA, RNA and protein levels from age and body 
mass index matched controls [426]. The investigators established that although  mtDNA 
copy number was reduced in the lipoatrophy samples, there was evidence of 
compensation as determined by normal activity of the respiratory enzyme cytochrome c 
oxidase and MT-CO2 protein levels. There was also evidence of increased 
mitochondrial biogenesis since several nuclear encoded mitochondrial genes (COX4I1 
and UCP2) and pathways were upregulated but interestingly the more conventional 
mitochondrial biogenesis related transcription factors such as the PGC-1 family, TFAM 
and NRF1 were at normal or decreased levels [426]. When Resnick et al investigated 
protein expression (by IHC) in relation to mtDNA copy number in different types of renal 
cancer tissue (papillary and clear cell) and bladder carcinoma, they found that in 2/3 of 
tumour types, most of the tumour samples showed decreased mitochondrial protein 
compared to normal tissue but in the bladder cancer tissue most of the samples 
exhibited increased mitochondrial protein levels. Interestingly, the bladder cancer 
samples also did not show a strong correlation between mtDNA copy number and 
metabolic gene sets but showed a strong correlation with cell cycle and immune 
response gene sets. Furthermore, the investigators also showed evidence that certain 
patient samples with specific mutations or copy number alterations correlated with 
different mtDNA levels. One example of this is that the serous-like endometrial subtype 
of endometrial cancer which is well known to be characterised by a high number of copy 
number alterations is positively correlated with increased mtDNA copy number [424]. 




respiratory and metabolic gene expression however there is clearly a subset of tumours 
for which the opposite is true. Further investigation is needed to establish which 
tumours upregulate mitochondrial function in response to diminished mtDNA copy 
number and the reason behind this. 
 
The MLH1 deficient cell lines in my study display decreased mitochondrial copy number 
which has been previously demonstrated by Van Osch et al. Most studies examining 
the functional relevance of decreased mitochondrial copy number have observed a 
corresponding decrease in the expression of respiratory chain genes. In my study I 
established that MLH1 deficient   cancers not  only  have  a  decreased  mitochondrial  
copy  number  but  also decreased expression of several mitochondrial encoded 
Complex I subunits (mt-ND2 and mt-ND5 as well as an overall decrease in Complex I 
activity. 
 
In this study I have shown that MLH1-deficient cell lines are selectively lethal with the 
ROS inducing agent Parthenolide due to the fact that they have deregulated 
mitochondria, decreased expression of PGC1β, NRF1 and an attenuated antioxidant 
defence system. It is important to remember that I found only Parthenolide to be 
selectively lethal with MLH1-deficient cell lines and not all ROS inducing agents most 
likely due to the mechanism in which Parthenolide induces ROS. Treatment with 
Parthenolide results in higher ROS levels in the MLH1-deficient cell lines, which is likely 
to result in oxidative DNA damage. It is likely that the ultimate reason for decreased cell 
viability in MLH1- deficient cell lines is due to their inability to repair the oxidative DNA 
damage in the mitochondria which has occurred due to increased ROS levels compared 
to MLH1-proficient cell lines. The fact that the MLH1-deficient cell lines have decreased 
mitochondrial copy number at baseline without the addition of ROS gives a potential 
insight into the fact that the mitochondrial DNA in these cell lines may already be 
compromised due to lack of MMR activity. Studies mentioned above support the fact 
that with increased ROS levels and increased oxidative DNA damage (caused by 
Parthenolide), MLH1-deficient cells are less able to repair the resulting mitochondrial 
oxidative DNA damage resulting in decreased cell survival in these cell lines compared 






To ascertain whether the mitochondrial phenotype that I observed in my MLH1 deficient 
cell lines is present in tumour samples from patients, I obtained RNA from tumour 
samples as well as the surrounding matched normal tissue from MSI and MSS samples  
from a collaborators laboratory (Professor Andrew Silver, Blizzard Institute, QMUL). The 
MMR defect in MMR deficient tumours is present in the tumour and not the surrounding 
normal tissue so in theory by comparing these samples any differences due to MMR 
deficiency should become apparent.  
 
Upon comparing the expression of genes involved in mitochondrial biogenesis PGC1β 
and NRF1) the antioxidant defense genes (NRF2, SOD1, Catalase and GPX1) in the 
patient samples, I did not observe a consistent difference in expression of these genes 
between the tumour samples and matched normal tissue in the MLH1-deficient tumours 
(Figure 4.15A-4.15F). There was also no significant difference in the expression of 
these genes between the MSI (Figure 4/15A-4.15F) and MSS (Figure 4.16A-4.16F) 
tumours (Table 4.17). One of the biggest problems with this sort of analysis is 
associated with problems due to RNA integrity and separating different types of tissue 
accurately. The routine use of laser capture microdissection has improved the precision 
in which tissue samples can be dissected however there are obviously still problems 
with contamination and with my study it is possible that there was some crossover 
between tumour tissue and surrounding normal tissue which would obviously 
affect my results.  
 
Laser capture microdissection does not obliterate problems with RNA integrity and in 
the study by Vandewoestyne et al describing the advantages and problems associated 
with two types of laser capture microdissection they carry out a qRT-PCR based RNA 
amplicon length testing looking for significant differences in ACTB expression between 
samples [379]. The authors concluded that they observed significant differences in 
amplicon length between samples and that these differences are due to RNA 
degradation which is inherent to the LCM system. The authors recommend designing 
your study to take these problems into consideration like avoiding the use of oligo-dT 
primers since these do not work well on degraded RNA [379]. It is very likely  that some 




ultimate results. Aside from the problems with experimental procedure described above 
I feel it is important to consider that ROS metabolism is influenced by the environment 
including factors like  hypoxia [371]. The majority of these tissue samples are several 
years old and it is impossible to know and account for differences in tissue handling and 
storage which may influence the expression of the antioxidant defense enzymes. 
 
5.5! Analysis!of!mitochondrial!phenotypes!in!other!MMRTdeficient!cells!!
The differences in the mitochondrial phenotypes I observed within tumours deficient in 
different MMR proteins compared to their proficient counterparts needs further 
exploration. All the MMR deficient tumours (DLD1, HEC59 and U251.TR3) displayed 
decreased expression and activity of Complex I (Figure 4.18A-4.18C and Figure 4.19A-
4.19C) compared to the corresponding MLH1-proficient cell lines (DLD1+chr2, 
HEC59+chr2 and U251). Only the MSH2 deficient cell line HEC59 exhibited the 
complete mitochondrial phenotype I observed in my MLH1 deficient cell lines with 
decreased expression of members of the antioxidant defense system (NRF2, catalase, 
GPx1and SOD1) (Figure 4.20A-4.20F) and mitochondrial biogenesis (PGC1β, NRF1 
and mitochondrial copy number) (Figure 4.21) compared to its isogenetically matched 
MSH2-proficient cell line HEC59+chr2. These findings could potentially be explained by 
the fact that all these proteins have a key role in post replicative repair and therefore are 
likely to harbour mutations in nuclear encoded Complex I genes not affecting 
mitochondrial copy number. This hypothesis is evidenced by the fact that the study by 
Mori et al examining frameshift mutations in 46 MSI-H tumours identified that in 28% 
there was a mutation in  the nuclear encoded B14.5B Complex I subunit [380]. It is also 
important to  note that there are several nuclear encoded genes, which are described to 
be essential in maintaining both mitochondrial and nuclear genomes. These include 
genes involved in non-homologous end joining such as Mre11–Rad50– Xrs2 and 
Yku70/80 complexes, the catalytic subunit of DNA polymerase ζ Rev3 involved in post 
replication repair and the BER enzymes Ogg1, Ntg1 glycosylases,  as  well  as  the  AP-
endonuclease  Apn1. Deficiencies in these genes can lead to mtDNA damage and 
metabolic dysfunction. It Is therefore possible that MMR deficiency in general can lead 
to mutations within any of these essential genes resulting in decreased Complex I 
expression and activity due to their affect on the nuclear and mitochondrial genome 





There are also several studies supporting the role for MSH2 in the repair of oxidative 
DNA damage in the nucleus and possibly the mitochondria. Colussi et al and DeWeese 
et al have shown that when embryonic stem cells (ES) and mouse embryo fibroblasts 
(MEFs) from MSH2 deficient mice are compared to wildtype controls, these cells have 
higher baseline and ROS induced 8-oxoG lesions [219, 220]. Furthermore, Colussi et al 
showed that there were high  levels of oxidative damage in MLH1 and MSH2 deficient 
cell lines due to defective removal of 8-oxoG that was present in DNA from the oxidized 
dNTP pool. The mutator phenotype observed in MSH2 deficient cell lines was reduced 
by the overexpression of the hydrolase MTHI which removes 8-oxodGTP [220]. We 
have shown that silencing of the nuclear encoded mitochondrial gene PINK1 is 
synthetically lethal with both MLH1 and MSH2 deficient cell lines due to an increase in 
oxidative DNA lesions in the nucleus and mitochondria of both these cell lines [97]. 
There are some studies contradicting a role for MSH2 in  the mitochondria. Hashiguchi 
et al detected mismatch repair activity in MSH2 deficient cell lines concluding that 
MSH2 is unlikely to be involved in repair if DNA lesions in the mitochondria [244]. 
 
The observed phenotype in MSH2 deficient cell lines is similar to that seen in MLH1-
deficient cell lines. It is possible that the reasoning behind this observed phenotype is 
similar to MLH1-deficient cell lines with decreased expression of PGC1β and NRF1 
resulting in decreased mitochondrial biogenesis, decreased expression and activity of 
Complex I and an attenuated antioxidant response. Due to time constraints, I have not 
established whether MSH2 deficient cell lines are synthetically lethal with Parthenoloide 
but it is likely that this is the case given the mitochondrial phenotype observed in these 
cell lines. We have previously shown that MSH2 deficient cell lines are selectively lethal 
with the oxidative DNA damaging agent Methotrexate which demonstrates that these 
cell lines are sensitive to oxidative DNA damage [98]. The  ultimate reason for a 
decrease in cell viability with ROS inducing agents in these cell lines may be different to 
MLH1-deficient cell lines given that there is more evidence to attribute a role to MLH1 in 
the repair of oxidative DNA lesions in the mitochondria than MSH2 deficient cell lines. 
As described earlier there are numerous studies suggesting MSH2 has a role for repair 
of oxidative lesions in the nucleus and therefore an accumulation of oxidative DNA 





5.6 DNA repair deficiency and mitochondrial  metabolism 
A role for some form of MMR in the mitochondria is emerging through work from our lab 
and others. This opens the question about whether deficiency in other nuclear DNA 
repair proteins causes mitochondrial dysfunction either directly or indirectly. 
 
5.6.1! ATM!and!the!mitochondria!
The DNA repair protein Ataxia-telangiectasia (ATM) is known to be a serine/threonine 
kinase recruited to sites of DNA damage resulting in DNA repair, apoptosis or cell cycle 
arrest [382, 383]. ATM deficiency leads to the autosomal recessive disease ataxia-
telangiectasia characterised by T-cell malignancies, cerebellar ataxia, insulin 
resistance, immune deficiency and premature ageing [384]. There is emerging evidence 
that the phenotype observed in ataxia-telangiectasia is unlikely to be solely related to 
the nuclear DNA repair functions of ATM and that ATM has other roles which have not 
been fully elucidated. Several studies have demonstrated that ATM deficiency is 
characterized by oxidative stress and sensitivity to ROS inducing agents [385, 386]. 
Ambrose et al investigated the link between ATM deficiency and high levels of oxidative 
stress by comparing wild type and A-T lymphoblastoid cells (ATM deficient). The 
investigators demonstrated that A-T cells had dysfunctional mitochondria compared to 
wild type cells as evidenced by abnormal mitochondrial structure, reduced mitochondrial 
membrane potential, increased levels of antioxidant enzymes, up regulation of 
mitochondrial targeted DNA repair proteins and decreased mitochondrial respiration 
[387]. Valentin-Vega et al demonstrated that in ATM deficient thymocytes isolated from 
mice the mitochondria were swollen with abnormal cristae as well as having increased 
mitochondrial ROS and decreased complex  I activity [388]. The authors explored these 
findings further to try and elucidate whether ATM has a direct role in the mitochondria 
which is distinct from its involvement in the nuclear DNA damage response. They were 
able to show that ATM is present in the mitochondrial fraction of human fibroblasts and 
that upon treating these cells with the mitochondrial uncoupling agent CCCP, the ATM 
kinase is activated without a corresponding activation of the ATM substrates related to 
DNA damage [388]. Eaton et al showed that ATM signalling is involved in the regulation 
of the rate-limiting enzyme essential for the synthesis of deoxyribonucleoside 
triphosphates and mitochondrial homeostasis, ribonucleotide reductase (RR). They 




the R1, R2 and P53R2 subunit of RR with a corresponding impairment of the increase 
in mtDNA copy number that is normally observed in relation to ionizing radiation. The 
study concluded that ATM and its downstream target RR are essential in the control of 
mtDNA copy number in response to oxidative DNA damage and also in actively dividing 
cells [389]. 
 
There are two main hypotheses explaining the role of ATM in controlling mitochondrial 
homeostasis that have emerged. The first hypothesis proposes a direct involvement of 
ATM in controlling the redox state of the cell by exerting control of the antioxidant 
defence enzymes of the cell at a transcriptional or post-translational level [390]. 
Furthermore, there is some evidence to form the conclusion that ATM is directly 
activated upon sensing oxidative damage and could potentially phosphorylate 
mitochondrial proteins [96]. The indirect model  is based on the premise that ATM 
deficient cells have lower levels of NAD+ due to the persistent DNA damage that is left 
unrepaired and the activation of repair enzymes such as PARP, which require NAD+ 
molecules. This leaves the cell with a reduced antioxidant capacity and increased ROS 
levels [391]. 
 
It is well established that when the MMR pathway is recruited to sites of DNA damage, 
MLH1 associates with ATM in recruiting other components of the DDR pathway [392]. 
Based on the studies mentioned above and the association of ATM with MLH1, it would 
be interesting to investigate whether the mitochondrial phenotype I have observed in my 
MLH1 deficient cell lines may be in part associated with ATM. It is possible that ATM 
may not be able to carry out its mitochondrial role in the absence of MLH1. 
 
5.6.2! DNA!repair!proteins!and!nucleusTtoTmitochondria!signalling!
Recent evidence suggests that nuclear DNA repair proteins and the nuclear DDR have 
an impact on mitochondrial function and that altered nucleus-to- mitochondria (NM) 
signalling contributes to ageing and age related disorders.[393-395]. This area of 
research has become a field of widespread interest. 
 
There are several DNA repair proteins that have been found to be present in both the 




integration frequent 1 (PIF1), DNA replication  helicase/nuclease 2 (DNA2) and 
suppressor of Var 3-like protein 1 (SUPV3L1). These proteins are thought to not only 
protect nuclear DNA integrity but  possibly have a role on maintaining mtDNA stability 
[396, 397]. There are also several DNA repair proteins where it is unclear whether they 
are imported into the mitochondria under conditions of increased stress or have both 
nuclear and mitochondrial localization. Furthermore, several DNA repair proteins and 
pathways are not present in the mitochondria but signalling through these pathways has 
an effect on mitochondrial homeostasis [398] . 
 
The primarily nuclear DNA repair protein RECQL4 is a DNA helicase which has been 
shown to localize to the mitochondria, be vital in the transport of p53 into the 
mitochondria and take part in mtDNA replication and repair [397]. Sengupta et al have 
shown that RECQL4 interacts (along with p53) with the mitochondrial polymerase 
PolγA/B2 [399]. P53 has been established to have a role in regulating  mitochondrial  
function  including  biogenesis,  mitophagy  and the antioxidant response[400]. By 
carrying out mitochondrial genome sequencing  on fibroblasts from patients with cancer 
predisposition syndromes due to RECQL4  and  p53  deficiency  (Rothmund-Thomson  
syndrome  (RTS)  and Li-Fraumeni syndrome (LFS) Rothmund, respectively) they were 
able to show increased somatic mutations and polymorphisms in mtDNA from these 
samples [401]These mutations have been found to be associated with ageing and  
cancer thereby eluding to the fact that the phenotypes seen in these syndromes could 
be due at least in part to mtDNA genome instability [396, 401] . Several lines of 
evidence have shown that DNA damage results in alterations to cellular metabolism, 
such that many diseases characterized by premature ageing result in weight loss [402]. 
An important pathway associating nuclear DNA damage to alterations in mitochondrial 
function is DNA damage leading to PARP1 activation and in turn alterations in the 
NAD+/NADH ratio of cells, which alters a multitude of metabolic processes. Evidence 
suggests that activation of the DNA damage response that leads to PARP1 activation 
leads to DNA repair signalling and a process known as PARylation which depletes the 
cells stores of NAD+ and acetyl-CoA which are essential for cell metabolism [403]. The 
consequence of NAD+ depletion is inhibition of the NAD+ dependent deacetylase 
enzymes known as the Sirtuins and alterations in the NAD+-SIRT1-PGC-1 axis [404]. 




regulation through their role in modifying proteins and consuming NAD+ as a  
consequence [405] 
 
It is clear from the evidence presented above that there is little doubt of the  huge 
influence DNA repair pathways and the DDR proteins have on cell metabolism and 
mitochondrial function. The MMR pathway is a key DNA repair pathway and given the 
evidence presented here linking DNA damage to metabolism, it is not surprising that 
this study has established a potential link between the MMR protein MLH1 and 
mitochondrial metabolism. This link may potentially be associated with increased single 
strand breaks in the MLH1 deficient tumours leading to PARP1 activation, depletion of 
NAD+ and inhibition of the Sirtuin family resulting in the mitochondrial phenotype I 
observed. Furthermore, it is possible that in the context of MLH1 deficiency ATM cannot 
carry  out  its  DDR  role  and  activate  AMPK  and  the  downstream  pathways 
including activating PGC1-α and FOXOs. 
 
5.7! ROS!induction!and!targeting!the!redox!capacity!of!cancer!cells!
ROS are continuously being produced by enzymatic (NADPH oxidase, xanthine 
oxidase, endothelial nitric oxide synthase, arachidonic acid, cytochrome p450 enzymes, 
lipooxygenase and cyclooxygenase) and non-enzymatic reactions (respiratory chain 
ROS). ROS levels can be induced by factors such as ER stress [460], hypoxia [461], 
oncogenes [462] and metabolic defects [463]. On the other hand, ROS scavengers 
such as the antioxidant defense system [464] and tumour suppressors [465] can reduce 
ROS levels [113]. There are many research groups investigating the differences in the 
redox state of cancer cells compared to normal cells with the aim of developing ROS 
inducing agents as a therapeutic strategy in cancer. There is evidence to suggest that 
cancer cells have higher ROS levels compared to normal cells but the picture is 
obviously much more complex than this since the cancer cells can upregulate their 
antioxidant defense systems to cope with increased oxidative stress [466]. 
 
ROS biology in cancer is complex with some evidence suggesting these molecules 
cause cancer progression and others suggesting they can cause cancer cell death. It 
seems the response to ROS is dependent on a multitude of situational factors including 




to find out under which circumstances these molecules act as tumour suppressors and 
when they act to cause tumour growth [467]. 
 
The first body of evidence linking ROS with increased cancer cell proliferation was 
carried out by Oberley et al showing that increased insulin caused raised levels of ROS 
and tumour proliferation [468]. Studies have shown that at low to moderate levels ROS 
can potentially act to facilitate tumour growth by causing oxidative stress and DNA 
mutations as well as acting directly or indirectly to affect the function of numerous 
enzymes, transcription factors and signaling pathways which in turn cause downstream 
genetic changes. ROS has been shown to modulate several pathways depending on 
the nature of the oxidative stress. Some of the pathways ROS can control include 
phosphorylating MAPK [469], ERK [470], cyclin D1 [471], ATM [472], NFkB [473], JNK 
activation   [474]  and inactivating tumour suppressors such as PTEN Moderate doses 
of ROS have been shown to cause temporary or more permanent cell cycle arrest and 
replicative senescence [113, 467]. 
 
Another consideration to bear in mind when considering using ROS inducing agents is 
the fact that evidence suggests that cancer stem cells or tumour initiating cells (TICs) 
have recently been found to have low ROS levels and increased antioxidant capacity 
[415]. This finding could possibly result in the TIC’s being selectively spared since they 
are able to cope with increased levels of oxidative stress compared to the more mature 
cancer cells [415]. 
 
High levels of ROS and severe oxidative stress cause cell death but the final 
mechanism by which this occurs is still controversial. Some research groups have 
carried out studies suggesting that the mechanism is apoptosis and others suggest that 
the mitochondrial transition pore is involved [113, 475]. Valencia et al have shown in in 
vitro that superoxide anions induce cell death in neuronal cells by apoptosis whereas 
hydrogen peroxide led to necrosis-like cell death [476]. 
 
There has also been a recent interest in studying ROS inducing agents as single 
treatments or in combination with conventional chemotherapy. These agents have been 




conventionally used chemotherapies with ROS generating properties, that have 
reached large scale phase III trials [364, 477]. 
 
5.7.1! Chemotherapeutics!as!ROS!inducing!agents!
Several conventionally used chemotherapeutic agents are known to increase ROS and 
oxidative stress in addition to their main mechanism of action. The chemotherapies that 
are known to induce high levels of ROS include the anthracyclines, platinum agents, 
epipodophyllotoxins and the camptothecins [475].   ROS   induction   can   either   
enhance   or   inhibit   the   efficacy chemotherapeutic  agents [478, 479]. The drug 5-
fu commonly used in CRC has also been shown to induce ROS through a p53 
dependent pathway. A study examining 5-fu resistance in B cell lymphoma discovered 
that cancer cells that adapted to the oxidative stress by increasing antioxidant enzymes 
(SOD2 and peroxiredoxin) were found to be resistant to 5-fu [480]. 
 
5.7.1.1!! The!quinones!as!ROS!inducing!agents!
In this study, I observed variable responses to the three ROS inducing agents 
Parthenolide, Menadione and β-lapachone. This observed difference could be due to 
the different mechanisms of action that these drugs have as outline below. 
 
There are numerous small molecules which belong to different classes of ROS inducing 
agents that have been developed to overwhelm the antioxidant capacity of cancer cells 
and cause cell death. Two of the drugs used in this study, β-lapachone and Menadione 
are ROS inducing agents which belong to a family of drugs called quinones. These 
drugs all undergo futile redox cycles on the respiratory chain but β-Lapachone and 
Menadione have slightly different ways in which they carry out their mechanism of 
action 
 
Menadione is a polycyclic aromatic ketone that is a vitamin k precursor [366]. It 
undergoes a one electron reduction by reductive enzymes including microsomal 
NADPH-cytochrome P450 reductase and mitochondrial NADH-ubiquinone 
oxidoreductase (Complex I) and the semiquinones formed as part of this reaction 
undergo futile redox cycling in the presence of molecular oxygen. Menadione has been 




causing ROS production [366]. Menadione is a redox- dependant signalling molecule at 
low doses (e.g., 2µM) but causes oxidative stress and cell death at higher doses [481]. 
Pre-clinical studies have shown Menadione to be an effective anti-cancer treatment 
[482] but no clinical trials to date have shown objective responses with this drug [483]. 
Given that my MLH1 deficient cell lines exhibit deficiencies in Complex I and that 
Menadione requires Complex I as part of its mechanism of action, this may explain why 
I did notobserve selective cell death in my MLH1 deficient cell lines with this ROS 
inducing agent 
 
NAD(P)H:quinone oxidoreductase 1 (NQO1) is another reductive enzyme which carries 
out two electron reduction reactions forming stable hydroquinones [484]. β-lapachone 
(clinical form ARQ761) is part of a group of novel quinones that undergo this reaction 
but form an unstable hydroquinone which in turn spontaneously undergoes oxidation 
consuming two oxygen molecules [485]. This reaction leads to futile redox cycling 
where one mole of β-lapachone leads to the formation of approximately 120 moles of 
superoxide within two minutes [486]. β-lapachone has been shown to be effective at 
killing cancer cells which overexpress NQO1 in experimental studies including a large 
proportion (>80%) of non-small cell lung cancer cell lines [485], pancreatic [487] and 
breast cancer [485] cell lines. The mechanism of death in these cell lines has been 
shown to be due to the generation of superoxide anions causing DNA damage, ca2+ 
release from the endoplasmic reticulum resulting in PARP1 hyperactivation and 
NAD+/ATP loss and programmed cell necrosis [488, 489]. Bey et al explored  the 
relationship of β-lapachone with the antioxidant system and established that catalase 
levels in addition to NQO1 levels was a major determining factor relating to the efficacy 
of this drug [486]. High levels of catalase and overexpression of this enzyme cause 
resistance to β-lapachone induced cell death [486]. ARQ761 is currently undergoing 
phase I clinical trials (ClinicalTrials.gov Identifier:NCT01502800) testing the maximum 
tolerated dose of the drug before moving into trials to assess efficacy I did not observe 
a synthetic lethal relationship with my MLH1 deficient cell line HCT116 and β- 
Lapachone compared to the MLH1 proficient cell line HCT116+chr3. This result could 
be due to the fact that these are isogentically matched cell lines and therefore are may 
have the same NQO1 levels and since β-Lapachone cell death has been shown to 





The sesquiterpene lactone Parthenolide is another ROS inducing agent used in this 
study. It is derived from the plan feverfew and it exerts its action through  its lactone ring 
which reacts with cysteine thiol groups which are present on many regulatory proteins, 
kinases, phosphatases and transcription factors. Cysteine thiols through their oxidation 
and reduction have an essential role in facilitating signalling pathways due to redox 
changes [490]. The main mechanism of cell death of Parthenolide is ROS induction and 
oxidative stress [362]. 
 
Wen et al treated sarcomatoid hepatocellular carcinoma cells (SH-JI) and hepatoma 
cells with Parthenolide and observed apoptosis of these cells at concentrations of 5-10 
µM and cell cycle arrest at 1-3 µM concentrations [491]. As a consequence of 
Parthenolide induced apoptosis, the authors observed depletion of glutathione, 
generation of ROS, reduction of mitochondrial transmemebrane potential, activation of 
caspases and increased expression of the oxidative stress gene GADD153 [491]. An 
interesting study by Sun et al examined in detail the selective cell radiosensitization 
they observed with Parthenolide in the prostate cancer cell line PC3 compared to the 
normal prostate epithelial cell line prEC [362]. The authors concluded that in PC3 cells 
Parthenolide induces ROS by activating NADPH oxidase and also acts on the 
antioxidant capacity of these cells by decreasing levels of reduced thioredoxin, 
supressing FOXO3a (via activation of PI3K/AKt pathway) and its downstream targets 
SOD2 and catalase. In the PrEC cells Parthenolide did not activate NADPH oxidase 
and increased glutathione levels. The authors were able to shown that the PC3 and 
PrEC cells have different redox status’ at baseline which was likely to account for the 
differences observed. The PC3 cells had higher Nox1 levels and lower SOD2 and 
catalase levels compared to  the normal cells and Parthenolide caused further oxidative 
stress by inhibiting antioxidant enzymes and activating ROS. The normal cells had high 
GSH and GST levels at baseline and Parthenolide increased these levels further in the 
PrEC cells only. The reason behind the sparing of normal cells from Parthenolide 
cytotoxicity was thought to be due to the high GSH and GST  levels which meant 
Parthenolide could conjugate with GSH facilitated by GST’s and then be transported 
outside the cell leading to Parthenolide resistance [362]. This is a very relevant study in 




cancer cell line, demonstrates  a decrease in antioxidant defence enzymes compared to 
the MLH1 proficient cell line HCT116+chr3. The selective cell death in my MLH1 
deficient cell   lines is likely to be due Parthenolide inhibiting the antioxidant defence 
enzymes in cells that already have deficiencies in these cell lines leading to increased 
ROS and cell death. 
 
A study by Carlisi et al examined the different radical species produced during 
treatment of the human breast cancer cell line MDA-MB-231with Parthenolide [363]. 
They illustrated that during the first 1-8 hours after treatment NADPH oxidase was 
stimulated and there were high levels of H2O2, during the second phase of treatment 
from 8-16 hours the main radical produced was mitochondrial O2- . Furthermore, the 
authors demonstrated that the levels of the antioxidant  enzymes  catalase  and  SOD2  
decreased  only  after  4  hours   of treatment and then gradually decreased over time 
after that with a 40% reduction at 16 hours. In my study I observed an increase in ROS 
within the first hour after treatment, using the dye DHE that detects superoxide anions. 
This is obviously different to the finding of Carlisi et al and may be due to differences in 
the cell lines used and experimental design such as the fact that they used flow 
cytometry to detect super oxide anions and I used the MitoXpress machine which is a 
fluorescent microscope. The short term cell viability assays carried out in this study 
were exposed to Parthenolide for five days which according to the study by Carlisi et al 
would be enough time to allow Parthenolide induced inhibition of the antioxidant 
defence enzymes.  Parthenolide has entered phase  I clinical trials which concluded 
that it has poor bioavailability [492] leading to a water-soluble analogue Dimethylamino 
Parthenolide (DMAPT) being  developed. DMAPT has shown promising pre-clinical 
results in lung, bladder and breast cancer cell lines [364, 493]. 
 
From the evidence above it seems clear that Parthenolide induces ROS  through acting 
on the antioxidant defence mechanism of cells. Menadione and β-lapachone are also 
ROS inducing agents but have a different mechanism of action to Parthenolide and 
have not been shown to act on the antioxidant system. It seems congruent therefore 
that Parthenolide has displayed a selective lethal relationship with my MLH1 deficient 







Several drugs have also been developed to counteract the upregulation of the 
antioxidant defense system in cancer cells by indirectly increasing ROS levels. 
Glutathione metabolism is an important therapeutic drug target that has been identified 
and drugs such as Buthionine Sulphoximine, which inhibit GSH synthesis, have shown 
promise in experimental studies [494]. GSH levels can also be altered by modifying 
cysteine levels and the drug Sulphasalazine has been shown to be able to carry out this 
function and be effective in pancreatic cancer cell lines in vitro and in vivo [495]. The 
drug NOV-002 alters the GSSG/GSH ratio and has been shown to improve the 
response rate when added to conventional chemotherapy in the adjuvant setting in 
HER-2 negative breast cancers [496]. Alterations to the antioxidant enzyme thioredoxin 
is another resistance mechanism that cancer cells have been shown to employ and the 
drug Auranofin has been developed to counteract this. This drug is a gold compound 
that has been used for rheumatoid arthritis. It has been shown to cause cell death with 
cytochrome-c release in ovarian cancer cell lines [497] . 
 
These therapeutics inhibiting the antioxidant defense system to modulate ROS levels 
have been developed some time ago but few have made progress beyond pre-clinical 
studies despite some promising results. The renewed interest in therapeutically 
targeting cancer cell metabolism should give the academic community a better 
understanding of cancer cell metabolism and hopefully move these drugs further 




With the increased move in oncology to try and specifically target cancer cells and 
spare normal body cells, several studies have been designed to specifically target cells 
with DNA repair deficiencies by introducing ROS and oxidative stress in these cell lines 
 
Sajesh et al manipulated the redox status of cancer cells deficient in the homologous 
recombination DNA repair enzyme RAD54B [498]. The investigators found that 




siRNA silencing results in selective cell death in the RAD54B deficient cell line 
(EC50=4.2 µM) compared to controls (EC50=67.7 µM). On further investigation, the 
authors show that the mechanism of cell death is due to a significantly increased 
accumulation of DNA double strand breaks due to increased ROS levels in the 
RAD54B-deficient colorectal cancer cell lines leading to apoptosis in these cell lines 
compared to controls. The authors discussed several possible reasons behind the 
selectivity including the fact that the damage caused by inhibiting SOD1 could be of a 
type (S-phase as a result of collapsed replication forks) that can only be repaired by the 
homologous recombination pathway and not compensated for by non homologous end 
joining. Other potential hypotheses include that ROS induction activates pathways that 
suppresses compensatory non homologous end joining or that the damage overwhelms 
the capacity of the non homologous end joining pathway [498]. 
 
A recent study by Chakrabati et al exploited the mechanism of action of ARQ761 (β-
Lapachone) and demonstrated that knocking down the BER scaffolding  protein  
XRCC1  sensitised  cells  to  PARP1  hyperactivation  with ARQ761 treatment resulting 
in enhanced cell killing in an NQO1 dependent manner in head and neck cell lines, 
breast cancer cell lines, non small cell lung cancer and pancreatic ductal 
adenocarcinoma [368]. On further exploring the observed selective cell death, the 
investigators observed that in pancreatic cancer tissue the levels of NQO1 were much 
higher compared to normal tissue. Interestingly, raised NQO1 levels in pancreatic 
cancer tissue were  accompanied by decreased expression of the antioxidant enzyme 
Catalase. The investigators demonstrated that exposing pancreatic ductal 
adenocarcinoma (PDA) MiaPaca2 cell lines to ARQ761 resulted in a NQO1 dependent 
increase in cytoplasmic ROS, DNA base damage and single strand breaks but no 
significant cell death [368]. Upon treating several different cell lines with sublethal doses 
of ARQ761 and the DNA repair inhibitor MeOx (binds to AP sites and prevents 
recruitment of BER complexes to damage [499]) this led to enhanced cell death in the 
cancer cell lines in an NQO1 dependent manner due to increased ARQ761 induced 
PARP1 hyperactivation. The overall mechanism by which the authors described cell 
death was occurring is that MeOx causes modification of AP sites means that there is 
already increased PARP1 activation and depletion of NAD+ which means that further 
damage by ARQ761 results in PARP1 not being able to be activated and repair the  




xenografts there was a significant decrease in tumour growth and increased survival in 
the mice treated with the combination of ARQ761 and MeOx [368]. 
 
My study has demonstrated that cells deficient in the MMR gene MLH1 have a 
mitochondrial  phenotype,  a  decreased  antioxidant  defense  capacity  and a synthetic 
lethal relationship with the ROS inducing drug Pathenolide. In a similar manner to the 
studies described above, it is likely that the mechanism of selectivity is related to the 
DNA repair function of MLH1. As outlined in section previously,  there is evidence to 
suggest that the MMR repair system has a role in the repair of oxidative DNA damage 
and treatment with the ROS inducing agent Parthenolide results in increased ROS in 
my MLH1 deficient cell lines compared to the MLH1 proficient cell lines and this is likely 





Dwyer et al have recently shown that several conventionally used antibiotics produce 
ROS as part of their mechanism of action despite having differing mechanisms by which 
they carry out their bactericidal activity [500]. The role of ROS in antibiotic lethality was 
demonstrated by overexpressing the H202 scavenging enzyme KatG in cell culture with 
several antibiotics which resulted  in decreased cell killing [500]. The role of the MutS 
was also investigated in this study such that overexpressing this MMR protein resulted 
in decreased antibiotic lethality. The authors concluded that the post replicative repair  
function of MMR was likely to be responsible for this but that other novel roles of MMR 
pathway in this context could not be ruled out [500]. It is feasible that the role of MMR in 
the repair of oxidative DNA damage could also be contributing to the increased cell 
survival. It would be interesting to investigate whether MMR deficient cells are 
synthetically lethal with the antibiotics used in this study and whether this is as a result 
of increased oxidative damage. 
 
Our laboratory has previously shown that treatment with the drug Methotrexate is 




oxidative stress [98]. The levels of 8-hydroxyguanine (8-OHG),  a precursor to 8-oxoG, 
were similar in the MSH2 proficient and deficient cell lines following methotrexate 
treatment, but over time the levels of 8-OHG returned to baseline in the MSH2 proficient 
cell lines. Levels of oxidative DNA damage remained elevated in the MSH2 deficient 
cell lines. This data suggests that  in  the  absence  of  MSH2,  oxidative  DNA  
damaging  agents  such as Methotrexate can cause oxidative damage, which is not 
efficiently repaired  and its accumulation results in loss of cell viability. These findings 
have been translated into an ongoing clinical trial at the Royal Marsden Hospital [98]. 
More recently, it has been shown that cytosine based nucleoside analogs are 
selectively lethal with MLH1 and MSH2 deficient cell lines due to an increase in ROS 
levels and elevated oxidative DNA damage leading to apoptosis [52]. 
 
The evidence presented here clearly highlights that targeting DNA repair deficient cells 
like the MMR deficient cell lines in this study with ROS inducing agents is a useful 
therapeutic strategy and warrants further study. 
 
There are obviously concerns about normal tissue damage with mitochondrial targeted 
agents especially ROS inducing drugs given the crucial role of ROS in signaling 
pathways in normal tissue physiology. Interfering with mitochondrial ATP production in 
cancer cells may have the unintended consequence of affecting ATP production in 
normal cells. A large amount of research is ongoing to try and develop an in-depth 
understanding of the differences between the mitochondria and redox status of cancer 
cells versus normal cells and indeed more recently that of cancer stem cells. This type 
of research will allow more selective targeting of cancer cells versus normal cells with 
mitochondrial- targeted drugs. There is a also a move to develop therapeutics to 
specifically target the mitochondria with the hope to improve efficacy and reduce 
toxicity. Direct targeting of the mitochondria is thought to have the advantage of  
avoiding any upstream pathways that may be involved in drug resistance. Methods of 
direct mitochondrial targeting that have been developed include: 1, Delocalized 
lipophilic cations (DLCs) which cross the mitochondrial membranes since they are 
designed to target the negative charge of the matrix [501]. 2, mitochondrial targeted 
sequences (MTSs)- containing polypeptides with amino acids designed to be 
recognized by the mitochondrial import machinery [502].  3, Synthetic amino acid and 




cell directly followed by entering the mitochondria facilitated by the electrical gradient 
and therefore avoid lysosomal or endosomal degradation [503]. 4, Mitochondria-






We and others have previously established a role for the MMR pathway in the repair of 
oxidative DNA damage in the nucleus (MSH2) and the mitochondria (MLH1). We have 
also shown MLH1 to be synthetically lethal with several mitochondrial-targeted drugs 
due to an increase in oxidative DNA damage in the mitochondria. This study has 
deepened our understanding of MMR deficient tumours further and identified several 
potential therapeutic targets.  
  
More specifically I have shown that MLH1-deficient cancers (and potentially MSH2 
deficient cancers) could be selectively targeted by exploiting the fact that they are 
susceptible to the ROS inducing agent Parthenolide because of deficiencies in their 
antioxidant defense capacity compounded by the fact that these cell lines cannot repair 
the resulting mitochondrial oxidative DNA damage (Figure 6.1A).  
 
I have identified the drug Parthenolide to be selectively lethal with MMR deficient 
tumours and further in vivo experiments need to be carried out to validate this before 
potentially moving into clinical trials. The plant Feverfew (Tanacet trade mark ) 
containing Parthenolide underwent a phase I clinical trial but was found to have poor 
bioavailability [381]. The drug has been re-formulated as a water soluble analogue 
known as Dimethylamino Parthenolide (DMAPT) and is currently undergoing phase I-II 
clinical trials. Interestingly Hassane et al, through chemical genomic studies, identified 
inhibitors of the PI3K/mTOR pathway which are known to interfere with the activation of 
NRF2 to work synergistically with DMAPT resulting in increased cell death in in vitro 
and in vivo experiments with primary human AML cells. [382], [383].  
 
There is much debate about using ROS inducing agents and drugs that cause oxidative 
DNA damage in cancer since they could potentially enhance tumourigenesis. It is 
important to note that several conventionally used chemotherapeutic agents such as the 
anthracycline group of drugs and methotrexate are know to induce ROS and cause 
oxidative DNA damage as one of their main mechanisms of action [188, 384]. These 
drugs have been given safely by having a good understanding of their potential 




advantage of targeted strategies like I have identified in this study is that these should in 













This study has shown for the first time that MMR deficient cell lines (MLH1 and MSH2 
deficient) exhibit a complex mitochondrial phenotype that could be exploited clinically. 
These cell lines have decreased expression of PGC1β, NRF, decreased mitochondrial 
biogenesis, decreased expression of the transcription factor NRF2 and this results in 
deficiencies in Complex I expression and activity, dysfunctional oxidative 














in! Complex! I,! decreased! oxidative! phosphorylation! and! an! attenuated! antioxidant! system.!








To gain a full understanding of the phenotype I observed in my MLH1 and MSH2 
deficient tumours, we need to understand why and how these tumours have 
deficiencies in PGC1β and downstream transcription factors. As a starting point, we 
could sequence these genes looking for mutations within microsatellites in their 
sequences. The fact that all the MMR deficient cell lines in this study exhibited 
decreased Complex I expression and activity means that it is possible they have 
mutations within microsatellites in Complex I genes or nuclear genes involved in mtDNA 
integrity. To investigate this we could sequence nuclear encoded Complex I genes as 
well as other key nuclear encoded mitochondrial genes such as TFAM. 
 
The next step towards translating the results of this study would be to carry out an in 
vivo experiment with the drug Parthenolide in mice xenografted with MLH1-deficient and 
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Pass:0.0:82:873:0:251:2.2828E69
chrM
16567
C
+GATGGATCA
integenic
CHR31M
TL1A
*/+GATGGATCA
795
528
128
16.10%
Pass:0.046875:34:494:6:122:3.0532E61
CHR31M
TL1B
*/+GATGGATCA
1002
665
142
14.17%
Pass:0.04929577464788732:41:624:7:135:3.6845E61
chrM
302
A
6C
integenic
CHR31M
TL2A
*/6C
4252
1531
2626
61.79%
Pass:892:639:265:2361:1E0
CHR31M
TL2B
*/6C
5021
1915
2948
58.81%
Pass:1143:772:338:2610:1E0
chrM
515
G
6CA
integenic
CHR31M
TL2A
6CA/6CA
5176
1053
4028
78.69%
Pass:421:632:2773:1255:1E0
CHR31M
TL2B
6CA/6CA
7153
1278
5747
81.26%
Pass:677:601:3537:2210:1E0
chrM
5895
A
+C
integenic
CHR31M
TL2A
+C/+C
2851
144
2497
87.40%
Pass:66:78:899:1598:1E0
CHR31M
TL2B
+C/+C
103
9
90
87.38%
Pass:7:2:36:54:1E0
chrM
6845
T
6C
M
T6CO
1#I314#fram
eshift
CHR31M
TL2A
*/6C
6662
4815
1783
26.80%
Pass:2401:2414:903:880:1E0
CHR31M
TL2B
*/6C
179
132
45
25.28%
Pass:67:65:30:15:1E0
chrM
16183
A
6C
integenic
CHR31M
TL2A
*/6C
7970
1926
3736
47.06%
Pass:923:1003:1749:1987:1E0
CHR31M
TL2B
*/6C
7947
2601
3471
43.75%
Pass:1205:1396:1596:1875:1E0
chrM
515
G
6CA
integenic
CHR32M
TL1A
6CA/6CA
768
168
571
76.03%
Pass:45:123:356:215:1E0
CHR32M
TL1B
6CA/6CA
2660
573
2041
77.69%
Pass:223:350:1431:610:1E0
chrM
16183
A
6C
integenic
CHR32M
TL1A
*/6C
2981
1138
1132
38.02%
Pass:283:855:514:618:1E0
CHR32M
TL1B
*/6C
7900
2417
3531
44.80%
Pass:869:1548:1520:2011:1E0
chrM
16562
C
+ATCACGATGGATCACAGGTCT
integenic
CHR32M
TL1A
*/+ATCACGATGGATCACAGGTCT
420
313
77
18.33%
Pass:0.0:22:291:0:77:6.8004E63
chrM
16567
C
+GATGGATCA
integenic
CHR32M
TL1A
*/+GATGGATCA
353
223
49
13.88%
Pass:0.02040816326530612:17:206:1:48:1.2991E61
chrM
302
A
6C
integenic
CHR32M
TL2A
*/6C
1621
628
939
58.07%
Pass:363:265:116:823:1E0
CHR32M
TL2B
*/6C
2447
893
1507
61.61%
Pass:528:365:168:1339:1E0
chrM
515
G
6CA
integenic
CHR32M
TL2A
*/6CA
4032
1225
2744
68.70%
Pass:558:667:1612:1132:1E0
CHR32M
TL2B
6CA/6CA
3478
754
2621
76.84%
Pass:310:444:1707:914:1E0
chrM
5895
A
+C
integenic
CHR32M
TL2A
+C/+C
1331
78
1172
87.86%
Pass:41:37:457:715:1E0
CHR32M
TL2B
+C/+C
1308
49
1167
89.02%
Pass:28:21:451:716:1E0
chrM
6845
T
6C
M
T6CO
1#I314#fram
eshift
CHR32M
TL2A
*/6C
2897
2057
815
28.16%
Pass:1053:1004:434:381:1E0
CHR32M
TL2B
*/6C
3186
2325
827
25.96%
Pass:1160:1165:436:391:1E0
chrM
16183
A
6C
integenic
CHR32M
TL2A
*/6C
7620
2982
3120
40.97%
Pass:1244:1738:1446:1674:1E0
CHR32M
TL2B
*/6C
7939
2733
3288
41.53%
Pass:1065:1668:1571:1717:1E0
chrM
515
G
6CA
integenic
CHR33M
TL1A
6CA/6CA
1947
420
1464
76.41%
Pass:144:276:947:517:1E0
CHR33M
TL1B
6CA/6CA
3200
630
2510
79.36%
Pass:245:385:1721:789:1E0
chrM
16183
A
6C
integenic
CHR33M
TL1A
*/6C
6478
2273
2681
41.47%
Pass:803:1470:1205:1476:1E0
CHR33M
TL1B
*/6C
7853
2392
3464
44.18%
Pass:1090:1302:1699:1765:1E0
chrM
16567
C
+GATGGATCA
integenic
CHR33M
TL1A
*/+GATGGATCA
1021
627
162
15.85%
Pass:0.08641975308641975:48:579:14:148:7.2488E61
CHR33M
TL1B
*/+GATGGATCA
791
422
106
13.40%
Pass:0.07547169811320754:69:353:8:98:1.2352E62
chrM
302
A
6C
integenic
CHR33M
TL2A
*/6C
5485
1904
3428
62.52%
Pass:1301:603:400:3028:1E0
CHR33M
TL2B
*/6C
5606
1939
3511
62.70%
Pass:1208:731:421:3090:1E0
chrM
515
G
6CA
integenic
CHR33M
TL2A
6CA/6CA
7177
882
6189
87.24%
Pass:353:529:3767:2422:1E0
CHR33M
TL2B
6CA/6CA
6956
1068
5742
83.76%
Pass:530:538:3677:2065:1E0
chrM
5895
A
+C
integenic
CHR33M
TL2A
+C/+C
3332
195
2923
87.49%
Pass:106:89:1042:1881:1E0
CHR33M
TL2B
+C/+C
3512
184
3101
87.92%
Pass:99:85:1138:1963:1E0
chrM
6845
T
6C
M
T6CO
1#I314#fram
eshift
CHR33M
TL2A
*/6C
6795
4988
1760
25.92%
Pass:2667:2321:966:794:1E0
CHR33M
TL2B
*/6C
7968
5833
2065
25.94%
Pass:3128:2705:1149:916:1E0
chrM
16183
A
6C
integenic
CHR33M
TL2A
*/6C
7989
2387
3563
44.64%
Pass:1196:1191:1671:1892:1E0
CHR33M
TL2B
*/6C
7985
2223
3605
45.24%
Pass:1041:1182:1809:1796:1E0
chrM
16567
C
+GATGGATCA
integenic
CHR33M
TL2A
*/+GATGGATCA
1009
581
110
10.90%
